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This thesis applies systems biology approaches to obtain a better understanding of complex cellular 
systems in Chronic Lymphocytic Leukaemia (CLL).CLL is a cancer of the blood which affects B 
cells. CLL cells accumulate quickly in the body but die rapidly by apoptosis when cultured in the lab, 
suggesting that CLL cell survival can be modulated by tumour cell interactions with the 
microenvironment in vivo.  
The first part of the thesis describes in vitro assays which demonstrated that CLL cell contact with 
endothelial cells in a co-culture system promotes CLL cell survival. The precise mechanisms 
involved remain unknown, however, they are thought to include both secreted factors and 
receptor:ligand interactions between CLL cells and the microenvironment. 
The second part of the thesis is based on gene expression profiling and investigates the 
transcriptional effects induced in CLL cells by co-culture. We identified genes that were statistically 
significantly up regulated >1.5 fold compared with liquid culture (q<0.001) and were common to two 
endothelial systems.  
The third part of the thesis focuses on cell surface proteins which allow CLL cells to communicate 
with other cells. In order to obtain a comprehensive analysis of the cell surface proteome of CLL 
cells, we developed a method utilising cell impermeable, cleavable sulfo-NHS-SS-biotin to enrich for 
cell surface proteins followed by high-content mass spectrometry (LC-MS/MS) for identification. 
Somewhat surprisingly, a number of proteins were identified which have traditionally been classified 
as intracellular. Some of these have been previously identified as specific binding partners for CLL 
B-cell receptor (BCR) stereotypes. It is possible that the BCR activation observed in CLL occurs as a 
consequence of binding to these aberrantly expressed autoantigens. This study provides insights 
into the mechanisms that underpin the cytoprotection afforded by CLL cell-endothelial cell co-culture 
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1. General Introduction  
 
1.1 Introduction to Chronic Lymphocytic Leukaemia (CLL) 
 
Chronic Lymphocytic Leukaemia (CLL) is the most common form of adult leukaemia in the Western 
World, accounting for about 40% of all leukaemias over the median age of 65-70 years of age. The 
incidence of CLL in England and Wales has been reported as 6.5 per 100,000 per year (4). CLL is 
20-30% more common in European, Australian and North American White and Black populations 
than in India, China or Japan (5) and is more common in males than females. Although the disease 
may present with systemic symptoms, such as night sweats, tiredness, unintentional weight loss and 
symptoms of anaemia or infection, 70-80% of patients are diagnosed due to an incidental finding of 
lymphocytosis upon a routine full blood count (6).    
CLL is regarded as a clinically heterogeneous disease and is characterised by a neoplasm of 
morphologically mature clonal CD5
+
 B lymphocytes (7), which are immunologically less mature. The 
World Health Organization (WHO) classification of haematopoieic neoplasias describes CLL as a 
stage of Small Lymphoytic Lymphoma (SLL), distinguishable only by its leukemic appearance (8). 
The cells found in a blood smear are small mature lymphocytes with a narrow border of cytoplasm 
and a dense nucleus, lacking distinctive nuclei and having aggregated chromatin.  CLL cells arise 
from the bone marrow and progressively accumulate in the blood, bone marrow and lymphoid 
tissues (9). The major cause of morbidity and mortality in CLL are secondary infections, attributed to 
abnormal immune function either as a result of the primary disease or through the 
immunosuppressive effects of the management of CLL. 80% of CLL patients will suffer infections 
during the disease course (10), the most common immune defect is hypoglobulinemia rendering 
patients susceptible to bacterial infections.  There are also various defects in the function of T cells 
that are induced via contact with CLL cells, including alterations in CD40L activation (11) and 
abnormalities in the expression of genes involved in the differentiation of CD4
+
 cells, cytoskeleton 
formation and vesicular trafficking and cytotoxicity of CD8
+
 cells  (12). The secretion of soluble 
mediators has also been shown to alter T cell function  (13). Impaired immune surveillance in the 




A diagnosis of CLL requires a count of greater than 5,000 B-lymphocytes per micorlitre in the 
peripheral blood for a period of at least three months. The clonality of these cells must be confirmed 
by flow cytometry. The monoclonal population of B cells in CLL typically express CD5, CD19 and 
CD23 and have reduced levels of IgM, IgD and CD79b present on the membrane surface compared 
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to those found on normal B cells (15). Other tests not required to establish diagnosis may be 
performed to give an insight into predicting prognosis or tumour burden. These include molecular 
genetics, fluorescence in situ hybridisation (FISH), mutational status of IgVH, serum marker and 
bone marrow examination.  
Dohner et al. (16) showed that cytogenetic lesions can be identified in more than 80% of CLL cases, 
with deletions in the long arm of chromosome 13 (del(13q14.1)) being the most common 
abnormality. Evidence is growing to suggest that detection of chromosomal deletions has prognostic 
significance, in particular patients with disease with del (17p) have poor prognosis and appear to be 
resistant to standard chemotherapy (17, 18). Detection of cytogenetic abnormalities may influence 
therapeutic decisions and repetition of FISH analyses could be important prior to commencing 
second and third line treatment as additional defects may be acquired during the course of the 
disease (19). 
The clinical course of patients with CLL varies dramatically with some patients having stable disease 
for a decade or more (20), whilst others have more aggressive disease. As CLL advances, the 
patient may experience swollen lymph nodes, spleen and liver, as well as anaemia, infections and 
ultimately bone marrow failure. There is currently no cure for the disease. Staging systems 
implemented by Rai and Binet are used to assess the extent of disease in a patient (Table 1.1). 
These systems are still used when assessing disease progression and treatment.  
However, these staging systems have no value in predicting the clinical course of a patient 
diagnosed with early stage CLL. A growing number of prognostic factors have now been identified to 













anaemia, or thrombocytopenia.  
Clinical Stage A Clinical stage A CLL is 
characterized by no anaemia 
or thrombocytopenia and 
fewer than three areas of 
lymphoid involvement (Rai 
stages 0, I, and II). 
Stage I Stage I CLL is characterized by 
absolute lymphocytosis with 
Clinical Stage B Clinical stage B CLL is 




hepatosplenomegaly, anaemia, or 
thrombocytopenia.  
or thrombocytopenia with 
three or more areas of 
lymphoid involvement (Rai 
stages I and II). 
Stage II Stage II CLL is characterized by 
absolute lymphocytosis with either 
hepatomegaly or splenomegaly 
with or without lymphadenopathy.  
  
Stage III Stage III CLL is characterized by 
absolute lymphocytosis and 
anaemia (haemoglobin <11 g/dL) 
with or without lymphadenopathy, 
hepatomegaly, or splenomegaly.  
Clinical Stage C Clinical stage C CLL is 
characterized by anaemia 
and/or thrombocytopenia 
regardless of the number of 
areas of lymphoid 




Stage IV CLL is characterized by 




) with or without 
lymphadenopathy, hepatomegaly, 





1.2.1. Prognostic factors  
 
CLL may progress slowly and patients with early, uncomplicated disease are not usually treated. 
Patients with advancing disease are treated with chemotherapy and monoclonal antibodies. CLL is 
considered incurable and treatments vary depending on diagnosis and the progression of the 
disease. As CLL progresses slowly in most cases, treatment is usually delayed until symptoms 
arise, indicating that the disease has progressed and may affect a patient’s quality of life. This is 
known as the ‘watch and wait’ approach.  
Table 1.1 CLL Staging System. Adapted from the National Cancer Institute (NCI) U.S. National 





CLL is considered an indolent disease, with life expectancy of 7 or more years. The average age of 
patients at diagnosis is 65 years. CLL also has a highly variable clinical course with some patients 
progressing much more quickly and severely than others. It would therefore be extremely valuable to 
be able to predict which patients are likely to have progressive disease and which are not. There has 
been much research into potential prognostic markers associated with CLL (reviewed in (22)), 
including CD44, CD49d, CD38, ZAP-70 VEGF, thymidine kinase (TK), LPL, CLLU1 expression, 
genome wide gene expression profiling (23) and immunoglobulin heavy chain variable (IgVH) region 
mutational status (24). 
CLL cells express immunoglobulin, which may or may not have undergone somatic mutations in the 
IgVH region. Patients with leukaemia cells which use an unmutated IgVH gene have a worse 
outcome than those patients using a mutated IgVH gene (25), whilst the use of the VH3.21 gene is 
an unfavourable marker independent of the mutational status (26). IgVH status has also been used 
to give clues to the origin of the CLL cell. IgVH mutational status is one of the most powerful 
prognostic features. Within the germinal centre, normal B cells undergo somatic hypermutation of 
their IgVH genes after exposure to T-dependent antigens. Around half of all CLL patients show 
evidence of somatic hypermuation, which is arbitrarily defined as a 2% deviation from the germ line 
sequence. These patients have better prognosis than those with unmutated IgVH genes.  
CD38 is another important prognostic feature in CLL. Its expression is dynamic and changes in 
response to contact with activated CD4
+
 T cells (27). CD38 is a transmembrane protein which may 
function as an ecto-enzyme and receptor involved in adhesion processes. Interactions between 
CD38 and its cognate receptor, CD31 promote the proliferation and survival of CLL cells (28). 





cells (30) generally have an aggressive disease, whereas the course of the disease in patients with 




 B cells is more likely to be indolent. The doubling 
time of circulating CLL cells (proliferation index) may also be used as a prognostic indicator (31).  
Whole-genome sequencing of four CLL patients followed by analysis of samples from a further 363 
patients have recently identified four genes that are recurrently mutated: notch 1 (NOTCH1) and 
exportin 1 (XPO1), predominantly found in patients with unmutated IgVH, and myeloid differentiation 
primary response gene 88 (MYD88) and kelch-like 6 (KLHL6), which are predominantly found in 
cases with mutated IgVH (32). Constitutive activation of NOTCH1 signalling has been observed in 
CLL cells (33) and about 4% of CLL patients are believed to have NOTCH1 mutations (32).  Stromal 
cell-mediated Notch signalling has been shown to play a role in CLL resistance to chemotherapy. In 
one study, CLL cells were co-cultured with autologous and allogeneic human BM-mesenchymal 
stromal cells (hBM-MSCs). The co-culture protected CLL cells from apoptosis spontaneously and 
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following treatment of CLL cells with Fludarabine, Cyclophosphamide, Bendamustine, Prednisone 
and Hydrocortisone. However, treatment with a combination of anti-Notch-1, Notch-2 and Notch-4 
antibodies reversed the protective effect  of co-culture by day 3, even in presence of the drugs listed 
(34). Together these data suggest that blocking Notch signalling could be an additional tool to 
overcome drug resistance in CLL and show how understanding CLL: microenvironment interactions 
may help guide new therapeutic approaches. 
1.2.2. CLL is a proliferative disease 
 
Our understanding of CLL has greatly evolved over the past fifteen years. In the past, CLL was 
considered a disease of accumulation of mature B cells rather than proliferation. However, recent 
studies measuring the dynamic cellular kinetics of CLL cells have shown CLL clones to be more 
dynamic than previously assumed (35). Cellular birth rates were measured by calculating kinetic 
profiles after giving patients deuterated water. The birth rates varied from 0.1% to greater than 1% of 
the clone per day with a correlation between cellular birth rates over 0.35% and disease 
progression. If a patient has a clonal burden of 10
12 







cells each day. 
Recently, Lin et al., (36) performed single-molecule telomere length and telomere fusion analysis of 
CLL patients at different disease stages and identified the shortest telomeres ever recorded in 
primary human tissue. This supports the proposition that significant cell division occurs in CLL. They 
also show that critical telomere shortening, dysfunction and fusion contribute to disease progression. 
However, this remains a contentious issue as other groups debate which is causative, the short 
telomeres observed in CLL or chromosomal abnormalities (37).  
1.2.3. The Microenvironment in CLL 
 
The infiltration of the bone marrow and the lymph node by abnormal B cells is one of the main 
manifestations of the disease that leads to progression and ultimately organ failure (38). It is 
therefore important to understand how interactions with the tissue microenvironment contribute to 
the pathogenesis of the disease. Important parameters that govern the progression of the disease 
include the proliferative capacity of the cells (39), the potential to evade apoptosis (40) and cell 
migration (41).  Some of the cell surface receptors and ligands which potentially play a role in the 







1.2.4. CLL cell adhesion and migration 
 
Homing to the secondary lymphoid tissues and the bone marrow is an important feature of the 
pathophysiology of CLL, but the molecular signals which result in the accumulation of CLL cells in 
these organs are largely unknown. To enter these organs, circulating cells need to arrest on specific 
endothelial barriers, to locomote over the endothelial surface toward inter-endothelial junctions and 
to cross these junctions while resisting disruptive shear forces. These functions depend on the ability 
of circulating cells to establish dynamic adhesive interactions through their α4 integrins. The VLA-4 
integrin dimer is composed of α4β1 (alpha 4 is also known as CD49d and beta 1 is also known as 
CD29). Other important integrins include α4β7 and the β2 integrins LFA-1 (αLβ2) and Mac-1 
(αMβ2). During these interactions, the integrins undergo reversible activation by endothelial-
presented chemokines. This is significant as VLA-4 has been shown to be activated by the bone 
marrow chemokine, CXCL12. It has been shown that CLL cells have impaired migration to lymph 
nodes and bone marrow (42). CLL cells express lower than expected levels of lymphocyte integrin 
LFA-1 (43). It is believed that low levels of LFA-1 result in failed transmigration across endothelium 
expressing ICAM-1, VCAM-1 and CXCL12. This suggests that CLL cells have a reduced capacity to 
adhere and transmigrate through multiple vascular endothelial beds and home poorly to lymphoid 
Figure 1.1 The CLL tissue microenvironment. The schema shows cell surface receptors on B 
CLL cells and their ligands on accessory cells. The CD38, BCR, CXCR4 receptors and adhesion 
molecules, CD49d, CD44 and CD18, together with MMP9, a cell surface docking molecule, 




organs other than spleen. Therefore, integrin blocking could thus be an efficient strategy to prevent 
circulating CLL cells from reaching pro-survival microenvironments.  
Till et al. (44), have suggested that the failure of chemokines to induce clustering of adhesion 
molecules on the CLL cell surface results in defective trans-endothelial migration as CLL cells but 
not normal B cells are dependent on autocrine VEGF and alpha4beta1 integrin for chemokine-
induced motility on and through endothelium. Integrins are responsible for mediating cell-cell or cell-
matrix adhesion. The expression of VLA4  (45) adhesion molecule segregates CLL patients into high 
and low risk categories. The interaction of VLA-4 with VCAM might facilitate B cell activation, firstly 
by mediating B cell tethering to the endothelial membrane and then by facilitating BCR/ antigen 
engagement. VLA-4 interaction with VCAM1 appears to synergise with the B cell receptor (BCR) to 
enhance signalling via the BCR. 
CD38
+ 
CLL cells have been shown to have greater chemotactic potential compared with CD38
-
 CLL 
cells (41).  Interactions between CD38 and its ligand CD31 define a genetic signature characterized 
by modulation of pathways involved in proliferation and migration of CLL cells (46, 47). The 
differential gene expression profile of CD38
+
 compared to CD38
-
 CLL cells highlights differential 
expression of CD44, CD49d, MMP9 and ZAP70, which are all known to be involved in cell adhesion 
and motility (41). The activity of CD38 can be blocked using domain-specific monoclonal antibodies 
(mAbs), which results in weakened CXCL12 responses. This may be partly due to the physical 
proximity on the cell membrane between CD38 and CXCR4 (the CXCL12 receptor). CD38 is 
associated with other cell surface molecules, such as ZAP70 amongst other adaptor membrane 
proteins and is in close proximity to the BCR (41). The BCR/CD38 complex is formed within lipid 
rafts upon binding of CD38 to CD31 (3). It is thought that stimuli from the microenvironment, such as 
the interaction between CD38 on CLL cells and CD31 found on endothelial cells (including HMEC-1, 
which is used in studies described in this Thesis), could activate CD38. This would result in 
downstream phosphorylation of Syk (spleen tyrosine kinase) and/ or ZAP70, leading to activation of 
intracellular cascades. These processes would result in turn in actin cytoskeleton changes, 



















1.2.5. Accessory cells in the microenvironment 
 
Factors that govern the progression of CLL include the proliferative capacity of the cells, the 
potential to evade apoptosis (48) and cell migration (49). Interactions between CLL cells and the 
tissue microenvironment contribute to these factors and ultimately to the pathogenesis of the 
disease (38).   
In vivo, CLL cells are in close contact with accessory cells in the microenvironment. Dendritic cells, 
stromal cells, bone marrow derived endothelial cells, as well as umbilical vein endothelial cells can 
all confer a survival advantage to CLL cells (50). Data from our laboratory and others have shown 
that activated CD4
+
 T cells and endothelial cells can be found in and around proliferation centres in 
the lymph nodes (51, 52). These data suggest that CLL cell survival is modulated by tumour cell 
interactions with the microenvironment in vivo. 
 In vitro assays have demonstrated that CLL cell contact with endothelial cells (HMEC-1) in a co-
culture system promotes CLL cell survival, whilst CLL cells cultured alone undergo extensive 
apoptosis (Figure 1.3) (1). Therapeutic applications are clear as agents which block pro-survival 
CLL-endothelial interactions could be developed as new therapies to treat CLL patients.  
Figure 1.2 The role of CD38/BCR and CXCR4 in cell migration. CD38 engages CD31 ligand 
found on the endothelial membrane. An intracellular signalling cascade involving ZAP70 and or 
Syk may feed in to a BCR signalling pathway, leading to actin reorganization and cell motility 














Our understanding of the mechanisms which operate in the CLL microenvironment is incomplete, 
although it is now appreciated that CLL is a dynamic disorder with significant tumour cell turnover 
every day with cellular birth rates between 0.1 and 1% of the entire leukaemic clone per day (53) as 
well as some cells undergoing apoptosis. These data suggest that the CLL clone is continually dying 
and replenishing itself, particularly in patients with stable WBC counts. Death rates approaching or 
exceeding 1% of the entire clone per day were reported in some patients, therefore in most patients 
a significant portion of the clone has the potential to undergo apoptosis. Primary CLL cells are 
notoriously difficult to culture in vitro (54) and establishing models for drug testing  has been 
hindered by the poor survival of these cells. This raises the question as to what signals are provided 
in vivo that enable these cells to survive and proliferate and can it be recapitulated in the laboratory? 
Recent work has highlighted the role of certain accessory cells within the tumour microenvironment 
in the survival and in inducing the proliferation of CLL cells (1, 55, 56). As a result of this, a variety of 
co-culture systems have been developed to mimic the tumour microenvironment. Tumour 
proliferation is believed to occur mainly in pseudofollicles, which are specialized structures that 
contain CLL-cells, T-lymphocytes and stromal cells (57). These structures develop in the lymph 
nodes, bone marrow and spleen (56, 58). Interactions with T-lymphocytes, the microvasculature, 
soluble factors and other stromal elements are all thought to play a major role in the survival and 
expansion of the tumour cells. In keeping with this, lymph node biopsies from CLL patients with 
aggressive disease contain activated T-lymphocytes. Work from our laboratory demonstrated that 
Figure 1.3 Co-culturing CLL cells with HMEC-1 cells protects CLL cells 
from apoptosis. Normal B cells do not receive a cytoprotective effect (from 




proliferating CLL cells co-localize with activated CD4
+
 T-cells in lymph node pseudofollicles (56) and 
ligation of CD40 on CLL cells by its ligand, CD40L (expressed by activated T lymphocytes) has 
recently been shown to induce responses, including up-regulation of surface markers and induction 
of chemokines (59). Lymph nodes of CLL patients with aggressive disease also contain large 
numbers of CD31
+
 blood vessels (56) and CD31
+
 nurse-like cells (28, 60). In a recent study, 
Buggins et al. (61) demonstrated that interactions with endothelial cells can promote the survival of 
CLL cells and induce the expression of CD38 and ITGA4 (CD49d) on the tumour cells (1). The 
expression of these molecules on CLL cells is associated with aggressive disease and clinical 
outcome (25, 45, 62). These studies indicate that interactions with accessory cells, such as activated 
T-lymphocytes and endothelial cells are likely to play a role in sustaining CLL cells in vivo. Therefore 
there is a need to model these interactions in vitro in order to define critical molecular interactions 
that may promote survival and proliferation in this disease.  
1.2.6. Effects of cell:cell interactions vs effects of soluble factors in CLL 
culture systems 
 
Various studies have investigated the contribution of cell:cell interactions and soluble factors in the 
cytoprotective effects of co-culture systems on CLL cells. Since CLL cells associate with one 
another at sites of tissue involvement in the lymph node, bone marrow and spleen, Pettitt et al. (63) 
postulated that homotypic interactions between the malignant cells might reduce CLL cell apoptosis. 
Highly pure CLL cell populations were cultured on a non-adherent surface and CLL cell viability was 
found to increase markedly with the level of crowding at the bottom of the culture vessel. The effect 
did not require direct cell:cell contact, indicating that cell survival was being regulated in an autocrine 
fashion by soluble products. Further experiments showed that conditioned media from crowded CLL 
cells enhanced the survival of autologous non-crowded cells, indicating that at least some of the 
autocrine survival factors produced by CLL cells could accumulate in the extracellular environment. 
Co-culture of CLL cells with an excess of autologous fixed cells also enhanced survival of CLL cells. 
Treatment of fixed cells with neuraminidase, which cleaves glycosidic linkages of neuraminic acids, 
abrogated the protective effect of cell:cell contact. These data indicate that cell surface specific post-
translational modifications are necessary to mediate a cytoprotective effect during co-culture. 
Other groups have also demonstrated the importance of the combination of cell:cell interactions and 
soluble factors for CLL cell survival in culture. In order to elucidate important survival signals acting 
on CLL cells, Burgess et al. (64) cultured primary CLL peripheral blood mononuclear cells (PBMCs) 
at high density and used antibody arrays to measure the level of 42 cytokines in tissue culture 
supernatants. These experiments showed that IL-6, IL-8, CXCL2 and CCL2 were highly up-
regulated in culture. The addition of either CXCL2 or CCL2 to CLL cultures enhanced CLL cell 
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survival and antibodies blocking these chemokines reduced survival. Co-culture of CLL cells and 
PBMC accessory cells separated by transwells provided a similar degree of survival protection 
compared to high density culture, whereas CLL cells cultured alone died rapidly. It was shown that 
CCL2 and CXCL2 were produced by CLL cells only when co-cultured with accessory cells, leading 
the authors to speculate that accessory cells release soluble factors that promote the production of 
these pro-survival chemokines from CLL cells. Data from Burgess et al. (64) suggest that soluble 
factors may be more important than cell:cell interactions. However, in other co-culture systems it 
appears that direct cell:cell interactions are more important for CLL cell survival. Maffei et al. (65) 
utilise HUVEC (Human Umbilical Vein Endothelial Cells) in direct cell:cell contact with CLL cells in 
their co-culture system. CLL cells cultured in conditioned medium from HUVEC did not receive a 
cytoprotective effect and co-cultures separated by a microporous membrane, or transwell to prevent 
physical contact died by apoptosis. In agreement with data from Burgess et al. (64), Maffei et al. (65) 
tested the contribution of soluble factors present in the co-culture conditioned medium to the 
observed inhibition of apoptosis in CLL cells, by collecting media from CLL cells co-cultured on 
HUVEC for 48 hours (co-culture conditioned medium) and then added them to CLL cells cultured 
alone. An increase in CLL cell viability was observed with the co-culture conditioned medium, 
suggesting that CLL cells are able to shape their microenvironment. 
1.2.7. Antigen stimulation, inflammation and CLL 
 
In CLL and other cancers, a unique microenvironmental organisation is active in the development 
and survival of malignant cells: chronic inflammation exposes cells to growth factors, newly formed 
blood vessels provide nutrients and immune tolerance avoids immune-mediated elimination. The 
concept of the microenvironment being a regulator of CLL proliferation is linked to a role of antigen 
stimulation through the BCR on the surface of CLL cells. The microenvironment, along with dead or 
dying CLL cells may act as a source of antigen for CLL B cells. Observations indicating an important 
role of antigenic pressure in the pathogenesis of CLL include the following: at least half of CLL 
patients have somatically mutated IgVH region, which track the clonal history to in vivo BCR 
activation (25, 66); more than 20% of cases express closely homologous, stereotyped BCR which 
may recognise auto-antigens or bacterial components (67); and in the TCL1  transgenic murine 
model of CLL (68) leukemic immunoglobulins are autoreactive and bind polysaccharides found in 
bacterial cell membranes. Autoantigens and molecular structures normally involved in scavenging 
debris, apoptotic cells and pathogenic bacteria appear relevant in triggering and/or facilitating the 
evolution of at least some CLL clones (69). Inflammatory receptors including Toll-like receptors 
(TLR) can be engaged concomitantly with the BCR, therefore TLR may also play a role in BCR co-
stimulation of CLL cells. It was recently shown that bacterial lipopeptides protect CLL cells from 
spontaneous apoptosis mediated by TLR signalling (70). The relationship between antigen 
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stimulation/inflammation and CLL pathogenesis is currently highly contentious and is likely to be an 
area of intense further research.  
Other evidence which supports the proposition that CLL cells are continuously exposed to antigen in 
vivo is the N-glycosylation pattern of surface IgM (sIgM). Krysov et al. (71) reported that sIgM exists 
in two distinct forms with different N-glycosylation patterns in the mu-constant region. One glycoform 
is similar to that found on normal B cells which bear mature complex glycans common to other cell-
surface glycoproteins. The other glycoform is immature, mannosylated and more characteristic of 
mu chains usually found in the endoplasmic reticulum. Unmutated CLL (U-CLL) were found to 
expresses a higher proportion of mannosylated surface mu chains than mutated CLL, whilst normal 
B cells express only the mature glycoform. Persistent engagement of sIgM on normal B cells can 
induce the expression of the immature form and this suggests that glycan modification is a 
consequence of antigen exposure. CLL cells were also shown to revert to the mature form after 
incubation in vitro, suggesting the source of antigen had been removed. These findings support the 
concept that CLL cells are continuously exposed to antigen in vivo. 
Evidence from numerous groups supports a role for antigen signalling and interactions with the 
microenvironment in the development and subsequent progression of CLL (72, 73). It has been 
shown that CLL cells resist apoptosis (74), but the mechanisms which connect BCR signalling to 
apoptotic resistance are not fully understood. Paterson et al. (75) investigated the downstream 
regulators of signalling pathways particularly the role of the pro-apoptotic molecule BIM and 
identified two major isoforms, BIMEL and BIML, which undergo phosphorylation in CLL cells 
stimulated with anti-IgM. Co-culture with HK (a follicular dendritic cell line) promoted 
BIMEL phosphorylation, suggesting that BIM may coordinate microenvironment and antigen-
mediated survival signals. Studies such as this provide new insights into BCR signalling and its 
relevance to CLL providing therapeutic targets (76). 
1.2.8. The use of endothelial cells in co-culture model systems 
 
An inflammatory microenvironment will have effects not only on CLL cells but also on other 
accessory cells, including endothelial cells. This should be considered when using a CLL, 
endothelial co-culture system in order that a suitable endothelial cell is chosen. Inflammatory 
responses are determined by the response of the vascular endothelium to extracellular injury. 
Stimuli trigger gene expression programs, which result in transcription of genes encoding pro- and 
anti-inflammatory proteins. These in turn guide attraction and interaction with leukocytes, affect 
vascular permeability and determine the composition of infiltrating leukocytes. For example, the 
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stimulation of endothelium markedly enhances CLL interaction with endothelium (77) via integrin 
alpha 4 beta 1 and VCAM-1.  
The diversity of the vascular bed is determined by the endothelial cells lining the inner vessel 
surface. The most frequently used models are micro-vascular (e.g. HMEC-1) and macro-vascular 
(e.g. HUVEC) cells. Results of studies based on one endothelial cell type are often assumed 
uncritically to apply to other endothelial cell types (78-80). However, E-selectin is frequently reported 
to be expressed differentially on HUVEC and HMEC-1 (81) and this highlights the potential for 
functional differences in models using particular endothelial cell types.  
It is generally assumed that the responses of different endothelial cells to distinct inflammatory 
stimuli are comparable and this may not be a reasonable assumption. One study compared the 
effect of TNF-α on blood brain barrier vs macro-vascular endothelial cells (HUVEC). Studies have 
shown differences in basal gene expression profiles of micro- and macro-vascular endothelial cells. 
TNF-α stimulation (2ng/ml for 5 hours) induces distinct gene expression programs in micro-vascular 
and macro-vascular human endothelial cells (82). However it is unclear whether differences in 
expression after TNF-α treatment were due to differences in basal gene expression or a different 
response to the stimulus. In this study, the responses of a micro-vascular endothelial cell HMEC-1 
and a macro-vascular endothelial cell type HUVEC to TNF-α were analysed by microarray analysis 
and compared. Many genes were comparably induced in HMEC-1 and HUVEC by TNF-α treatment 
but around half of the 86 genes induced by TNF-α treatment were specific for HMEC-1 or HUVEC. 
The genes which differed encode chemokines, cytokines and cell surface molecules. These specific 
effects were restricted to subtypes of endothelial cells rather than in cell type dependent regulation 
and included mRNA encoding proteins involved in cell differentiation or cell cycle control. A 
confounding factor in the design of this experiment was the use of one cell line and one primary cell 
when the vital comparison was between gene expressions of micro- and macro-vascular endothelial 
cells. In addition, the TNF-α stimulation used in this study (2ng/ml) is of a higher concentration than 
cytokine concentrations produced by CLL cells in culture (117pg/ml), and higher still than levels 
found in sera (39.6pg/ml) (83).  
HMEC-1 is the first immortalized human micro-vascular endothelial cell line that retains the 
morphologic, phenotypic and functional characteristics of normal human micro-vascular endothelial 
cells. HMEC-1 cells express cell surface molecules typically associated with endothelial cells, 
including CD31 (PECAM-1) and CD36. CD31 is the only known ligand for CD38 (84), which is 
expressed by CLL cells and is a negative prognostic marker. The HMEC-1 cells also express the cell 
adhesion molecules ICAM-1 and CD44 and following stimulation with IFN-gamma, express major 
histocompatibility complex class II antigens. HMEC-1 cells also specifically bind lymphocytes in cell 
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adhesion assays (85). The studies described above demonstrate that because of the diversity of 
endothelial cells that are used in in vitro models, it may be more important to determine which 
effects occur in common when different endothelial cell lines are used in co-culture systems. 
Endothelial models have been used to study mechanisms in other haematological malignancies, 
such as the importance  of VCAM-1 in Hairy Cell Leukaemia (HCL) (86) and cell adhesion-mediated 
immune resistance against cytotoxic T cell  lysis in Multiple Myeloma (MM) (87). 
 
1.2.9. The bi-directional effect of co-culture 
 
Co-culture has effects on the accessory cells as well as on the CLL cells. For example, Plander et 
al. (88) showed that CLL cells have an anti-apoptotic effect on the bone marrow stroma. Briefly, CLL 
cells were purified by flow cytometric sorting, which removed cells with glycophorin A, CD14, CD56 
and CD3 on their cell surface. Purified CLL cells were co-cultured with allogeneic, normal bone 
marrow stromal cells (BMSC) with or without CD40L, both resulted in CLL cells being rescued from 
apoptosis. The CLL cells up-regulated the expression of CD18 and CD49d, which are ligands for 
adhesion molecules found on BMSC. This may reflect what occurs in vivo since CLL cells from bone 
marrow aspirates express higher levels of CD49d compared with CLL cells from peripheral blood 
samples. The BMSC themselves increased secretion of IL-6 and IL-8 and up-regulated expression 
of ICAM-1 and CD40L mRNA. These studies demonstrate that CLL cells produce cytokines which 
can shape the microenvironment, resulting in bi-directional signalling between the different cell types 
in the co-culture system.  
1.2.10. Effect of co-culture on different CLL subtypes 
 
Co-cultures using various model systems provide the CLL cells with a cytoprotective effect when 
compared with liquid culture, regardless of the clinical features of the disease (16). However, there 
are some differences between CLL cells from patients with different clinical features when these 
cells are cultured alone in vitro. The percentage of CLL cells undergoing spontaneous apoptosis in 
vitro appears to be higher for samples from patients with unmutated (UM) IGHV compared with 
mutated (M) IGHV, and co-culture achieves a 2.2-fold increase in relative viability in M-CLL 
compared with a 6.1-fold increase in UM-CLL (65) with co-culture. This suggests that cells from UM-
CLL patients are more dependent on the microenvironment for support. However, it is unknown 
whether the same pathways are up-regulated as a result of co-culture or if there is a completely 
different mechanism in each of these CLL subtypes. Other studies have highlighted the different 
functions of clinically relevant proteins in CLL. For example, CD49d is thought to have important 
roles in homing (89). Expression of CD49d and CD38 are higher on CLL cells from the bone marrow 
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compared to those in the peripheral blood and die quicker in liquid culture. This may suggest that 
these cells are more dependent on the tumour microenvironment for survival than those cells found 
in the peripheral blood. 
1.2.11. Targeted therapies for CLL 
 
Targeted therapies are  medications which preferentially block the growth of cancer cells by 
interfering with specific molecules needed for carcinogenesis and tumour growth (90), rather than 
affecting all dividing cells as with traditional chemotherapy. The paradigms for such therapies are the 
development and use of all-trans retinoic acid (ATRA) for treating patients with acute promyelocytic 
leukaemia (APML) (91), Gleevec/Imatinib Mesylate for treating patients with Chronic Myeloid 
Leukaemia (CML) (92) and monoclonal antibody therapies for HER2 positive breast cancers (93). 
Traditionally, CLL was treated with chemotherapy including purine analogues such as fludarabine 
(F) and alkylating agents such as cyclophosphamide (C). Recent advances in the treatment of CLL 
have seen the introduction of monoclonal antibody therapies, including alemtuzumab (directed 
against CD52), rituximab (R) and ofatumumab (directed against CD20). Modern regimens combine 
chemotherapy with monoclonal antibodies such as FC, FR, FCR and CHOP (cyclophosphamide, 
doxorubicin- anthracycline, vincristine- mitotic inhibitor and prednisolone-corticosteroid), which 
produce a synergistic effect on CLL cells (94).  
CLL is currently incurable even with combination therapies which have improved response rates but 
not overall survival, because the disease becomes resistant to the therapy being used. Therefore, 
novel therapies. Targeted therapies are particularly attractive prospects for the treatment of patients 
with complicated disease, including 17p deletion, TP53 mutation, fludarabine-refractory CLL and 
those with suboptimal response to treatment. A personalized approach to treatment is likely to be 
important for CLL patients given the heterogeneity in both clinical manifestations and prognosis of 
the disease. For example, a Bruton’s Tyrosine Kinase (BTK) inhibitor has been used to treat patients 
with relapsed disease, leading to a high frequency of durable remissions (95). It is hoped that a 
better understanding of novel aspects of CLL biology can lead to the rational design of other agents 
and combinations of agents which specifically target the pathophysiology of the disease, resulting in 
more effective and less toxic therapies. Some targeted therapies currently under investigation are 











protein Bcl-2 is over 
expressed in CLL and 
results in chemo-
resistance (96).  
BH3 mimetic, small 
molecule binds with 
high affinity to Bcl-2, 







Cyclin D1 is over 
expressed in  a subset 
of CLL (99), cyclin D2 is 
over expressed in 
proliferation centres in 
CLL (100)  reducing 
threshold for cell cycle 
checkpoints.  
Caspase-3 activation, 
broad acting inhibitor 
including off target 
effects. Action is p53 
independent, 
therefore could be 
used in high-risk 
cytogenetic features 






BCR signalling provides 
growth signals to CLL 
cells (72, 103). 
Inhibition of Btk 
results in transient 
lymphoctosis, usually 
associated with a 






In CLL, the PI3K 
pathway is constitutively 
activated and dependent 
on PI3Kδ (106). 
Isoform-selective 
inhibitor of PI3Kδ that 
inhibits PI3K 
signalling and 
induces apoptosis of 
CLL cells.  
(107) 
Fostamatinib Syk inhibitor BCR signalling activates 
Syk, which leads to 
downstream signalling 
promoting cell survival 
and growth (108). 
Blocks BCR 
signalling, inhibiting 






Other potential therapies target accessory cells rather than the CLL cells directly, for example, the 
immunomodulatory drug lenalidomide. CLL cells like malignant cells in other cancers modify the 
immune microenvironment to block effective host anti-tumour responses. CD4 and CD8 T cells from 
patients with CLL exhibit exhaustion (120) and globally impaired LFA-1-mediated migration (43) and 
this defect is mediated by direct tumour cell contact. Treatment with lenalidomide was shown to 
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Hsp90 expression data 
in CLL cells is equivocal 
(115, 116). However, 
CLL cells over express 
several Hsp90 client 
proteins making CLL 





cytoprotection and is 
highly synergistic 








regulatory proteins  that 
are aberrantly active 
in CLL e.g. p53, Bcl-2, 






activation of NF-B. 
(119) 
Table 1.2 Targeted therapies currently under investigation in CLL. 
Targeted therapies currently under investigation in CLL. 
38 
 
1.3  Systems Biology and Bioinformatics 
 
Denis Noble, one of the pioneers of Systems Biology has said that “Systems biology...is about 
putting together rather than taking apart, integration rather than reduction...” and “ It means changing 
our philosophy, in the full sense of the term" (121). 
Historically, scientific research has focussed on individual proteins or protein complexes and how 
they interact in a static time-frame in a particular cellular localisation. This is known as a reductionist 
approach and provides little information about the dynamic and temporal context in which these 
protein:protein interactions may occur. Systems Biology combines a series of overlapping concepts 
to integrate complex data from a number of diverse data sources and disciplines in a holistic 
approach (122) and shown in Figure 1.4. For the cellular proteome, analyses are carried out at 
various levels from individual protein:protein interactions, to networks of potential protein:protein 
interactions right through to the dynamics of these interactions and regulation of their encoding 
mRNA and gene expression. These studies may incorporate wet-laboratory experiments, including 
proteomics using high-content mass spectrometry, microarrays to monitor the expression levels of 
mRNA transcripts or RNA deep sequencing to analyse transcriptomes (123). These datasets are 
interrogated using ever more sophisticated bioinformatics methods. The application of these 
techniques results in a greatly increased volume of complex, interconnected data and an 
understanding of the cell as a complex system (124)(125). Once a biological system can be 
modelled, the ultimate aim of Systems Biology is to predict how the molecular behaviour of a cell will 
change in a certain environment, in response to a particular stimulus or when a component protein is 









Figure 1.4 Schematic of 
Systems Biology. The 
interface between life 
sciences, physical sciences, 






The concept of Systems Biology is being utilised to analyse and make intelligent use of high 
throughput, data-rich, ‘omics’ experiments in order to better understand the complexity of cell 
functions, which may potentially lead to improvements in our knowledge of health and disease. One 
aim of my Thesis is to apply Systems Biology approaches to obtain a better understanding of the 
behaviour of CLL cells as a complex biological system (126, 127). 
Bioinformatics, the application of statistics and computer science to the study of biology, is at the 
centre of Systems Biology. Bioinformatics requires databases, algorithms, computational and 
statistical techniques to solve problems arising from the management and analysis of biological 
data, such as analyses of gene expression datasets and of high throughput mass spectrometry 
experiments. Large scale post genomic experiments require powerful tools in order to analyse and 
make sense of the high throughput data. Bioconductor (www.bioconductor.org) (128) is open 
source, open development software which uses the R statistical programming language to handle 
and analyse large data sets. It may be used for microarray analysis, high throughput datasets (such 
as mass spectrometry), sequence data and annotation of data (combining and converting multiple 
formats).  
1.3.1. Protein:protein interaction networks 
 
There is currently a great deal of interest in protein:protein interaction networks. Their appeal lies in 
their ability to integrate multiple data types, often from high throughput screens, which may be 
interrogated to identify novel targets for research and to provide a visual display of such data. 
Networks may be built based on high throughput screens such as yeast two-hybrid assays (which 
are able to detect a binary interaction between proteins). This technique has come under much 
criticism due to its high false positive rate (129). Other predictive protein: protein interaction 
networks are built on the knowledge of interactions of proteins in other organisms, which is then 
used to predict data on orthologous human proteins. Additional data on domain-domain interactions, 
co-occurrence and co-expression of genes can also be used.  OPHID (130) and HomoMINT (131) 
both integrate data from protein:protein interactions in other organisms with predicted data on 
orthologous human proteins. A third method for creating networks employs data-mining, whereby 
protein interaction networks are based on literature searches. These databases may be created 
using language processing algorithms or curated manually, for example the GeneGO platform. 
A combination of data are used by HumanNet (132), which is a probabilistic functional gene network 
created by our collaborators, Professor Marcotte’s laboratory at the University of Texas at Austin 
which uses modified Bayesian integration of literature mining along with many different data types 
from different organisms. Each data type is weighted according to how well it is able to link genes 
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known to function together in H.Sapiens. The weighting of different types of data reduces the effect 
of bias upon a network and the different types of evidence used by HumanNet are shown in Table 
1.3. 
Networks generated by such algorithms may be used to create predictions of important 
protein:protein interactions in order to provide a guide or focus for a research project. It is now 
possible to begin the search for novel potential regulators of an important pathway or process before 
beginning any wet-laboratory experiments. It is widely regarded that the value of such networks lies 
in their selective use and validation of components predicted to be of functional importance by wet-
laboratory experiments. A good example of this is the application of the Phenolog method (133). 
This method is based on the fact that many functionally important genes are conserved in different 
species. Phenologs are identified by mapping orthologous genes between species in which deletion 
of the orthologues leads to characteristic phenotypes in each organism. Orthologues are genes in 
different species which are descended from a single gene in an ancestral organism (134). However, 
the phenotype produced by gene deletion may be different in each organism and while proteins 
encoded by conserved groups of genes may still work together, they lead to different phenotypes in 
different species. A breakthrough study using the Phenolog approach was reported in the New York 
Times, where the method predicted a yeast model for mammalian angiogenesis (133) and recently, 
this method was used in a project that re-positioned/re-purposed thiabendazole, an anti-fungal drug 
to inhibit neo-vascularisation (135).  
Co-citation of worm gene  
Co-expression among worm genes  
Worm genetic interactions  
Literature curated worm protein physical interactions  
High-throughput yeast 2-hybrid assays among worm genes  
Fly protein physical interactions  
Co-citation of human genes  
Co-expression among human genes  
Co-occurrence of domains among human proteins  
Gene neighbourhoods of bacterial and archaeal orthologues of human genes  
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Literature curated human protein physical interactions  
Human protein complexes from affinity purification/mass spectrometry  
Co-inheritance of bacterial and archaeal orthologues of human genes  
High-throughput yeast 2-hybrid assays among human genes  
Co-citation of yeast genes  
Co-expression among yeast genes  
Yeast genetic interactions  
Literature curated yeast protein physical interactions  
Yeast protein complexes from affinity purification/mass spectrometry  
Yeast protein interactions inferred from tertiary structures of complexes  




1.3.2. Gene expression profiling 
 
The principle of gene expression profiling is based on complimentary base pairing or hybridisation 
(see: http://www.ncbi.nlm.nih.gov/About/primer/microarrays.html). DNA probes are manufactured so 
that in theory each probe sequence only occurs once in the genome. Thousands of different probes 
are arrayed or synthesised on a surface and typically each array (chip) contains several probes 
corresponding to each transcript of every protein encoding gene. RNA is extracted from the cell of 
interest, copied to cDNA or cRNA and washed over the probe sets. If the sequence of RNA bases 
matches a probe, the sample will bind to the probe. A fluorescent dye is then washed over the probe 
and laser light is used to visualise the fluorescent stain. Fluorescence is therefore correlated with 
gene expression. Fluorescence is then quantified against a background fluorescence reading from 
mismatched probes using a statistical package, such as Bioconductor.  
Important points to consider when analysing gene expression data include the promiscuity of the 
probe set being used. In practice, a specific probe will not always bind to a unique sequence within 
the genome. Promiscuous probes bind multiple sequences within the genome and therefore these 
Table 1.3 Evidence used to construct HumanNet. A probabilistic functional 





data cannot be used in further analyses. It is good practice to check the specificity of each probe 
used by running a Basic Local Alignment Tool (BLAST) search.  
A bioinformatic package such as Biomart (www.biomart.org, a data integration system) may then be 
used in further analyses of the data created. Biomart is used to convert between proprietary probes 
(such as Affymetrix
®
) and their corresponding gene identifiers (IDs), such as Ensembl IDs or Entrez 
IDs. Depending on the downstream use of these data, multiple identifiers may be required. This time 
saving application is one of the strengths of using a high throughput programme. Care must be 
taken when converting between identifiers as these do not map uniquely. One Affymetrix
®
 probe 
may map to several Ensembl identifiers, which may map to several Entrez identifiers. Therefore it is 
good practice to verify ID conversions independently of automated versions, for example using 
http://www.genecards.org/. Genecards is a searchable, integrated database of human genes that 
provides concise genomic related information on all known and predicted human genes using 
standard nomenclature and approved gene symbols. 
 
1.3.3.  Gene ontology annotation 
 
The Gene Ontology (GO) project is a bioinformatics initiative which aims to ‘standardise the 
representation of gene and gene product attributes across species and databases’ (136). A 
controlled vocabulary is used to describe gene products and gene characteristics. GO annotations 
include the gene product identifier, a GO term, the reference used to make the GO annotation such 
as a journal article, an evidence code which describes the type of evidence upon which the 
annotation was based and the date and creator of the annotation. GO terms may refer to a process 
(GOP), a function (GOF) or a cellular component (GOC). For example, using the appropriate GO 
terms, a search may be carried out for gene products with a particular cellular localisation (through 
GOC) and which are involved in a certain function (GOF). GO is structured as a ‘tree’ with parent 
and child terms (see Figure 1.5 for an illustration).  
GO terms should be treated with caution. Incomplete annotation can be misleading and some gene 
products remain un-annotated. Some GO terms have extremely broad definitions, rendering them of 



























1.3.4. Cellular localisation prediction algorithms 
 
Other bioinformatic tools use statistical analyses in order to make predictions about gene products. 
Examples of this include the prediction of transmembrane and secreted proteins. Statistical methods 
for predicting transmembrane helices use hydrophobicity analysis. A stretch of about twenty amino 
acids may indicate that these amino acids are part of an alpha helix spanning a lipid bilayer, which is 
composed of hydrophobic fatty acids. Hydrophilic amino acids following this sequence are likely to 
be in contact with aqueous environments and are therefore likely to be present either on the outer 
surface of the cell or as part of an intracellular tail. A second common analysis used in the prediction 
of transmembrane helices is the abundance of positively charged amino acids on the cytoplasmic 
side of the membrane. This is known as the ‘postive inside rule’ (137). 
 
all : all [446404 gene products]  
  
GO:0005575 : cellular_component [303782 gene products]  
o  
GO:0005623 : cell [215774 gene products]  
  
GO:0044464 : cell part [215737 gene products]  
  
GO:0016020 : membrane [77561 gene products]  
  
GO:0044425 : membrane part [52378 gene products]  
  
GO:0031224 : intrinsic to membrane [44628 gene products]  
  
GO:0016021 : integral to membrane [43502 gene products]  
  
GO:0005887 : integral to plasma membrane [3989 gene 
products]  
Figure 1.5 GO ontology hierarchy. An example of a search for gene products 
‘integral to plasma membrane’. Each layer of description results in a smaller number 





Transmembrane Hidden Markov Model (TMHMM http://www.cbs.dtu.dk/services/TMHMM/) is 
perhaps the most well-known transmembrane prediction algorithm. It combines hydrophobicity, 
charge bias, helix length and grammatical constraints to correctly predict 97-98% of transmembrane 
helices (138). It can also discriminate between soluble and membrane proteins at 99% accuracy, 
although this accuracy drops when a signal peptide is present. TMHMM predicts that 20-30% of all 
genes in most genomes encode membrane proteins. However, membrane proteins are notoriously 
difficult to characterise in wet–laboratory experiments due to their structure, requiring solubilisation 
and stabilisation. This means that transmembrane proteins are grossly underrepresented in 
databases of known proteins, especially in databases with structural information. 
Other subcellular localisations of proteins can be predicted on the basis of amino acid sequence. 
Tools include: 
TaretP (http://www.cbs.dtu.dk/services/TargetP) for secretory peptides, mitochondrial targeting 
peptides and chloroplast transit peptides,  
SignalP3.0 (http://www.cbs.dtu.dk/services/SignalP) for secretory signal peptides in eukaryotes, 
Gram-negative and Gram-positive bacteria, 
big-Pi (http://mendel.imp.ac.at/sat/gpi/gpi_server.html) for  GPI membrane anchors 
PredictNLS (http://www.predictprotein.org) and NucPred (http://www.sbc.su.se/~maccallr/nucpred) 
to predict nuclear localisation signals in eukaryotes.  
When screening for unknown transmembrane or signal peptides, a combination of different 
algorithms should be used to maximise the number of proteins identified. 
1.3.5. Membrane protein enrichment  
 
Low abundance membrane proteins must be enriched from cell extracts before they can be 
analysed using proteomic tools. Methods available for enriching membrane proteins from cell 
extracts include subcellular fractionation, de-lipidation and affinity purification. 
The stability of the non-covalent interaction between avidin and biotin (Kd 10
-15
 M) has been 
exploited in many applications and is commonly used in chemistry and biology. Methods for 
modification of molecules with biotin have been used to allow protein recovery, immobilization and 
detection using avidin-based reagents. The study of cell surface proteins is one major area which 
has greatly benefited from this application. A reactive ester such as an N-hydroxysuccinamide 
(NHS) group is used to covalently link biotin to the molecule of interest. NHS undergoes a 
nucleophilic substitution reaction in the presence of primary amines, such as the amino group in 
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exposed lysine residues in proteins. The presence of a charged group in sulfo-NHS-biotin renders 
the reagent membrane impermeable, allowing the labelling of cell surface proteins only. This type of 
reagent has been used in a number of studies, including the isolation of viruses to increase effective 
titre (139) and analyses of individual cell surface proteins and identification of components of the cell 
surface proteome (140). The use of cleavable spacers has been introduced to some reagents with 
the aim of facilitating the release of biotinylated proteins after capture on immobilized avidin. The 
most common cleavable group is a disulfide bridge that can be broken by reducing agents such as 
dithiothreitol (DTT). Figure 1.6 schematically summarises one method of concentrating membrane 
proteins that utilises the biotin-avidin interaction. 
 
 
1.3.6. Protein identification by mass spectrometry 
 
Mass spectrometry (MS) is a powerful tool in proteomics and can be used to identify proteins 
present in a complex mixture, such as those produced using a biotin-avidin capture system (see 
Figure 1.6). Two experimental approaches are commonly used in MS experiments. In the first 
method, biochemical fractionation methods are used to separate individual proteins present in cell 
lysates prior to MS analysis. Complex protein mixtures of a cell lysate may be separated by gel 
electrophoresis, such as SDS-PAGE or 2-dimensional (2-D) gels, which separate proteins based on 
size (SDS-PAGE) and pI (isoelectric focussing, IEF). Bands or spots at the size and pI of interest or 
bands/spots that are different in experimental compared with control samples are cut out form the 
gel. The protein(s) contained in the gel slice are digested by a proteolytic enzyme such as trypsin 
using an ‘in gel’ digestion method. The tryptic peptides are then separated by High Performance 
Liquid Chromatography (HPLC) (usually referred to as liquid chromatography (LC)) to reduce 
sample complexity by separating the peptides prior to MS analysis. The tryptic peptides are 




reconstituted in a mobile phase, which is forced at high pressure through a column that contains the 
stationary phase particles with a particular surface chemistry (this varies depending on the type of 
HPLC being performed). The motion of the peptides in the mobile phase is retarded by interactions 
with the stationary phase. The time taken for an analyte to elute from the column is the ‘retention 
time’. Analytes with different properties have different retention times, allowing unknown analytes to 
be separated. 
The second common method used in MS experiments involves the digestion of all proteins in a cell 
lysate with trypsin, in a process known as ‘in solution’ digestion, releasing a complex mixture of 
thousands of peptides. The peptides can then be separated by one-dimensional LC, such as a C18 
reverse phase column, or by two-dimensional LC, for instance employing a cation exchange column 
followed by a C18 column. The separated peptide mixtures are then analysed by MS.  
In the next stage of MS analysis, the tryptic peptides are ionised in the MS machine, causing 
fragmentation of peptides into charged ions (141). Two common ionization techniques are 
Electrospray Ionisation (ESI) or Matrix Assisted Laser Desorption Ionisation (MALDI). These peptide 
ions are then introduced into the mass analyser using an electric field and the ions are sorted 
according to their mass to charge ratio (m/z). An identification of the amino acid composition of 
peptides analysed helps increase the number of identifications made. In effect, this is peptide 
sequencing and can be achieved by selecting peptides individually in the ion trap and fragmenting 
each one by collision-induced dissociation (CID). In CID, the molecular ions are accelerated by an 
electrical potential and allowed to collide with molecules of either helium, nitrogen or argon. The 
collision results in bond breakage and the fragment ions can then be analysed to give an accurate 
amino acid composition.  
Two Orbitrap mass spectrometers were used in the study, the LTQ-Orbitrap (142) and the Velos 
Pro-Orbitrap (143).  The LTQ quadrupole linear ion trap instrument (Thermo Finnegan) collects and 
traps ions in a plane between electrodes. When a specified number of ions have been collected (or 
after a defined time) the ions are ejected from the trap. In the LTQ instrument, the rate of increase in 
the ejection voltage allows different m/z ions to be ejected at different times and analysed, which 
creates an MS spectrum. The ions ejected from the LTQ are then directed into the Orbitrap, which 
increases the accuracy of the m/z measurements. The second mass spectrometer used in this study 
was a Velos Pro-Orbitrap machine. This uses an improved Velos ion trap as the front end rather 
than the LTQ described above.  
Ions trapped by the LTQ or the Velos are subsequently injected into the Orbitrap. The Orbitrap uses 
an oscillating electrostatic field between two non-linear electrodes, ions oscillate around the central 
electrode and the frequency of oscillation is inversely proportional to the square root of the m/z. This 
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machine has a high mass accuracy (1ppm for the Velos Pro-Orbitrap), improved resolution and 
dynamic range over previous ion trap technologies and is easy to use for routine analyses and a 
wide dynamic range (144, 145).  
Trypsin digestion of proteins results in cleavage at specific amino acids, namely at the carboxyl side 
of lysine or arginine, except when these residues are followed by proline. Using a process known as 
peptide mass fingerprinting  (146), the spectra produced are compared against an online database 
of peptides generated from a predicted digest of all known proteins for a given organism (e.g. using 
MASCOT or SEQUEST (147)).  
 
1.3.7. Quantification of protein expression in mass spectrometry 
 
Quantification of differences in protein abundance by mass spectrometry is technically challenging. 
The MS signal intensity or peak height of a peptide does not correlate directly with the abundance of 
the protein. Different peptides have a different tendency to ionise due to their different chemical 
structures and properties. The chemical environment also affects ioinzation efficiency (148), such as 
the buffers used to dissolve the peptides before MS analysis. Therefore it is possible that a low 
abundance protein may be interpreted as high abundance because some of its peptides are more 
easily ionisable and so detected more frequently than those derived from other proteins. For these 
reasons, until recently only a fraction of the thousands of MS studies published provided a 
comprehensive quantification by MS and reports quantifying proteins in mixtures reliably are even 
more  limited (149). 
Advances are being made towards quantitative proteomics including relative and absolute 
quantification. One technique used for relative quantification requires in vivo stable isotope labelling 
prior to MS analysis. For example, ‘Stable Isotope Labelling with Amino acids in cell Culture’ 
(SILAC) (150). In this approach, two different samples are cultured in media containing amino acids 
labelled with different isotopes, such as ‘heavy’ 
13
C-arginine and ‘light’ 
12
C-arginine respectively. The 




C-arginine into all newly-synthesised proteins. Protein 
lysates from these cultures can be pooled and analysed together by MS. MS analysis can 
distinguish the same peptides from the two different cell cultures, because they will have different 
m/z values and the different characteristic MS spectra can be used for relative quantification (151). 
Another in vitro labelling technique is iTRAQ (isobaric Tags for Relative and Absolute Quantification) 
(152). This method uses isotope-coded covalent tags, each of which fragments in the mass 
spectrometer to produce a distinct fragmentation m/z pattern. The ratio of peak intensities for a given 
protein can then be used for relative quantification between experimental conditions. The labelling 
48 
 
allows a 4-plex or 8-plex format, enabling 4 or 8 experimental samples to be compared in the same 
MS run. As an example, the iTRAQ method has been used to investigate the effects of Imatinib 
treatment on CML cells and identify potential protein markers for response to Imatinib treatment 
(153). 
Label-free quantification methods are also advancing protein quantification in mass spectrometry. 
This approach harnesses statistical methods such as Absolute Protein Expression (APEX), which 
was developed by Professor Marcotte, our collaborator at the University of Texas at Austin (154). 
Previous label-free quantification approaches had concentrated on measuring the peak height of the 
peptide and did not take into account other information such as the peptide count. However, the 
peptide count can be used to provide further information as larger proteins will contribute more 
peptides than smaller proteins to an analysis (154). Therefore, the probability of observing a peptide 
from a larger protein is higher than that of the smaller protein and this may lead to an overestimation 
of the abundance of large proteins without normalisation. The APEX method includes a correction 
factor for each protein, which accounts for variable peptide detection by MS techniques. It corrects 
the observed peptide count (sampling depth) which has been biased by the MS technique by a pre-
calculated estimate of the number of peptides which would be generated if a bias did not occur. This 
APEX tool provides a Z score for the identification of statistically significant differences in protein 
abundances between samples and has been successfully applied in our recent study, which 
quantifies changes in chromatin and nuclear matrix-bound proteins in human T cells during entry 





The aim of my PhD project was to apply Systems Biology methods to answer biological 
questions about interactions between CLL cells and the tumour microenvironment, including: (i) 
the effects of co-culture model systems on primary CLL cell viability and phenotype, (ii) 
investigating the transcriptional effects of endothelial cell co-culture on primary CLL cells, 
particularly control mechanisms responsible for co-ordinated gene expression and (iii) a 
systematic identification of primary CLL cell surface proteins. Increasing our knowledge of CLL 
biology provides more potential targets for rational therapeutic intervention. 
The study in Chapter 3 and recently published in the British Journal of Haematology, focuses on 
the effects of co-culture on primary CLL cells. CLL cells undergo apoptosis when cultured in the 
laboratory away from the supportive tumour microenvironment found in the body. In Chapter 3 a 
direct comparison of the effects of different co-culture systems on primary CLL cells is made. 
The effects of interactions between primary CLL cells and endothelial cells (HMEC-1), and with 
mouse fibroblasts expressing the human proteins CD40L (expressed on activated T cells) or 
CD31 (expressed on endothelial cells), are compared using cell based assays. 
The study in Chapter 4 examines the mRNA changes which occur when cells from CLL patients 
are co-cultured with an endothelial cell line, HMEC-1 and the primary endothelial cells, HDBEC. 
Based on the observation that both co-culture systems improved CLL cell viability and induced a 
similar phenotype in CLL cells, I sought to determine whether there were mRNA changes which 
occurred in the cells from all CLL patients as a result of co-culture. The rationale behind these 
biofinformatic analyses was that any mRNA or pathways up-regulated in both systems may 
represent cellular mechanisms which the CLL cells have become addicted to and rely upon for 
survival and therefore present targets for intervention.  
The final study in Chapter 5 focuses on identifying cell surface proteins on primary CLL cells 
which may be required for cell:cell contacts made in the tumour microenvironment and therefore 
may be important to receive signals which can result in the transcriptional changes observed in 
Chapter 4. I developed methods to identify cell surface proteins by MS using HeLa cells, as a 
test cell. I then applied these methods to analyse the cell surface proteins isolated from primary 







Aims of thesis: 
 To investigate the effects of different co-culture models on the viability of primary CLL cells. 
 To investigate common transcriptional effects induced in CLL cells by endothelial cell co-
culture. 
























Chapter 2  

















2.1.1. General chemicals, consumables and kits  
7-amino-actinomycin (7AAD) BD Bioscience 
Acetonitrile (ACN)  Sigma 
Annexin V-FITC BD Bioscience 
Anti-CD3/CD28 immunomagnetic beads (Dynabeads) Invitrogen, Life Technologies 
Anti-mouse IgG immunomagnetic beads (Depletion 
Dynabeads) 
Invitrogen, Life Technologies 
Bovine serum Albumin (BSA) Sigma 
Bromophenol Blue  Sigma 
Cell Surface Protein Isolation Kit, comprising: 
EZ-Link Sulfo-NHS-SS-Biotin,  
Quenching Solution,  
Lysis Buffer,  
NeutrAvidin Agarose,  





Collection Tubes  
Pierce (Thermo Scientific) 
Coomassie brilliant blue R250  Pierce (Thermo Scientific) 





Dithiothreitol (DTT) Sigma 
Dulbecco’s Modified Eagle Medium (DMEM) Sigma 
ECL plus Chemiluminescent Western Blot Detection 
Kit 
GE Healthcare 
1.5ml microcentrifuge tubes 
0.5ml micocentrifuge tubes 
Starlabs 
EasySep Human B Cell Enrichment Kit without CD43 
depletion 
STEMCELL Technologies 
Endothelial Cell Growth Medium Promocell 
Ethanol  Fisher Scientific 
15ml and 50ml Falcon tubes  VWR international 
5ml FACS tubes BD Biosciences 
0.2µm filter TPP, Helena Bioscience 
Fixation/Permeabilisation concentrate eBioscience 
Fluorescein isothiocyanate (free FITC) Sigma 
Foetal bovine serum (FBS) Sigma  
GeneChip Human Gene 1.0 ST Array Affymetrix 
GeneChip WT Expression Kit (Buffers proprietary 
composition) 
Ambion 
GeneChip WT Terminal Labelling Kit (Buffers 
proprietary composition) 
Affymetrix 
GeneChip Expression Wash, Stain and Scan Kit 





Histopaque 1077 Sigma 
Hybond- C Extra membrane GE Healthcare 
Hyperfilm ECL GE Healthcare 
Hypersep C18 Columns Thermo Scientific 
IGEPAL-CA-630 (Nonidet P40) Sigma 
Iodoacetamide Sigma 
M199 Medium Gibco 
Methanol  Fisher Scientific 
Mini-Protean TGX 4-15% (w/v) polyacrylamide gel Bio Rad 
Neubauer Improved Haemocytometer VWR international LTD 
Nitrocellulose membrane (Hybond C Extra) GE Healthcare 
Non-fat dried milk (Marvel) Sainsbury’s 
Novex sharp protein standards Invitrogen, Life Technologies 
NuPAGE gels, running and transfer buffer  Invitrogen, Life Technologies 
Paraformaldehyde (PFA) Sigma 
Penicillin Sigma 
Phosphate buffered saline (PBS) tablets  Oxoid  
Pre-separation filter, 30µm nylon mesh Miltenyi 
Propodium Iodide (PI) Sigma 
RNeasy kit Qiagen 
RNAse A Sigma 
Rosswell Park Memorial Institute medium (RPMI-1640) Invitrogen, Life Technologies 
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RNase Out Invitrogen, Life Technologies 
Single donor buffy coats/ cones National Blood Transfusion 
Service 
Streptomycin Sigma 
Trifluorethanol (TFE) Sigma 
T cell negative isolation kit  Invitrogen, Life Technologies 
Trizol Invitrogen, Life Technologies 
Trypsin Sigma 
Trypsin (proteomics grade) Sigma 
Tween-20 Sigma 
Whatman 3MM paper VWR international LTD 
X-ray film (Hyperfilm–ECL) GE healthcare 
X-Vivo 15 cell culture media Lonza 
Table 2.1 General chemicals, consumables and kits 
 
2.1.2. Buffers and solutions 
Cell cycle stain 40µg/ml Propidium Iodide, 5µg/ml Fluorescein 
isothiocyanate and 1µg/ml of RNase A in PBS 
Mini Complete Protease inhibitor 
cocktail tables EDTA free (serine 
and cysteine protease inhibitor) 
Roche proprietary composition 
Fixing solution 1% (w/v) PFA 
Fluorescein Isothiocyanate 
(FITC) 
1µg/ml in PBS 




1 x MES SDS running buffer 50mM MES, 0.1% (w/v) SDS, 1mM EDTA, 50mM Tris-
HCl pH 7.3 
MS buffer A 100% (v/v) H20, 0.1% (v/v) formic acid 
MS buffer B 100% (v/v) Acetonitrile, 0.1% (v/v) formic acid 
MS buffer C 95% (v/v) H20, 5% (v/v) Acetonitrile, 0.1% (v/v) formic 
acid 
1 x NuPage transfer buffer 25mM Bicine, 1mM EDTA, 25mM Bis-Tris pH 7.2, 20% 
(v/v) Methanol 
Phosphate Buffered Saline 
(PBS) 
1 tablet (phosphate buffer, 0.02% (w/v) potassium 
chloride, 0.8%(w/v) sodium chloride) dissolved per 100ml 
of H2O and autoclaved 
Phosphatase inhibitors  2mM β-glycerophosphate, 5mM NaF, 1mM Na3VO4, 
0.1μM okadaic acid 
Propodium Iodine (PI) 1mg/ml in dH2O 
RNAse A 10mg/ml in dH2O 
10% (w/v) sodium dodecyl 
sulphate (SDS) 
50g SDS dissolved in 500ml of dH2O 
2x SDS Lysis Buffer  125mM Tris-HCl pH 6.8, 4% (w/v) SDS, 40% (v/v) 
Glycerol, 200mM DTT and 0.002% (w/v) Bromphenol 
blue 
Secondary antibody incubation 
buffer 
10% (w/v) Non-fat dried milk, PBS, 0.05% (v/v) Tween-20 
Tris Buffered Saline (TBS) 25 mM Tris-HCl pH 7.2, 150 mM NaCl 
Western blot wash buffer PBS, 0.05% (v/v) Tween-20 




Endothelial Cell Growth Medium-
2 
2% (v/v) FBS, (5ng/ml) Epidermal Growth Factor, 
(10ng/ml) Basic Fibroblast Growth Factor, (22.5µg/ml) 
Heparin, (0.5ng/ml) vascular endothelial growth factor 
165, (20ng/ml) insulin-like growth factor, (1µg/ml)  
ascorbic acid, (0.2µg/ml) hydrocortisone 
HMEC-1 Medium M199 medium, 10% (v/v) FBS, 2mM L-glutamine, 
10µg/ml Endothelial cell growth supplement (ECGS), 
1µg/ml Hydrocortisone, 5µM 2-mercaptoethanol, 10ng/ml 
human epidermal growth factor (hEGF), 1µg/ml Ascorbic 
acid in M199, 0.5ng/ml vascular endothelial growth factor 
(VEGF), 10ng/ml insulin like growth factor 1 (IGF-1) 
Table 2.2 Buffers and solutions 
 
2.1.3. Antibodies for western blotting 
Antibody Clone or identifier Supplier 
BCL2  100/D5 Abcam 
CD5  MEM-32 Abcam 





Blood Service, Bristol, UK 
CD79B   CD79B Santa Cruz Biotechnology  
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Cdk6  C19 Santa Cruz Biotechnology 
Histone H3 Ab1791 Abcam 
HRP-conjugated rabbit anti goat 
antibody 
P 0449 DAKO  
HRP-conjugated goat anti rabbit 
antibody 
P 0448 DAKO 
HRP-conjugated goat anti mouse P 0447 DAKO 
MHC1  HC10 From Dr Linda Barber 
ZAP70  D1C10E Cell signalling 
technologies  
Table 2.3 Antibodies for western blotting 
 
2.1.4. Antibodies for flow cytomety 
Antibody  Clone or identifier Supplier  
CD3-FITC Okt3 eBiosciences 
CD5-PECy7 UCHT2 eBioscience 
CD11c-FITC KB90 Dako 
CD19-Pacific blue  48‐0199 eBioscience 
CD38-PE HB7 eBioscience  
CD44-PE IM7 eBioscience 
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CD49d-FITC Bu49 Serotec 
CD69-APC FN50 eBioscience 
CD69-PE FN50 eBbiosciences 
CD103-PE Ber-ACT8 Dako 
CD138-APC MI 15 Dako 
Ki-67-FITC 51-36524 BD Pharmingen 
Mouse isotype control PE IgG1 kappa Pharmingen 
Mouse isotype control PE IgG2a eBioscience 
ZAP70-FITC IE7.2 eBioscience 
Table 2.4 Antibodies for flow cytometry  
 
2.2 Cell culture 
 
2.2.1. Culturing HeLa cells 
 
HeLa, a human cervical cancer cell line (162) were cultured as an adherent monolayer in DMEM 
supplemented with 10% (v/v) FBS, 1% glutamine, 100U/ml penicillin, 100µg/ml streptomycin at 37
o
C 
in a humidified 5% (v/v) CO2 atmosphere. HeLa were passaged when they reached about 80% 
confluency. The cells were washed in 1x PBS, followed by the addition of trypsin to the adherent 
monolayer of cells. The cells were incubated at 37
o
C for 2-5 minutes until the cells began to detach. 
Approximately 5ml PBS containing 10% (v/v) FBS was added to the cells to quench the trypsin and 
cells were then centrifuged at 150 x Gmax for 5 minutes and the supernatant containing trypsin was 
removed. 




Adherent HMEC-1,  Human microvascular endothelial cells (85) were passaged when they reached 
about 80% confluency. The cells were washed in 1x PBS, followed by the addition of trypsin to the 
adherent monolayer of cells. The cells were incubated at 37
o
C for 2-5 minutes until the cells began 
to detach. Approximately 5ml PBS containing 10% (v/v) FBS was added to the cells to quench the 
trypsin and cells were then centrifuged at 150 x Gmax for 5 minutes and the supernatant containing 
trypsin was removed. For assays in Chapter 3, the cells were then resuspended in HMEC-1 media 
and seeded at a lower density and returned to the 37
o
C, 5% CO2 incubator in HMEC-1 media 
without antibiotics. For assays in Chapter 4, the cells were resuspended in Endothelial Cell Growth 
Medium 2. When co-culturing HMEC-1 and CLL cells, 1% (w/v) BSA was added to the prepared 
HMEC-1 media and filter sterilised using a 0.2 µM filter.  
2.2.3. Culturing primary endothelial cells 
 
HDBEC (from Professor Mark Peakman) and HDMEC (Promocell) primary endothelial cells were 
cultured in Endothelial Cell Growth Medium 2 at 37
o
C in a humidified 5% (v/v) CO2 atmosphere and 
trypsinised as described in section 2.2.2.  
2.2.4. Cryopreservation of cells  
 
Cells were frozen in liquid nitrogen and stored long term for use at a later date. The appropriate 
quantity of cells were pelleted by centrifugation at 200 x Gmax for 5 minutes and resuspended in a 
solution containing 50% (v/v) of the appropriate storage medium (either RPMI-1640 or DMEM, 
depending on cell type), 40% (v/v) FBS and 10% (v/v) DMSO. The cells were aliquotted into 
cryovials and frozen overnight at -80
o
C in a Nalgene Mr Frosty freezer container. The cryovials 
containing the frozen cells were then transferred to a liquid nitrogen storage vessel for long term 
storage. The liquid nitrogen storage is in the vapour phase, maintained and monitored as part of our 
accredited departmental Tissue Bank. 
2.2.5.  Reviving cryopreserved cells  
 
Frozen cells are revived by immediate thawing under warm water after retrieval from liquid nitrogen. 
Immediately after thawing, the cells are washed in PBS to remove the freezing mix, which contains 
DMSO. The cells are then transferred to the appropriate pre-warmed medium. 
2.2.6. Isolation of quiescent T cells 
 
Normal human T Cells were isolated from single donor Buffy Coats, recently superseded by 
Leukocyte Cones. Peripheral blood mononucleocytes (PBMCs) were obtained by density-gradient 
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separation using Histopaque 1077, the cells were centrifuged for 30 minutes at 560 x Gmax with no 
brake.  The PBMCs were then removed with a Pasteur pipette and washed in 50ml of PBS and 
centrifuged at 400 x Gmax for 10 minutes.  Platelets were removed by centrifuging twice in 50ml of 
PBS with 2% (v/v) FBS at 200 x Gmax.  Non-activated T cells were isolated from the PBMCs by 
negative selection using the T Cell Negative Isolation Kit, which contains antibodies against 
monocytes (CD14 and HLA Class II DR/DP), granulocytes (HLA Class II DR/DP), B Cells (HLA 
Class II DR/DP), NK Cells (CD16 a and b, CD56), erythroid cells (CD235a) and activated T Cells 





C with rotation for 20 minutes with 20μl of antibody mix per 1 x 10
7
 cells.  Unbound 
antibody was removed by washing with PBS/2% (v/v) FBS and centrifugation at 500 x Gmax for 8 
minutes.  Cells were resuspended at 1 x 10
7
/ml in PBS/2% (v/v) FBS with 100μl anti-immunoglobulin 
conjugated magnetic beads per 1 x 10
7
 cells and incubated at room temperature, with gentle rolling, 
for 15 minutes.  Bead clumps are dispersed with gentle pipetting and labelled cells were removed 
using a magnet (Dynal Magnetic Particle Concentrator).  The supernatant containing the non-
labelled quiescent T cells was transferred to a clean tube and collected by centrifugation.  T cells 
were cultured at 4 x 10
6
/ml in X-VIVO 15 with 10% (v/v) FBS.   
2.2.7. Culturing T Cells 
 
The quiescent (G0) T cells were generally cultured at 4 x 10
6
/ml in X-Vivo 15 with 10% (v/v) FBS, L-
glutamine (2mM final), penicillin (2,000 units per ml), streptomycin (2mg/ml) at 37
o
C in a fully 
humidified atmosphere of 5% CO2. 
2.2.8. Stimulation of quiescent (G0) T cells 
 
Where required, quiescent T cells were stimulated by the addition of anti-CD3/CD28 magnetic beads 
at a ratio of 0.5 beads/cell.  
2.2.9. CLL cell isolation 
 
An EasySep negative selection kit was used to enrich human B cells from patients with CLL without 
depletion of CD43. Bi-specific Tetrameric Antibody complexes (TAC) label unwanted cells by 
recognising antigens (CD2, CD3, CD14, CD16, CD56 and glycophorin A) expressed on T and NK 
cells. These complexes are then removed by dextran coated magnetic nanoparticles. PBMCs were 
obtained by density-gradient separation using Histopaque 1077, as described in 2.2.6 above for the 
isolation of T cells. The cells were centrifuged for 30 minutes at 560 x Gmax with no brake.  PBMCs 
were then removed using a Pasteur pipette and cells were re-suspended at a concentration of 5 x 
10
7
 cells/ml in PBS containing 2% (v/v) FBS. EasySep Negative Selection Human B cell enrichment 
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cocktail without CD43 depletion was then added at 50 µl/5 x 10
7
 cells,  mixed and incubated at room 
temperature for 10 minutes, after which the cell suspension was brought up to a total volume of 2.5 
ml with PBS containing 2% (v/v) FBS to remove unbound antibody. The magnetically labelled 
unwanted cells are removed using a magnet. The negatively selected, enriched B cells remain in the 
supernatant. 
2.2.10. CLL Patient Samples  
 
PBMCs were collected and cryopreserved as previously described (52) from randomly selected 
patients with confirmed CLL. PBMCs were isolated by density gradient separation, as described in 
2.2.6 (Histopaque-1077). Cells were either processed fresh or cryopreserved in RPMI 1640, 40% 
(v/v) FBS and 10% (v/v) DMSO as previously described (52). Ethical approval was obtained from the 
local institutional review board of King’s College Hospital NRES Reference 08/H0906/94+5 (see 
appendix for Participant Information Sheet) and in every case, informed written consent was 
obtained.  
 
Table 2.5 Patient samples used in this study (Non routine diagnostic data provided by Dr 
Najeem Folarin) 





Status Serotype FISH Cytogenetics
LSL/004448 A
LSL/004467 C 52 unmutated IGHV: 1-2 Identity: 100% IGHD: 6-19 IGHJ: 4





LSL/004513 B 57 unmutated IGHV: 1-69 Identity: 100% IGHJ: 3 IGHD: 3-16 normal (p53 mut)
45,XY,del(1)(q42q44),add(17)(
p11),-18 [3]46,XY [27]
LSL/004539 A 35 normal normal
LSL/004589 A 48 mutated IGHV: 4-34 identity: 95.89%  IGHJ: 6 IGHD: 6-13 normal 46,XX,add(19)(q13)[3]46,XX [7]
LSL/004631 B 96 mutated IGHV 3-21 Del one copy 13q14.3 normal
LSL/004635 A 1.5
LSL/004654 A 1
LSL/004749 B 3 mutated IGHV: 3-23 Identity: 86.5% IGHD: 6-19 del 13q14.3 normal
LSL/005030 85 unmutated IGHV: 5-51 Identity: 98.7 Trisomy 12 46,XY [15]
LSL/005033 C 22 unmutated IGHV: 4-4 identity: 100% IGHJ: 6 IGHD: 1-7 47,XY,+12,del(14)(q24q32) [15]
LSL/005195 0 mutated
LSL/005417 A 49
LSL/005502 A 1 del 13q14.3 
46,XX,del(13)(q14.1q14.3) 
[12]46,XX [18]
LSL/005539 A 2 unmutated IGHV: 2-70 Identitiy: 100% IGHD: 3-3 IGHJ:4  Del 13q14.3
46,XY,del(13)(q14.1q14.3) 
[6]46,XY [9]
LSL/005750 B 44 normal normal
LSL/006022 B 98 mutated IGHV: 1-8 Identity: 95.4% IGHJ: 5 IGHD: 3-9 Del one copy of p53 normal
LSL/006171 A 49 unmutated IGHV:4-34 Identity: 100% IGHD:6-19 IGHJ:5 Del 13q14.3  del TP53 45,XY,add(5)(q13),-17 [12]
LSL/006811 B 98 unmutated IGHV:1-69 Identity: 100% IGHD:2-21 IGHJ:3 Trisomy 12 detected 
LSL/006917 49 unmutated
LSL/007739 43 unmutated VH4-39




CLL PBMCs were cultured at 2 x 10
6
/ml in HMEC-1 recommended medium in Chapter 2 and 
Endothelial Cell Growth Medium 2 in Chapter 3, each with 2mM L-glutamine, 2,000 units per ml 
penicillin, 2mg/ml streptomycin, 1% (w/v) BSA. Cells were incubated at 37
o
C in a fully humidified 
atmosphere of 5% CO2. 
 
2.2.12. CLL co-culture conditions 
 
HMEC-1, HDMEC and HDBEC were seeded at 1 x 10
5
/ml in 24 well plates in the recommended 
medium and incubated overnight to allow cells to adhere. CLL PBMCs were cultured alone and on 
endothelial cells at 2 x 10
6
 cells/ml, as previously described (1) and harvested at the time points 
indicated. 
2.3  Flow cytometry 
 
2.3.1. Analysis of the cell cycle by flow cytometry 
 
The percentage of cells in each phase of the cell cycle was determined by analysing the DNA and 
total protein content, as used for previous studies in our laboratory e.g. (163). 2 x 10
5
 cells per 
sample were collected by centrifugation at 200 x Gmax for 5 minutes. 2 x 10
5
 T cells were taken at the 
indicated time points and were fixed in 500μl of 70% (v/v) ethanol. The fixed cells were then 
centrifuged in FACS tubes at 350 x Gmax for 8 minutes and the supernatant was removed. The cell 
pellet was resuspended in 400μl FITC/PI cell cycle stain, which contains DNAase-free RNAase. 
RNA in the sample was digested for 30 minutes at 37ºC. Flow cytometric analysis was then 
performed using a Becton Dickinson FACS Calibur machine. The WinMDI2.9 or FlowJo program 
was used to analyse the data. Cells which pass the flow cytometer laser as doublets or aggregates 
were excluded from the analyses. This was done as, for example doublets of cells in G0/G1 will have 
2 x 2n DNA content and will therefore be quantified as being in G2/M and having 1 x 4n DNA 
content. To avoid the artefact that the doublets will be scored as being in G2/M rather than in G0/G1, 
a doublet discriminator gate was applied in all flow cytometry analyses. The principle is that total 
fluorescence detection, which is equivalent to the area under the curve (FL2-A Area), is proportional 
to the time that a cell needs to pass a detector (FL2-W Width). Doublets will have a much larger 
FL2-W, due to their bigger size. Therefore plotting the area (FL2-A) against width (FL2-W) and 
applying a gate around cells with a correct pulse width corresponding to single cells, excludes the 
doublet events. PI (FL-2A) was then plotted against FITC (FL-1H), which quantifies total protein 
content and is a surrogate measure of cell size (see Figure S1C of  Orr et al. (155)). The 
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percentages of cells in each cell cycle phase were calculated by manually applying gates around 
populations of cells in G0, G1, S phase, G2/M and apoptosis. Cells undergoing apoptosis typically 
have a DNA content <2n (also known as sub-G1). 
2.3.2. Determination of the activation state of T cells 
 
Quiescent T cells were stimulated with CD3/CD28 beads overnight and harvested by centrifugation 
at 200 x Gmax for 5 minutes. Cells were then resuspended in 100 µl PBS at a concentration of 1- 2 x 
10
6
 cells/ml and stained with anti-human CD69-PE or PE-labelled isotype-matched control at 4
o
C for 
30 minutes. Expression of CD69 was determined by flow cytometric analysis using a Becton 
Dickinson FacsCalibur instrument.   
2.3.3. Flow cytometric analysis of cell surface antigens 
 
Phenotypic analyses were performed on cells isolated from CLL patient samples by flow cytometry. 
2 x 10
5 
cells were incubated with the appropriate antibodies at 4
o
C for 20 minutes. The samples 
were then washed with PBS and centrifuged at 150 x Gmax for 5 minutes. The samples were then 
fixed in 1% (w/v) PFA. The phenotype of CLL PBMCs at time zero and following co-culture for 24 
hours with HMEC-1 cells or control medium was analysed by 5-colour flow cytometry using a BD 
FACS Canto II instrument. CD38, CD44, CD49d, ZAP-70 and CD69 expression were determined 
using CD19-PB, CD5-PeCy7, CD38-PE, CD44-PE, CD69-APC, ZAP-70-FITC, CD49d-FITC. 
Apoptosis of cells was assessed after 7 days co-culture using flow cytometry following labelling with 
CD19-PB, CD5-PeCy7, Annexin V–FITC, and 7-amino-actinomycin D (7-AAD) according to the 
manufacturer's instructions. Proliferation was analysed at various time points by measuring Ki-67 
expression using flow cytometry (FACS Canto II). Cells were labelled with CD19-PB, CD5-PeCy7 
before treatment with Fix and Perm reagent supplemented with 5% (v/v) NP-40 and labelling with Ki-
67-FITC or matched isotype control. 
2.3.4.  Flow cytometric analysis of intracellular antigens 
 
Antibodies to cell surface antigens were added using the above protocol. After washing with PBS, 
the cell pellet was resuspended by vortexing as 100µl fixation buffer was added. After thorough 
mixing, the sample was incubated in the dark at room temperature for 20 minutes. 1ml of 
permeabilisation buffer was then added to each sample, mixed and centrifuged at 150 x Gmax. An 
antibody to the intracellular protein, ZAP70 was then added to appropriate tubes and the samples 
were incubated at room temperature for 20 minutes. The samples were then washed once in 
permeabilisation buffer and once in PBS, with centrifugation performed at 150 x Gmax. The samples 
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were then be fixed in 1% (w/v) PFA and stored in the dark at 4
o
C until analysed using the FACS 
Canto II. 
2.3.5. Flow cytometric viability assay 
 
The viability of cells was assessed using flow cytometry. Annexin V binds to phosphatidyl serine, 
which is normally on the intracellular leaflet of the plasma membrane, but is moved to the 
extracellular leaflet when apoptosis is triggered. Detection of extracellular phosphatidyl serine can 
therefore be used as an early marker of apoptosis. 7AAD is a dye which stains DNA. Cells which are 
negative for both Annexin V and 7AAD are viable cells. This viability protocol was used after 
following the cell-surface antigen labelling protocol described above, or independently. Briefly, 100µl 
of Annexin V binding buffer was added to each tube and 2.5µl Annexin V and 1µl 7AAD was added 
as required. The samples were then incubated in the dark for 15 minutes before a further 400µl of 
Annexin V binding buffer was added to each tube. The samples were analysed immediately and the 
percentage of cells staining positive for Annexin V (FITC) and 7AAD (PE Cy5.5) was determined by 
flow cytometry (FACS Canto II). 
 
2.4 Protein analysis 
 
2.4.1. Total Protein Lysates 
 
Cells were harvested by centrifugation at 200 x Gmax for 5 minutes, washed with PBS and 
centrifuged again at 200 x Gmax for 5 minutes. The cell pellet was disrupted by flicking the tube and 
an appropriate volume of 2X SDS Lysis Buffer was added.  The tube was flicked vigorously to 
resuspend the pellet before heating at 100
o
C for 10 minutes.  Samples were briefly centrifuged (30 
seconds, 1,000 x Gmax) and stored at –20
o
C if not used immediately. 
2.4.2.  Western Blotting 
 
Protein samples were separated by Polyacrylamide Gel Electrophoresis (PAGE) using the NuPAGE 
system and 4-12% (w/v) polyacrylamide bis-Tris gels. Novex Sharp pre-stained ladders were used 
as protein standards.  Gels were assembled in a NuPAGE gel apparatus and electrophoresis was 
carried out for 1 hour at 200V in 1X MES SDS Running Buffer. After electrophoresis, the separated 
proteins were transferred to a nitrocellulose-coated nylon membrane (Hybond C-Extra) using the 
NuPAGE gel blotting module at 25V and NuPAGE Transfer Buffer with 20% (v/v) methanol, 
according to the manufacturer’s instructions.  The membrane was then removed from the apparatus 
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and blocked for 30 minutes in 10% (w/v) non-fat dried milk in PBS, 0.05% (v/v) Tween-20.  After 
three brief washes in PBS, Tween-20 the blot was placed in primary antibody. 
Primary antibodies for Western blotting were typically used at dilutions of 1:1000 in PBS, 3% (w/v) 
BSA, 0.01% (v/v) NaN3. The dilution corresponds typically to a final immunoglobulin concentration of 
0.1-0.2 g/ml. Blots were incubated in primary antibodies overnight at 4
o
C or for 1 hour at room 
temperature. They were then washed three times in PBS, 0.05% (v/v) Tween-20 and incubated in 
secondary antibody for 45 minutes. Horseradish peroxidase (HRP) conjugated secondary antibodies 
were used at a dilution of 1:2000 in PBS, 10% (V/V) dried milk. Blots were washed three times in 
PBS, 0.05% (v/v) Tween-20 before the addition of 1ml ECL-Plus for 10 minutes. To visualise protein 
bands, the blots were exposed to Hyperfilm-ECL X ray film and developed using a Compact X4 X-
Ray developer. 
2.5 RNA analysis 
 
RNA isolation, sample processing and microarray analyses were carried out under the supervision 
of Mrs Megan Musson at the Central Biotechnology Service Laboratory, University of Cardiff as part 
of a collaboration with Professor Chris Pepper. 
2.5.1. Isolation of total RNA 
4 x 10
6
 cells were centrifuged at 300 x Gmax for 5 minutes and the supernatant was discarded. The 
pellet was resuspended in 1ml of Trizol by pipetting and incubated at room temperature for 5 
minutes. The sample was stored at -80
o
C until processed further when the sample was transferred 
to a 1.5ml micro-centrifuge tube and 150µl of Chloroform was added to the sample for phase 
separation. After mixing vigorously, the sample was incubated at room temperature for 3 minutes, 
followed by centrifugation at 13,000 x Gmax for 2 minutes. The separated upper aqueous phase was 
transferred to a fresh micro-centrifuge tube and RNA was co-precipitated with 1µl glycogen using 
500µl of isopropanol. The addition of glycogen helps to visualise the RNA pellet. Samples were 
incubated at room temperature for 10 minutes before centrifugation at 12,000 x Gmax, 4
o
C for 10 
minutes. The supernatant was removed and the pellet was washed in 750 µl of 75% (v/v) ethanol. 
The sample was then centrifuged at 7,500 x Gmax for 5 minutes at 4
o
C. The supernatant was 
removed until approximately 10µl remained, then the pellet was air dried at room temperature. The 
pellet was dissolved in 100µl of RNase-free dH2O at 65
o
C for 5 minutes. The samples were then 
cooled on ice for 15 minutes. The quantity and quality of the RNA was determined using a Nanodrop 
appatatus (see section 2.5.3 and the quality was determined by a second method using the 2100 
Bioanalyser (Agilent) as described in section 2.5.4.  
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2.5.2. RNA further purification 
 
Total RNA ‘clean up’ was performed using RNeasy mini kit. 350 µl buffer RLT was added to the 
sample of 100 µl total RNA and mixed well. 250 µl 100% (v/v) ethanol was then added to the diluted 
RNA and mixed by pipetting. The sample was immediately transferred to an RNeasy mini spin 
column, which was placed in a 2ml collection tube. After closing the lid gently, the samples were 
centrifuged at room temperature at 8,000 Gmax for 15 seconds. The column was carefully removed 
from the collection tube to prevent contact with the flow through and the flow through was discarded. 
Using the same collection tube, 500 µl RPE buffer was then added to the RNeasy spin column. The 
lid was closed gently and samples were centrifuged at room temperature at 8,000 Gmax for 15 
seconds to wash the spin column membrane. The flow through was discarded. A further 500 µl RPE 
buffer was added to the RNeasy spin column and samples were centrifuged at room temperature 
8,000 x Gmax for 2 minutes to wash the spin column membrane. The long centrifugation step dries 
the spin column membrane, ensuring that no ethanol is carried over during RNA elution as residual 
ethanol may interfere with downstream reactions and measurements of the RNA. The RNeasy spin 
column was removed from the collection tube and placed in a new collection tube. Samples were 
centrifuged at room temperature at 13,000 x Gmax for 1 minute to eliminate any possible carryover of 
RPE buffer or to remove any residual flow through from the outside of the RNeasy spin column. The 
RNeasy spin column was then placed in a new 1.5ml collection tube and 50 µl of RNase-free water 
was added directly to the spin column membrane. The lid was closed gently and samples were 
centrifuged at room temperature at 8,000 x Gmax for 1 minute to elute the RNA. The quantity and 
quality of the RNA was determined using the Nanodrop apparatus and 2100 Bioanalyser (see 
sections 2.5.3 and 2.5.4). Samples were then stored at -80
o
C. 
2.5.3. Determination of RNA concentration 
 
RNA concentration was determined by Nanodrop spectrophotometry. This method measures the 
absorbance of DNA or RNA in solution at 260nm and the quality is assessed by determining the 
260nm/280nm ratio. The Beer-Lambert equation A= E x b x c is used to calculate the DNA/RNA 
concentration. A is the absorbance value, E is the wavelength-dependant molar absorption 




, b is the path length in cm, c is the analyte 
concentration in mol/l. Typically 1µl of DNA or RNA in dH2O was placed on the Nanodrop pedestal 
and the absorbance of the material in the sample column was measured against a blank of dH20. 
The 260nm/280nm ratio is considered to be a good indicator of protein contamination since proteins, 
particularly those containing aromatic amino acids which absorb light at 280nm (164) therefore the 
purity of the sample can be assessed The A260/A280 ratio should be close to 2.0 for pure RNA. 
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2.5.4. Determination of RNA quality 
 
RNA quality was determined using an RNA 6000 Nano Assay and 2100 Bioanalyser. Briefly this 
micro fluidics-based platform method separates and quantifies RNA by electrophoresis in micro 
fluidic networks of channels and wells etched into glass chips. The RNA Integrity Number (RIN) 
algorithm allows the reproducible comparison of RNA quality between different samples. Sample 
integrity is not determined by just the ratio of the ribosomal RNA, but by the entire electrophoretic 
trace of the RNA sample, including the presence or absence of degradation products. A RIN score 
of greater than 8 out of 10 is usually preferred for microarray applications. 
2.5.5. Sample preparation for microarray analysis 
 
RNA samples were prepared for Affymetrix whole transcriptome microarray analysis using the 
Ambion Whole Transcript (WT) Expression Kit.  First, sense strand cDNA was generated from total 
RNA. The WT Expression Kit uses a reverse transcription priming method that specifically primes 
non-ribosomal RNA from the sample, including both poly(A) and non-poly(A) mRNA. Primers that 
avoid rRNA binding are designed by using a proprietary-oligodeoxynucleotide matching algorithm. 
These primer sequences provide complete and unbiased coverage of the transcriptome while 
significantly reducing the priming of rRNA. cDNA was then fragmented and labelling was carried out 
using the Affymetrix GeneChip WT Terminal Labelling Kit. Hybridisation of labelled, fragmented 
cDNA to the GeneChips occurs overnight (16 hours) in a hybridisation oven at 45
o
C. 
100ng RNA was used for microarray analysis. A set of poly(A) RNA controls (Affymetrix GeneChip 
Poly(A) RNA Control Kit) were added to the RNA, which have been designed specifically to provide 
exogenous positive controls to monitor the entire target labelling process. Each eukaryotic 
GeneChip probe array contains probe sets for several B. Subtilis genes that are absent in eukaryotic 
samples. The polyadenylated transcripts for the B. subtilis genes are added directly into RNA 





Figure 2.1 Sample work up for microarray analysis (from the Whole Transcript (WT) 






2.5.6. First-strand cDNA synthesis 
 
In this reverse transcription procedure, total RNA was primed with engineered primers containing a 
T7 promoter sequence (165). The reaction then synthesizes single stranded cDNA containing a T7 
promoter sequence. Briefly, first-Strand Master Mix was added to nuclease free PCR tubes, and 
then 5 µl of RNA (with poly(A) spike) was added to each tube. Samples were mixed by vortexing 
and centrifuged briefly to collect the reaction at the bottom of the tube. Samples were then incubated 
for 1 hour at 25
o
C, then for 1 hour at 42
o
C, then for 2 minutes at 4
o
C in a thermal cycler. Immediately 
after the incubation the samples were centrifuged briefly (approximately 5 seconds) to collect the 
first-strand cDNA at the bottom of the tube. The samples were then placed on ice for 2 minutes to 
cool. 
2.5.7. Second-strand cDNA synthesis 
 
Single-stranded cDNA was converted to double-stranded cDNA, which acts as a template for 
transcription. The reaction uses DNA polymerase and RNase H to simultaneously degrade the RNA 
and synthesize second-strand cDNA.  
Second-Strand Master Mix is placed in a nuclease-free tube and mixed by vortexing. 50µl of the 
second-strand master mix was then added to each tube containing the first-strand synthesis cDNA 
sample and mixed gently by flicking the tube. Samples were centrifuged briefly to collect the reaction 
at the bottom of the tube and then incubated for 1 hour at 16
o
C, then for 10 minutes at 65
o
C, then for 
at least 2 minutes at 4
o
C in a thermal cycler. Immediately after the incubation, samples were 
centrifuged briefly (approximately 5 seconds) to collect the double-stranded cDNA at the bottom of 
the tube and samples were placed on ice to cool. 
2.5.8. In vitro transcription cRNA synthesis 
 
Antisense cRNA was synthesized and amplified by in vitro transcription (IVT) of the second-strand 
cDNA template using T7 RNA polymerase (165). Briefly, an IVT Master Mix was prepared in a 
nuclease-free tube, mixed by vortexing and centrifuging briefly before adding 30 µl of the IVT Master 
Mix to each tube containing a Second-Strand cDNA sample. Samples were mixed thoroughly by 
gently vortexing, then centrifuged briefly to collect the reaction at the bottom of the tube and then 
incubated for 16 hours at 40
o
C, then overnight at 4
o
C in a thermal cycler. After incubation, the 




2.5.9. Purification of cRNA 
 
Enzymes, salts, inorganic phosphates and unincorporated nucleotides were removed to improve the 
stability of the cRNA. Briefly, cRNA Binding Mix was prepared in a nuclease-free tube and 60μl of 
cRNA Binding Mix was added to each sample and mixed by pipetting. Samples were then 
transferred to a “U” bottomed plate and 60μl of isopropanol was added to each tube and mixed by 
pipetting. The samples were mixed for 2 minutes by shaking. The cRNA in the sample binds to the 
Nucleic Acid Binding Beads during this incubation. The plate was then transferred to a magnetic 
stand to capture the magnetic beads. After approximately 5 minutes the supernatant was carefully 
aspirated without disturbing the magnetic beads and then the plate was removed from the magnetic 
stand. Samples were then washed twice with 100μl of Nucleic Acid Wash Solution for 1 minute on a 
plate shaker. After the last wash, the pellets were allowed to air dry. Then, 40μl of preheated (55 to 
58
o
C) Elution Solution was added to each sample to elute the purified cRNA from the Nucleic Acid 
Binding Beads and incubated for 2 minutes. After incubation, the plate was shaken vigorously for 3 
minutes before removing the supernatant containing the eluted cRNA to a fresh plate, which was 
cooled on ice. 
2.5.10. Second-cycle cDNA synthesis 
 
Sense-strand cDNA was synthesized by the reverse transcription of cRNA using random primers. 
The sense-strand cDNA contains dUTP at a fixed ratio relative to dTTP. 10μg of cRNA was required 
for second-cycle cDNA synthesis. Briefly, 10μg of cRNA was prepared in a volume of 22μl and 2μl of 
random primers were added. Samples were mixed by vortexing and centrifuged briefly to collect the 
reaction at the bottom of the tube. Samples were incubated for 5 minutes at 70
o
C, then 5 minutes at 
25
o
C, then 2 minutes at 4
o
C in a thermal cycler. After the incubation, samples were cooled on ice 
and centrifuged briefly to collect the second-cycle cDNA at the bottom of the tube. The second-Cycle 
Master Mix was prepared on ice and then 16μl was added to each cRNA/Random Primer sample. 
Samples were mixed by vortexing and centrifuged briefly. The samples were incubated for 10 
minutes at 25
o
C, then 90 minutes at 42
o
C, then 10 minutes at 70
o
C, then for at least 2 minutes at 
4
o
C in a thermal cycler. Immediately after incubation, samples were centrifuged briefly and cooled 
on ice. 
2.5.11. Digestion using RNase H 
 
RNase H (2μl) was added to the second-cycle cDNA. Samples were vortexed and centrifuged briefly 
before incubation for 45 minutes at 37
o
C, then 5 minutes at 95
o





in a thermal cycler. Following incubation, samples were centrifuged briefly and cooled on ice. RNase 
H degrades the cRNA template leaving single-stranded cDNA. 
2.5.12. Second-cycle cDNA purification 
 
The second-strand cDNA is purified to remove enzymes, salts and unincorporated dNTPs, preparing 
the cDNA for fragmentation and labelling. Briefly, 18μl of nuclease free water and 60μl of cDNA 
Binding Mix was added to each sample and mixed by pipetting before being transferred to a “U” 
bottomed plate. 120μl of ethanol was added to each sample before shaking the plate gently for 2 
minutes.  The cDNA in the sample binds to the Nucleic Acid Binding Beads during this incubation.  
After incubation, the plate was placed on a magnetic stand to capture the Nucleic Acid Binding 
Beads and the supernatant was discarded, each sample was washed twice with 100μl Nucleic acid 
wash solution for 1 minute. The cDNA was eluted with 30μl of preheated (55-58
o
C) Elution Solution. 
Samples were incubated with Elution Solution for 2 minutes without shaking then a further 3 minutes 
with vigorous shaking. The plate was placed on a magnetic stand and the supernatant containing 
the eluted cDNA was removed to a new nuclease free plate on ice. 
2.5.13. Fragmentation and labelling the single-stranded cDNA 
 
The Affymetrix GeneChip WT Terminal Labelling Kit is used for the fragmentation and labelling of 
the cDNA. The second-cycle (sense-strand) cDNA contains dUTP and the kit uses uracil-DNA 
glycosylase (UDG) and apurinic/apyrimidinic endonuclease 1 (APE1) to recognize and fragment the 
cDNA at the unnatural dUTP residues. The DNA is then labelled by terminal deoxynucleotidyl 
transferase (TdT) using the Affymetrix proprietary DNA Labelling Reagent. 
16.8μl of the Fragmentation Master Mix containing UDG and APE was added to each ssDNA 
sample and mixed by vortexing and centrifuged briefly. Samples were incubated at 37
o
C for 60 
minutes then 93
o
C for 2 minutes then 4
o
C for at least 2 minutes. After incubation, samples were 
mixed by flicking the tube and centrifuged briefly. Size analysis was then performed using the 
Bioanalyzer RNA 6000 Nano LabChip. The range in peak size of the fragmented samples was 







2.5.14. Labelling of fragmented single-stranded DNA 
 
Component Volume in one reaction 
Fragmented single-stranded DNA 45µl 
5X TdT Buffer 12µl 
TdT 2µl 
DNA labelling reagent, 5mM 1µl 
Total Volume 60µl 
Table 2.6 Labelling of fragmented single-stranded DNA 
 
A master mix was made containing TdT and DNA labelling reagent was made and 15μl of the 
labelling master mix was added to each tube containing fragmented ssDNA. Samples were mixed by 
flicking the tubes and centrifuged briefly to collect the reaction at the bottom of the tube before 
incubating at 37
o
C for 60 minutes then 70
o
C for 10 minutes then 4
o




Samples were processed using the GeneChip Hybridization, Wash and Stain Kit.  
Component Volume for one 49/64 
Format Array 
Final Concentration 







20 x Eukaryotic 
hybridisation controls 
(bioB, bioC, bioD, cre) 
11µl 1.5, 5, 25 and 100pM 
respectively 
2 x Hybridisation mix 110µl 1X 
DMSO 15.4µl 7% 
Nucelase-free water 19.9µl  
Total Volume 220.0µl  




The hybridization cocktail was mixed according to Table 2.7 and heated at 99oC for 5 minutes, 
cooled at 45
o
C for 5 minutes and then centrifuged at 13,000 x Gmax for 1 minute. Gene Chip ST 
Arrays were equilibrated to room temperature before use and then the sample was injected onto the 
array through the septa on the back of the array plastic casing. The array was placed in a 
hybridization oven at 45
o
C overnight (17 hours). After hybridization, the arrays were vented by 
inserting a clean pipette tip into one of the septa and the probe arrays were re-filled with Wash 
Buffer A. Probe arrays were then washed and stained according to the GeneChip Expression Wash, 
Stain and Scan Kit (Affymetrix) before scanning. 
 
2.6 Proteomic methods 
 
2.6.1.  Isolation of cell surface proteins 
 
Cell surface proteins were isolated using the Cell Surface Protein Isolation kit as per the 
manufacturer’s instructions. Briefly, approximately 3 x10
7
 cells were washed in ice-cold PBS. The 
cell pellet was resuspended in 30 ml of freshly prepared Sulfo-NHS-SS-Biotin solution and incubated 
at 4
o
C for 30 minutes on a roller. The reaction was terminated by the addition of 1.5 ml of Quenching 
Solution and the cells were washed twice with TBS. The cell pellet was resuspended in 1.5 ml of 
Pierce Lysis Buffer containing protease inhibitors and phosphatase inhibitors, sonicated 6 x 10 
seconds on medium power in a Bioruptor water bath (Diagenode), incubated on ice for 30 minutes 
and centrifuged at 10,000 x Gmax for 2 minutes at 4
o
C. The clarified supernatant containing the 
solubilised proteins was incubated with immobilized NeutrAvidin Gel for 1 hour at room temperature 
on a rolling platform. Unbound proteins were removed from the tube by three washes with TBS 
containing protease inhibitors. Biotinylated proteins bound to the gel were eluted by incubation with 
SDS-PAGE Sample Buffer containing 50 mM DTT for 1 hour at room temperature and subsequent 
centrifugation at 1,000 x Gmax for 2 minutes. The eluted proteins were separated by electrophoresis 
for western blot using a NuPAGE Bis-Tris 4% to 12% (w/v) polyacrylamide gel, as described in 2.4.2 
or stored at -80
o
C for mass spectrometry analysis. 
2.6.2. In solution trypsin digestion protocol for mass spectrometry (MS) 
 
Protein samples were firstly eluted from the NeutrAvidin matrix by incubation in 40µl elution buffer 
containing 50mM DTT in 30mM Tris-HCl pH8.0 at 95
o
C for 5 minutes. Protein samples were then 
solubilised by the addition of Trifuoroethanol (TFE) to a protein/TFE of 1-2mg/ml. Next, DTT was 
added to a final concentration of 15mM in order to break disulfide bonds, which stabilise tertiary 
protein structure. The samples were then heated to 55
o
C for 45 minutes to fully denature the 
proteins. The samples are then allowed to cool to room temperature before iodoacetamide (IAM) 
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was added to a final concentration of 55mM.  IAM is an alkylating agent, which is used to prevent 
peptides from forming disulfide bonds. It covalently modifies to the thiol group of cysteine residues. 
Samples were then incubated in the dark at room temperature for 30 minutes before diluting in 
50mM Tris-HCl, 2mM CaCl2 pH8.0 to reduce the TFE concentration to 5% (v/v). Sequencing grade 
trypsin was resuspended in 1mM HCl at a concentration of 100µg/ml. 1µg of the trypsin solution was 
used per mg of protein to be digested. Trypsin is a serine protease and cleaves peptides at the 
carboxyl side of the amino acids lysine or arginine, except when either is followed by proline. The 
samples were incubated for 5 hours at 37
o
C and then formic acid was added to 1% (v/v) to stop 
trypsin digestion. The sample was then stored at 80
o
C or processed further. 
2.6.3. Detergent removal by electrophoresis for MS analysis 
 
Samples were eluted from the NeutrAvidin matrix by incubating at 95
o
C for 5 minutes in 40µl elution 
buffer containing 50mM DTT in 30mM Tris-HCl, pH8.0. The eluate was removed by centrifugation at 
14000 x Gmax for 5 minutes. 4 x SDS sample buffer was added to the sample and loaded into a 
BioRad pre-cast Mini-Protean TGX 4-15% (w/v) polyacrylamide gel. Once all the sample had 
entered the gel (typically after about 10 minutes), electrophoresis was stopped and the gel was 
stained with coomassie blue. To speed up staining, the gel was heated gently in the microwave in 20 
second bursts, without boiling. The gel was then placed on a shaker for at least an hour. The gel 
was then destained overnight in 40% (v/v) Methanol, 10% (v/v) Glacial Acetic Acid on a shaking 
platform. The gel was then placed in dH20 to fully rehydrate before cutting gel slices. 
2.6.4. In-gel reduction, alkylation and digestion for MS 
 
The protein in the gel appears as a blue band. The gel containing this protein band was excised 
using a scalpel blade and transferred to a micro centrifuge tube. The gel slice was completely 
rehydrated with dH20 and then cut into small pieces of approximately 3x3mm. Destaining solution 
(200mM NH4HCO3, 50% (v/v) acetonitrile) was added to cover the gel pieces and the sample was 
incubated at 30
o
C for 20 minutes with intermittent vortexing. The supernatant was discarded and the 
gel was rehydrated with 200mM NH4HCO3, before replacing with fresh destain solution until the gel 
pieces were fully destained. Once fully destained, the gel sample was dried in a vacuum centrifuge 
apparatus (SpeedVac). The dried gel pieces were then submerged in reducing buffer (10mM DTT, 




1 hour. Excess reducing buffer was removed and the 
gel pieces were resuspended in alkylating solution (100mM iodoacetamide in H20) and incubated in 
the dark at room temperature for 30 minutes. The supernatant was then removed and the gel pieces 
were washed twice with 200mM NH4HCO3. The gel pieces were again washed twice with 100% (v/v) 
acetonitrile, which caused them to shrink and then rehydrated with 200mM NH4HCO3. After drying 
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the gel pieces in the SpeedVac, the gel pieces were rehydrated in enough digestion buffer (50ng/µl 
trypsin in 1mM HCl) to just cover the gel pieces. After allowing the gel pieces to re-swell for 5 
minutes, 20µl 200mM NH4HCO3 was added. After a further 5 minutes, excess digestion buffer was 
removed. The gel pieces were covered with 200mM NH4HCO3 and incubated at 30
o
C overnight. 
The digestion reaction was stopped by adding 1% (v/v) formic acid. The supernatant was removed 
to a new micro centrifuge tube. Peptides were then extracted from the gel pieces using an extraction 
buffer containing 0.1% (v/v) formic acid, 60% (v/v) acetonitrile. Gel pieces were incubated in the 
extraction buffer at 30
o
C for 40 minutes with intermittent vortexing. The extraction buffer containing 
liberated peptides was removed and combined with the supernatant from the digestion reaction. The 
extraction procedure was repeated and the supernatants were combined. The volume of the 
extraction supernatant was reduced to about 10-20µl in the SpeedVac. 
2.6.5. Sample preparation for MS analysis 
 
After trypsin digestion, protein samples were purified of contaminants (such as small molecules and 
salts) by solid phase extraction using Hypersep C18 tips. The stationary phase in the tip is formed 
using silica bound to C18 hydrocarbon chains and peptides in solution can be separated from other 
compounds in the mixture according to their physical and chemical properties based on how they 
interact with the C18 chains. The C18 resin was first equilibrated by washing three times with 50µl of 
40% (v/v) Acetonitrile solution (40% (v/v) MS Buffer B, 60 % (v/v) MS Buffer A), followed by three 
washes with 50% (v/v) MS Buffer A. The sample was loaded onto the resin and the resin was then 
washed three times with 50µl of MS Buffer A. The sample was eluted with 50µl of 40% (v/v) 
Acetonitrile solution. All samples were dried to 10-20µl with a SpeedVac and resuspended in 60µl of 
MS Buffer C.  
2.6.6. Mass spectrometry analysis 
 
I spent three months in Prof Marcotte’s laboratory at the University of Texas at Austin, USA during 
the Summer of 2012 where I carried out the initial mass spectrometry analyses, in collaboration with 
Dr Daniel Boutz, a Post-Doctoral Research Fellow. Further analyses of my samples were carried out 
subsequently, after my return to the UK. Mass spectrometry analyses of the processed peptide 
samples were carried out using a Surveyor Plus HPLC system connected to an LTQ-Orbitrap or 
Velos-Orbitrap mass spectrometer (Thermo Scientific). 
High pressure liquid chromatography (HPLC) is used to separate a mixture of peptides before 
analysis by Mass Spectrometry (MS). The peptides were separated based on their partition 
coefficients between a polar mobile phase (ACN or MeOH) and a hydrophobic stationary phase 
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(C18 column). HPLC column conditions can be altered so that peptides can be separated better. 
The composition of the mobile phase is altered to change the retention time of analytes. Altering the 
time taken to complete the run can also adjust the separation of peptides. 
The tryptic peptides were separated by reverse phase chromatography on a Zorbax C18 column in-
line with the LTQ-Orbitrap mass spectrometer. The separation of peptides was accomplished by 
running a 5-38% (v/v) acetonitrile gradient over 230 minutes. Eluted peptides were directly injected 
by electrospray ionization into the LTQ-Orbitrap, which is equipped with a nano-spray ion source for 
analysis. Full parent spectra (MS1) were collected at 60,000 resolution and the dominant ion was 
chosen from these spectra for further analysis. This becomes the parent ion; this precursor ion is 
activated to undergo fragmentation by collision with inert gas (Collision-Induced Dissociation (CID)), 
which is known as tandem mass spectrometry. Therefore, in further analyses, a data-dependent 
scan can be performed where the mass spectrometer identifies products with these characteristic 
parent ion M/Z values. These parent ions can then be fragmented in order to confirm their 
composition. The subsequent ion fragmentation spectra (MS2) were collected in a data-dependent 
manner, with ions required to carry +2 or greater charge for MS2 selection. The top 12 most intense 
qualifying peaks were selected per round, with peaks selected twice within 30 seconds excluded 
from selection for 45 seconds to avoid the detection of only the most abundant peptide in the time 
period. Data were analysed using the Sequest search algorithm within the Proteome Discoverer 1.3 
software package (Thermo). Sequest is a tandem mass spectrometry data analysis program, which 
identifies tryptic peptide sequences from the tandem mass spectra.  The tryptic peptide sequences 
are generated computationally from protein sequences predicted from the latest build of the human 
genome. The spectra were searched against the non-redundant Ensembl v64 Homo sapiens 



























Previous work from our laboratory using confocal immunofluoresence microscopy of CLL lymph 
nodes showed the presence of microvessels (endothelium) at centres of CLL cell proliferation (52). 
Furthermore, in vitro assays have demonstrated that CLL cell contact with endothelial cells (HMEC-
1) in a co-culture system promotes CLL cell survival, whilst CLL cells cultured alone undergo 
extensive apoptosis (1). Therapeutic applications are clear as agents which block pro-survival 
interactions could be developed as new therapies to treat CLL patients. The use of endothelial cell 
lines or primary endothelial cells have several advantages over other co-culture systems described 
in the literature, not least their ready availability and comparative ease of culture. Co-culture systems 
utilising mesenchymal stem cells (MSC) from bone marrow aspirates of CLL patients suffer from 
poor availability, low cell recovery and poor growth in ambient oxygen (166). 
A variety of co-culture systems have been developed to mimic the tumour microenvironment by 
imitating different cell:cell interactions and the effects of soluble factors. The components of some of 
these systems are described in Table 3.1.  
Culture Details Reference 
Murine fibroblasts 
transfected with human 
CD40L 
Drug testing model for Hsp90 inhibitor in combination 
with Fludarabine inhibits proliferative/activated CLL cell 
phenotype. 
(118) 
Soluble CD40L and IL4  Drug testing model for Fludarabine in combination with 
soluble CD40L, IL-4 or a combination. 
(167) 
High density CLL  Conditioned media from crowded cells increased 
survival of non-crowded cells.  
Co-culture of fixed cells with viable CLL cells was also 
protective, suggesting homotypic interactions are 
important.  
(63) 
Bone marrow stromal 
cells derived from MSC 
Human and murine marrow stromal cells (murine BM-
derived cell line M2-10B4) were shown to protect CLL 
cells from spontaneous and drug-induced apoptosis: 
development of a reliable and reproducible system to 





Blood derived nurse like 
cells 
Blood-derived nurse-like cells protect chronic 
lymphocytic leukemia B cells from spontaneous 
apoptosis through stromal cell-derived factor-1. 
(169) 
Human microvascular 
endothelial cell line 
(HMEC-1) 
Co-culture of CLL cells with a microvascular 
endothelial cell line protects cells from apoptosis and 
upregulates NFB. 
(1) 
Human umbilical vein 
endothelial cells 
(HUVEC) 
Physical contact with endothelial cells through β1- and 
β2- integrins rescues chronic lymphocytic leukemia 
cells from spontaneous and drug-induced apoptosis. 
(170) 
CCL2, CXCL2  Cytokine screen paper highlights the need for 
accessory cells. The addition of either CXCL2 or CCL2 
enhanced CLL cell survival, while antibodies blocking 
these chemokines reduced survival. 
(64) 
T cells Co-culture of pre activated T cells with CLL cells at 
different T:B cell ratios 
(52, 171) 
Bone marrow stromal 
cells (BMSC) 
BMSC promote cell survival and drug resistance by 
modulating the redox status of CLL cells. 
(172) 
Table 3.1 CLL co-culture model systems and their uses 
 
3.1.1. Comparison of co-culture systems 
 
To date no study has systematically characterised the effects of the different co-culture systems or 
provided a direct comparison of CLL cell survival, proliferation and phenotype. In collaboration with 
Professor Chris Pepper (Cardiff University) we sought to compare three co-culture systems 
designed to mimic the lymph node and vascular microenvironments. The aim was to determine key 
effects on CLL cells which occur in common in each of the systems tested as well as differences 
between the systems. Two model systems utilised mouse embryonic fibroblasts transfected with 
human CD40L (expressed by activated T-lymphocytes) or human CD31 (CD38 ligand) and were 
carried out by Cardiff University. The third model used human micro vascular endothelial cell line, 
HMEC-1, described in Chapter 1. 
These studies provide an insight into the different signals being provided by different co-culture 
systems and the cellular components required for an in vitro model of the CLL tumour 
microenvironment. Results of this study were published in the British Journal of Haematology (173) 
and according to the regulations governing PhD Theses at King’s College London, I have chosen to 
present this work in the form published.  
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3.2  Results 
 
The paper presented below was produced as part of our collaboration with Professor Chris Pepper 
at Cardiff University. I performed experiments and analysed data from assays using HMEC-1 cells at 
King’s College London and experiments utilising transfected fibroblasts were carried out by the joint 
first author, Dr Laurence Pearce at the Cardiff University. I contributed to the writing of the Materials 
and Methods section of the paper and edited the manuscript. Dr Andrea Buggins and Professor 
















































In addition to the detailed Discussion in the paper, the work described above highlights the 
importance of considering the effect of co-culture systems on primary CLL cells and what the 
implications of this are for experiments carried out using these systems. Co-culture systems should 
be chosen to reflect the question being addressed, since different systems may best reflect different 
compartments of the CLL microenvironment. For example, it has been suggested that CLL cells 
exist in distinct compartments, namely the proliferative compartment in the lymph node (56) and the 
resting compartment in the vasculature (174). We suggest that the endothelial co-culture system 
models the resting compartment, however in the peripheral blood the time spent in direct contact 
with endothelial cells is small as the cells are not stationary. This problem is being addressed with 
the development of a new dynamic co-culture circulation system designed to mimic the interaction 
between CLL cells and endothelial cells in the peripheral vasculature. I have carried out preliminary 











Chapter 4  

















As described in Table 3.1 (Chapter 3), laboratories across the world have utilised numerous 
different co-culture model systems to maintain primary CLL cell viability and investigate the effects of 
accessory cells on CLL cells.  A focus of work in our group has been to investigate the supportive 
effects of endothelial cells in co-culture. We reported cytoprotective effects and changes in CLL cell 
phenotype after co-culture with the HMEC-1 endothelial cell line (1, 61, 173), which is further 
described in Chapter 3. It is likely that direct cell:cell interactions in the microenvironment and 
indirect interactions, such as through the release of soluble factors from CLL or accessory cells act 
in concert to produce a cytoprotective effect (65, 156, 176, 177). Whether the cytoprotective stimulus 
comes from direct or indirect interactions, the effects on the CLL cells will affect both transcriptional 
and post-transcriptional mechanisms. 
In this chapter, the mechanisms involved in CLL cell cytoprotection are investigated by examining 
the effects of co-culture on mRNA expression in the CLL cells by gene expression microarray 
analysis. We expand on the study described in Chapter 3, which focused on the effects of 
endothelial cell co-culture using a cell line, HMEC-1. Here, we also include primary endothelial cells 
HDBEC and HDMEC, which may provide a closer representation of endothelial cells found in the 
body than immortalised endothelial cell lines. 
Both the primary and immortalised endothelial co-culture systems were found to protect CLL cells 
from apoptosis (see section 4.2.1) and induce an activated CLL cell phenotype (see section 4.2.2). 
The aim of work described later in this chapter was to investigate the transcriptional effects of co-
culture with endothelial cells and to identify mRNAs which were up-regulated by both systems. 
Bioinformatic analyses were then performed to identify mechanisms that occur in common between 
CLL cells cultured in different co-culture systems which may provide rational therapeutic targets to 
abrogate the cytoprotective effect of the tumour microenvironment.  
4.1.1. Experimental approach to investigate the transcriptional effects of co-
culture with endothelial cells on CLL cells 
 
Previous work from our group showed that CLL cell viability was increased with endothelial cell co-
culture regardless of CLL cell phenotype or prognostic marker status (1) and this observation is 
supported by the work presented in Chapter 3. Therefore, we chose to investigate the transcriptional 
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effects of endothelial cell co-culture using CLL samples with a variety of prognostic markers. The 










purified from CLL PBMCs which had previously been frozen, as 





purity were used for the assay. Sample purity was determined by staining with 
fluorochrome-conjugated antibodies for CD5 and CD19 and quantifying the percentage of 
CD5/CD19 double-positive cells by flow cytometry. The cells purified from each of the six CLL 
patients were split between conditions, as shown in Figure 4.1. RNA was isolated as described in 
section 2.5 (Materials and Methods) at time 0 hours and after 12 hours in liquid culture, 12 hours co-
culture with the HMEC-1 cell line and 12 hours co-culture with HDBEC primary endothelial cells. 
RNA was isolated at a 12 hour time point in order to ensure that good quality RNA could be isolated 
from CLL cells in the liquid only culture. After longer time points cell death would occur in this liquid 
only culture, releasing ribonucleases (RNases) and resulting in degradation of sample RNA. CLL 









1 LSL 4631 mutated 96
2 LSL6811 unmutated 98
3 LSL6917 unmutated 49
4 LSL4589 mutated 48
6 LSL5539 unmutated 2
10 LSL5195 mutated 0








4.2.1. Co-culturing CLL cells on endothelial cells increases CLL cell viability 
 
To investigate whether the viability of cells isolated from CLL patients was affected by co-culture 
with different endothelial cells, an assay was established using Annexin V and 7AAD, as described 




cells selected from 
six CLL patients, as described in section 2.3.9 (Materials and Methods). The purity of all samples 
after selection was greater than 98%, which was determined by staining with fluorochrome-
conjugated antibodies for CD5 and CD19 and quantifying the percentage of CD5/CD19 double-
positive cells by flow cytometry. The CLL samples were cultured alone and with each of the 
endothelial cell types. In each case, 2x10
6 
viable CLL cells were co-cultured with 1x10
5
 endothelial 
cells, the same ratio as used for assays in Chapter 3. In preliminary experiments, this ratio of 
endothelial cells protected CLL cells from apoptosis and prevented outgrowth of endothelial cells by 
day 5. The endothelial cells are adherent and the CLL cells remained in suspension, allowing CLL 
cell removal with gentle pipetting. If the endothelial cells were allowed to overgrow, they would 
detach from the culture vessel and contaminate the CLL cell suspension. Samples were taken after 
5 days of co-culture and the viability of the CLL cells was determined by flow cytometry of Annexin V 




 cells. The data in Figure 4.2 show that co-culturing CLL cells 
with each of the endothelial cell types tested increased the viability of CLL cells compared with CLL 








Figure 4.1 Experimental approach to investigating transcriptional effects in common in 




CLL cells from six different patients were divided 
between each of four different conditions to compare changes in transcription associated with 







4.2.2. Endothelial cell co-culture induces a phenotypic change in CLL cells 
 
To determine whether the co-culture systems have an effect on the phenotype of these viable CLL 
cells, CLL cells were isolated from 6 patients (the same patients used in the assay described above) 
and cultured for 24 hours alone and in the HMEC-1, HDBEC and HDMEC co-culture systems and 
flow cytometry was used to assess a panel of activation (CD69) and negative prognostic markers 
(CD44, CD38). Figure 4.3 shows that statistically significant changes in expression of CD44 are 
observed in CLL cells in all co-culture systems compared with the paired sample of CLL cells 
cultured alone and statistically significant changes in expression of CD69 and CD38 were observed 
in CLL cells co-cultured with HMEC-1 and HDBEC compared with CLL cells cultured alone.  
Figure 4.2 CLL cell viability analysis by flow cytometry. The viability of CLL 
cells cultured alone, on HMEC-1, HDBEC and HDMEC for 5 days were analysed 
by flow cytometry using Annexin V-FITC and 7AAD (paired t-test, mean±SEM, 







4.2.3. Analysis of RNA quality isolated from co-cultured CLL cells 
 
In order to analyse a variety of CLL phenotypes (described in Table 4.1) using the same endothelial 
cells in the co-culture, it was necessary to use CLL samples which had been frozen. It is extremely 
important to verify that the quality of the sample starting material is good enough to produce robust 
data since inclusion of samples with degraded RNA can affect gene expression levels (178). 
The quality of the RNA isolated from each sample was analysed using the Agilent 2100 Bioanalyser, 
a microfluidics based platform for quality control as described in section 2.5.4. RNA quality is 
Figure 4.3 Phenotyping of CLL cells by flow cytometry. CLL cells from 6 
different CLL patients were cultured alone and on HMEC-1, HDBEC and HDMEC 
cells for 24 hours. The expression of CD44, CD38 and CD69 were determined in 
each case by flow cytometry (paired t-test, mean±SEM, experiments with cells 
from n=6 different CLL patients). 
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measured using the RNA Integrity Number (RIN) algorithm (179), which is rapidly becoming 
standard practice. The RIN analysis allows the reproducible comparison of RNA quality between 
different samples at different times. The Agilent software assigns an integrity number to the total 
RNA sample based on the entire electrophoretic trace of the RNA sample rather than just rRNA 
ratios as was used historically. In this way, the RIN algorithm includes the presence or absence of 
degradation products. As the RIN algorithm provides a numerical assessment of the integrity of 
RNA, it facilitates the direct comparison of RNA samples and enables the reproducibility of 
experiments. Ideally, all RNA samples used for a microarray experiment would be of comparable 
RIN number and integrity. RNA and microarray processing were carried out under the supervision of 
Mrs Megan Musson in the Central Biotechnology Services at the University of Cardiff, as part of 
collaboration with Professor Chris Pepper. Figure 4.4 shows an example of the readout from an 





Although the use of the RNA 6000 Nano chip here was not intended to measure RNA quantity, 
Figure 4.4A clearly shows a difference in the amount of total RNA isolated from each sample, for 
example in lane 1A corresponding to 0 hours and lane 1B corresponding to 12 hours liquid culture. 
However, Figure 4.4B demonstrates clear peaks of 18S and 28S rRNA, little RNA degradation 
between the peaks and a low baseline. Therefore, as the quality of the RNA was comparable across 
samples as identified by the RIN score, these samples were considered suitable for microarray 
analysis. 
 
Figure 4.4 An Agilent 2100 Bioanalyser RNA 6000 Nano chip trace.  A. Shows a 
computer generated electrophoretic trace for the samples analysed. Numbers identify 
different patients and letters identify conditions A = 0 hours B = 12 hours liquid culture 
C = 12 hours HMEC-1 co-culture D = 12 hours HDBEC co-culture B. Arrows indicate 
the 18S and 28S RNA peaks identified by the algorithm. 
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4.2.4. Analyses of gene expression array data 
 
Affymetrix Whole Transcript Human Gene 1.0 ST arrays were used in this study covering 21,014 
Refseq (Entrez) genes and 36,079 RefSeq transcripts (coverage derived from RefSeq download as 
of February 2012 (180)).The data from gene expression array chips, such as the one shown in 
Figure 4.5 were analysed during a rotation in Bioinformatics with Dr Eric Blanc in the MRC Centre 
for Developmental Neurobiology, King’s College London. Data were analysed using Bioconductor 
(128), version 2.10, and biomaRt version 2.12.0, which use the R statistical programming language 
and provides tools for the analysis and comprehension of high-throughput genomic data. BiomaRt 
(181) provides an interface to a collection of databases, allowing retrieval of large amounts of data in 
a uniform way without knowledge of the underlying database (182, 183). Examples of BiomaRt 
databases are Ensembl, Uniprot and HGNC. 
 
 







4.2.5. Gene expression array data cluster by co-culture condition 
 
Samples from a variety of CLL patients with different phenotypes were used for this study, as 
described in Table 4.1. Therefore it was important to establish whether any differences in mRNA 
expression observed were a result of the different clinical features of patients’ disease or a result of 
the co-culture condition. Gibbons and Roth (184) report that no method outperforms Euclidean 
distance for ratio-based measurements as a measure of dissimilarity between the expression 
patterns of two genes. Data clustering in this study  was based on the intensity record of the raw 
data and the average Euclidian distance between samples was calculated and visualised using the 
function rma() in R. As shown in Figure 4.6, raw data clustered by condition represented by colour 
and letters. The number corresponds to the CLL patient sample and clustering of patient number is 
not observed. The analysis represented in Figure 4.6 suggests that the differences observed in 
gene expression are due to condition rather than to differences intrinsic to cells isolated from 
particular CLL patients. As the data did not cluster by patient or disease phenotype, these gene 
 
Figure 4.5 A scanned image of a GeneChip array ready for data processing. An 
Affymetrix Human Gene 1.0 ST Gene Chip used in this study, scanned after hybridisation 
overnight. Brightness is proportional to the amount of RNA hybridised to each probe. 
101 
 
expression data from six patients were treated as biological replicates and used to investigate 





Next, the data were normalised using the Robust Multichip Average (RMA) method (185). RMA 
analysis is comprised of three steps: background adjustment, quantile normalization and 
summarisation.Figure 4.7 shows the effect of normalisation on the data. Different conditions are 
shown in different colours and the line style represents the CLL patient. In the raw data, spread is 
greatest in the centre of the plot, where density is greatest. After normalisation, there is less spread 
between the arrays, this means that any differences observed in mRNA expression are due to 
biological rather than technical reasons. Clustering of the normalised data is shown in Figure 4.8. 
This plot shows that the normalised data cluster by condition rather than by patient or the phenotype 
of the cells, as was the case for the raw data. 
Figure 4.6 Dendrogram showing clustering of raw data. Average Euclidian distance 
between clusters is plotted. Condtions are grouped by colour and letter, A= t=0h, B= 12h 
liquid culture, C= 12h HMEC-1 co-culture, D=12h HDBEC co-culture. Individual CLL 









Figure 4.8 Dendrogram showing clustering of normalised data. Average 
Euclidian distance between clusters is plotted. Conditions are grouped by colour 
and letter. A= t=0h, B= 12h liquid culture, C= 12h HMEC-1 co-culture, D=12h 
HDBEC co-culture. Individual CLL patients are identified by number. 
 
Figure 4.7 Expression values: raw vs. normalised data. Density plotted against 
Log2 expression values. Conditions are shown by colour and letter, A= t=0h, B= 
12h liquid culture, C= 12h HMEC-1 co-culture, D=12h HDBEC co-culture. Individual 
CLL patients are identified by number. The line style represents the CLL patient. 
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Conclusions of statistical testing: 
 the gene expression array data are technically sound and  
 changes in the signals observed are due to the biological experiment rather than for 
technical reasons.   
 
4.2.6. Differential expression of mRNA as a result of endothelial co-culture 
 
When analysing mRNA expression, the claim that a particular mRNA is differentially expressed in 
different samples can have several interpretations. In formal statistical terms, an mRNA is said to be 
differentially expressed if its expression level changes between two treatment conditions, regardless 
of how small the difference might be. However, in scientific discussion, an mRNA is likely to be 
considered differentially expressed only if its expression level changes by a biologically worthwhile 
amount that is likely to have a biological effect. Therefore, it is apparent that there is a disparity 
between the mathematical and biological concepts of differential expression. Many different cut-off 
methods have been applied to gene expression array data and it is useful to think of these methods 
as filtering tools to produce smaller, biologically meaningful datasets. For example, one method of 
differential analysis may be to calculate the fold change of expression. However small changes can 
still be biologically relevant, such as minor alterations in key regulators such as TP53 mRNA 
expression (186). Another method is to calculate the significance of a change in expression between 
two conditions. A study from Patterson et al. (187) required genes to satisfy a modest level of 
statistical significance (p <0.01 or p <0.05) then ranked significant genes by fold-change with a cut-
off of 1.5, 2 or 4. Peart et al. (188) and Raouf et al. (189) used cut offs of fold-change >1.5 and 
p <0.05 after adjustment for multiple testing, whilst Huggins et al. (190) required a 1.3 fold-change 
and p <0.2. Dalman et al. (191) showed that changing fold change and p-value cut-offs significantly 
altered microarray interpretations for their data when GO annotation categories were analysed, 
implying that different signalling pathways and functions involved when different cut off criteria were 
used. It is becoming increasingly common to require that differentially expressed genes satisfy 
both p-value and fold-change criteria simultaneously. Normally, a combination ranking gives better 
agreement between platforms and typically identifies more biologically meaningful sets of genes 
than p-values alone (191). 
For the data reported here, I chose to apply cut-off criteria including significance q<10
-3
 and fold 
change >1.5. A p-value is a measure of how likely you are to observe a difference in expression if no 
real difference existed between the two conditions. The q-value is the name given to adjusted p-
values, using an optimized false discovery rate (FDR). The FDR is the expected proportion of false 
104 
 
positives among all discoveries (rejected null hypotheses). For example, in this case if the null 
hypotheses of 1000 hypothesis tests were experimentally rejected and the maximum FDR level (q-
value) for these tests was 0.001, fewer than 1 of these rejections would be expected to be a false 
positive. Changes in the expression of 103 CLL cell mRNA met these cut-off criteria for the HDBEC 
co-culture dataset and 134 from the HMEC-1 co-culture dataset, when compared with their 
expression in CLL cells in liquid culture (for full data set see Supplementary Table 4.2.6). Table 4.2 
shows the top five up-regulated mRNA for each co-culture system which met the significance 
criteria.  
The Limma package in R was used to analyse differential mRNA expression of data from this study. 
Limma fits a linear model to the expression data for each gene (192). The approach requires two 
matrices to be specified. The first is the design matrix which identifies which RNA samples have 
been applied to each array. The second is the contrast matrix which specifies which comparisons 
you would like to make between the RNA samples, for example samples after 12 hours liquid culture 
or 12 hours endothelial co-culture. The philosophy of the approach fits a linear model to the data 
which fully models the systematic part of the data. The model is specified by the design matrix. Each 
row of the design matrix corresponds to an array in the experiment and each column corresponds to 
a coefficient that is used to describe the RNA sources in the experiment. A contrast matrix can then 




















IL13RA interleukin 13 
receptor, alpha 1
5.65 THBS1 thrombospondin 1 5.65
TM4SF1 transmembrane 4 L 
six family member 1




TFPI2 tissue factor 
pathway inhibitor 2
5.01 CCL2 chemokine (C-C 
motif) ligand 2
5.01
CAV1 caveolin 1 4.83 SERPINE1 serpin peptidase 
inhibitor, clade E
4.83
ANAX1 annexin A1 4.78 ANKRD1 ankyrin repeat 
domain 1
4.78
Table 4.2 Top up-regulated mRNA by fold change. The top five up-regulated mRNA for each 
co-culture system are shown. The full data sets are available in Supplementary Table 4.2.6. 
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4.2.7. Analyses of  GO term annotations enriched in co-culture datasets 
 
In order to determine whether the mRNA identified by the microarray analyses contained an over 
representation of corresponding genes involved in particular biological processes, cellular 
components or biological functions, hypergeometric testing was performed on GO annotated genes. 
Hypergeometric testing identifies over representation of genes with particular annotations relative to 
the reference database. 
Genes were assigned GO annotation terms which are curated by the Gene Ontology Consortium 
(136) using the OBOv1.2 file from http://www.geneontology.org/GO.downloads.ontology.shtml. The 
GO ontologies resemble a tree where child terms are more specialized and parent terms are less 
specialized, and each term may have more than one parent term (see section 1.3.3 (Introduction)). 
The relationships used in GO are also directed, for example a mitochondrion is an organelle, but 
an organelle is not a mitochondrion.  GO annotations in OBOv1.2 are linked to UNIPROT identifiers, 
however the microarray data were annotated with Ensembl identifiers and so the GO ontologies had 
to be mapped through ID conversions using BiomaRt, GO annotation → UNIPROT ID → Ensembl 
ID. A GO term hierarchy was also created for the terms for each GO term to give a list of ancestors. 
This step was important to account for the presence of child terms which result from a parent term 
rather than over representation. 
When converting between IDs, it is important to repeat checks on the data to ensure genes are not 
lost or duplicated through incorrect mapping. This was achieved by monitoring the length of the gene 
lists created at each stage of the ID conversion. Problems can arise during mapping where one 
gene may give rise to several different proteins due to transcript variants with different IDs, therefore 
mapping of GO annotations was done at the transcript level.  Another example of difficult mapping is 
where many proteins arise from a transcript. The aim was to annotate each transcript with all of the 
GO terms associated with the related proteins. Any IDs which did not map were removed to speed 
up computation. A gene ‘universe’ or gene list of 19177 with mappings was created. Hypergeomtric 
testing was then applied to the data to determine the probability of enrichment of any GO term in this 
‘gene universe’. This was calculated using nList, the number of genes annotated with the term, 
nCAT, the number of genes annotated with that term and the length of the gene universe (the 19177 
genes with complete mapping).  
Table 4.3 shows the top 10 GO annotations with the lowest q value from the HDBEC dataset, 
including processes such as angiogenesis, cell adhesion and cellular components including 
extracellular space, external side of plasma membrane and cell surface. For the complete dataset 






Table 4.4 shows the top ten GO annotations with the lowest q value from the HMEC-1 dataset. 
These include processes such as cell division and mitosis and cellular components such as cytosol 
and cytoplasm. This is interesting given that no evidence for CLL cell proliferation was observed in 
the HMEC-1 co-culture system, as described in section 3.2, Chapter 3.  For the complete dataset 
see Supplementary Table 4.2.7. 
 
 
4.2.8. 31 genes are up-regulated in both co-culture systems 
 
As described in section 4.2.1, both endothelial co-culture systems increased the viability of CLL 
cells. In order to determine whether this was though a common mechanism, I next identified mRNA 
significantly up regulated in both co-culture systems as compared with liquid culture. When applying 
a 1.5 fold change condition, 103 mRNA are significantly up-regulated in CLL cells by HDBEC co-
culture compared with liquid culture and 134 mRNA up-regulated by HMEC-1 co-culture compared 
with liquid culture. Only 31 mRNA were identified to be up-regulated in CLL cells in both co-culture 
Definition GO Term nList nCat p.value q.value
angiogenesis GO:0001525 25 186 6.22E-23 8.00E-19
cell adhesion GO:0007155 29 455 2.28E-17 1.47E-13
extracellular space GO:0005615 36 833 5.04E-16 2.16E-12
extracellular matrix GO:0031012 18 154 1.13E-15 3.62E-12
extracellular region GO:0005576 46 1445 2.25E-15 5.79E-12
external side of plasma membrane GO:0009897 17 166 6.70E-14 1.44E-10
cell surface GO:0009986 19 318 3.34E-11 6.14E-08
integrin binding GO:0005178 11 77 5.24E-11 8.43E-08
plasma membrane GO:0005886 64 3431 1.36E-10 1.94E-07
blood cogulation GO:0007596 20 463 2.98E-09 3.83E-06
Definition GO Term nList nCat p.value q.value
mitotic cell cycle GO:0000278 52 340 2.05E-30 2.64E-26
cell division GO:0051301 48 302 6.85E-29 4.41E-25
mitosis GO:0007067 35 189 1.38E-23 5.93E-20
cytosol GO:0005829 120 2305 2.72E-23 8.74E-20
microtubule-based movement GO:0007018 25 101 1.98E-20 5.10E-17
cytoplasm GO:0005737 156 4129 8.19E-17 1.76E-13
protein binding GO:0005515 174 4908 2.20E-16 4.04E-13
cytoskeleton-dependant intracellular transport GO:0030705 10 13 3.00E-15 4.83E-12
G2/M transition of mitotic cell cycle GO:0000086 22 123 6.22E-15 8.89E-12
M phase of mitotic cell cycle GO:0000087 19 93 3.55E-14 4.56E-11
Table 4.4 Enriched GO terms in the HMEC-1 vs. liquid culture dataset. A hypergeoetric test 
was applied and data were ranked by q score. Analyses of all the data are shown in 
Supplementary Table 4.2.7.   
 
Table 4.3 Enriched GO terms in the HDBEC vs. liquid culture dataset. A 
hypergeometric test was applied and data were ranked by q score. Analyses of all the data 
are shown in Supplementary Table 4.2.7.   
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systems with a significant q value and an increase in mRNA expression >1.5 fold when compared 
with liquid culture. The overlap between the co-culture datasets is shown in Figure 4.9 and a 




Some of the mRNA identified by these analyses are already known to play a role in the biology of 
CLL, such as IL-6 (13) whilst others are less well characterised in CLL, such the metallothioneins 
(MT). Increased MT levels have been observed in several tumour types including  breast, kidney, 
nasopharynx, lungs, prostate, testes, urinary bladder, cervix, endometrium, salivary glands, 
pancreas, acute lymphoblastic leukaemia and melanoma (193). MT have also been shown to play a 
role in drug resistance (194). The 31 mRNA up-regulated by both systems with >1.5 fold change are 
shown in Table 4.5 with ontology annotations retrieved from HumanNet 
(http://www.functionalnet.org/humannet/). mRNA were identified that are involved in processes 
including cell:cell adhesion, signal transduction and anti-apoptosis mechanisms. In the following 
sections, I performed bioinformatic analyses to determine whether these mRNA up-regulated by 
both endothelial co-cultures are co-regulated. 
 
Figure 4.9 mRNA up-regulated by both endothelial co-culture systems. The overlap of 
mRNA up-regulated by both endothelial cell co-culture systems was identified using 
transcript lists which met significant q-value and FC>1.5 compared with liquid culture for 








4.2.9. Network analyses of genes up-regulated by both co-culture systems 
 
I chose to further analyse all 53 mRNA which showed a significant increase in expression, 
regardless of the magnitude of fold change because the dataset of 31 mRNA with a greater than 1.5 
fold change was too small for network analyses. I performed network analyses using HumanNet 
(132), an algorithm produced by our collaborators at the University of Texas at Austin. The algorithm 
consists of a probabilistic functional gene network which was constructed by integrating 21 types of 
'omics' data from multiple organisms, with each data type weighted according to how well it links 
genes that are known to function together in H. sapiens. An interaction network was calculated 
EntrezGene SYMBOL
Average 
FC GO Biological Process GO Cellular Component GO Molecular Function
301 ANXA1 4.01
 lipid metabolic process; anti-apoptosis; cell 
motility; inflammatory response; cell cycle; 
cell surface receptor linked signal 
transduction; peptide cross-linking;  
regulation of cell proliferation; 
 cornified envelope; cytoplasm; 
sarcolemma;
 phospholipase inhibitor activity; receptor 
binding; structural molecule activity; calcium 
ion binding; calcium-dependent phospholipid 
binding; phospholipase A2 inhibitor activity; 
protein binding, bridging;
857 CAV1 3.94
 inactivation of MAPK activity; negative 
regulation of endothelial cell proliferation;  
negative regulation of signal transduction;  
regulation of vasoconstriction; regulation of 
vasodilation; 
 Golgi membrane; integral to membrane 
of membrane fraction; endoplasmic 
reticulum; plasma membrane; integral to 
plasma membrane; caveolar membrane; 
lipid raft; perinuclear region;
 structural molecule activity; protein binding; 
cholesterol binding;
7057 THBS1 3.88
 cell motility; inflammatory response; cell 
adhesion; multicellular organismal 
development; blood coagulation; negative 
regulation of angiogenesis;  extracellular region; extracellular space;
 endopeptidase inhibitor activity; signal 
transducer activity; structural molecule 
activity; calcium ion binding; protein binding; 
heparin binding;
4071 TM4SF1 3.83 na
 integral to plasma membrane; 
membrane; integral to membrane; na
3569 IL6 3.46
 neutrophil apoptosis; acute-phase 
response; humoral immune response; cell 
surface receptor linked signal transduction; 
cell-cell signaling; positive regulation of cell 
proliferation; negative regulation of cell 
proliferation; negative regulation of 
apoptosis; negative regulation of 
chemokine biosynthetic process;  extracellular region; extracellular space;
 cytokine activity; interleukin-6 receptor 
binding; protein binding;
4495 MT1G 3.21 na na
 copper ion binding; zinc ion binding; 
cadmium ion binding; metal ion binding;
5054 SERPINE1 3.03
 blood coagulation; fibrinolysis; regulation 
of angiogenesis;  extracellular region;
 protease binding; serine-type endopeptidase 
inhibitor activity; protein binding; 
plasminogen activator activity;
2791 GNG11 2.99
 signal transduction; G-protein coupled 
receptor protein signaling pathway;
 heterotrimeric G-protein complex; 
membrane;  GTPase activity; signal transducer activity;
55970 GNG12 2.91
 signal transduction; G-protein coupled 
receptor protein signaling pathway;
 heterotrimeric G-protein complex; 
membrane;  signal transducer activity;
131566 DCBLD2 2.76
 cell adhesion; negative regulation of cell 
growth; intracellular receptor-mediated 
signaling pathway; wound healing;
 integral to plasma membrane; cell 
surface; membrane;  protein binding;
Table 4.5 Commonly up-regulated mRNA. Ontology from HumanNet 
(http://www.functionalnet.org/humannet/). The mRNA significantly up-regulated in both co-culture 
systems with a fold change >1.5 compared with liquid culture. The top 10 mRNA with the 
greatest average FC are shown. A complete list of these mRNA is in Supplementary Table 4.2.8. 
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which predicts that proteins encoded by 39 of the 53 mRNA identified by gene expression analyses 
interact with one another. The HumanNet analyses were mapped with Cytoscape software to 
visualise the connections between the proteins and the network is shown in Figure 4.10. The 
Cytoscape network represents proteins as nodes and the edges indicate a predicted interaction 
between the proteins. Data were presented using the y-files organic layout tool. This bioinformatic 
analysis predicts that proteins encoded by 39 of the 53 genes interact with each other, suggesting 
that these proteins may work together functionally.  It is also likely that genes encoding proteins with 






4.2.10. GSCA identifies a potential novel transcription factor module in CLL 
 
In order to investigate any potential control mechanisms which may be responsible for the co-
ordinated expression and therefore function of the 53 mRNA identified by analyses in section 4.2.8, 
I performed further bioinformatic analyses to look for predicted transcription factor (TF) modules. 
Chromatin immunoprecipitation (ChIP) followed by high-throughput sequencing (ChIP-Seq) allows 
interrogation of the genome-wide effects of TFs. The Gene Set Control Analysis (GSCA) algorithm 
integrates 142 publicly available ChIP-Seq datasets for both normal and leukaemic murine blood cell 
Figure 4.10 HumanNet analyses predict that proteins encoded by 39/53 genes up-





types (195). It can be used to predict likely upstream regulators for lists of genes based on statistical 
significance of TF binding event enrichment within the gene loci of a chosen input gene set. GSCA 
was performed on the 53 genes identified in section 4.2.8 and a potential TF module was identified, 
as described in Figure 4.11, comprising STAT1, PU.1, p65, CEBPα and CEBPβ. The combined 





Examination of the original publically available ChIP-Seq datasets used to create the GCSA 
algorithm for these TF data (196-198) showed that 40 out of the 53 genes have putative binding 
sites for at least 3 of the 5 TF identified in the module. Table 4.6 below shows the 40 genes 
identified with at least three TF putative binding sites and their GO annotations retrieved using 
HumaNet.  
Figure 4.11 GSCA analyses (http://bioinformatics.cscr.cam.ac.uk/GSCA/GSCA) predict a 
TF module previously identified in macrophages that co-ordinates expression of 53 CLL 







Symbol GO Process GO Compartment GO Function
3312 HSPA8  protein folding; response to unfolded protein;  intracellular; nucleus; cell surface;
 nucleotide binding; protein binding; ATP binding; 
ATPase activity, coupled;
84790 TUBA1C  microtubule-based movement; protein polymerization;  mitochondrion; microtubule; protein complex;
 nucleotide binding; GTPase activity; structural molecule 
activity; GTP binding;
1973 EIF4A1  translation;  eukaryotic translation initiation factor 4F complex;
 nucleotide binding; RNA cap binding; nucleic acid 
binding; mRNA binding; translation initiation factor 
activity; protein binding; ATP binding; ATP-dependent 
helicase activity; hydrolase activity;
5717 PSMD11 na  proteasome complex (sensu Eukaryota); cytosol; na
5694 PSMB6  ubiquitin-dependent protein catabolic process;  cytosol; proteasome core complex (sensu Eukaryota);  threonine endopeptidase activity;
595 CCND1
 G1/S transition of mitotic cell cycle; re-entry into mitotic cell cycle; 
protein amino acid phosphorylation; cell cycle; unfolded protein 
response; fat cell differentiation; cell division;
 cyclin-dependent protein kinase holoenzyme complex; 
intracellular; nucleus; cytosol;
 protein kinase activity; protein binding; cyclin-dependent 
protein kinase regulator activity;
2791 GNG11
 signal transduction; G-protein coupled receptor protein signaling 
pathway;  heterotrimeric G-protein complex; membrane;  GTPase activity; signal transducer activity;
1984 EIF5A  regulation of translational initiation; apoptosis; viral genome replication;  nucleus; cytoplasm;  translation initiation factor activity;
7052 TGM2
 G-protein coupled receptor protein signaling pathway; peptide cross-
linking; positive regulation of cell adhesion;  extracellular matrix (sensu Metazoa); cytosol; membrane;
 protein-glutamine gamma-glutamyltransferase activity; 
calcium ion binding; GTP binding; acyltransferase activity; 
transferase activity;
55970 GNG12
 signal transduction; G-protein coupled receptor protein signaling 
pathway;  heterotrimeric G-protein complex; membrane;  signal transducer activity;
301 ANXA1
 lipid metabolic process; anti-apoptosis; cell motility; inflammatory 
response; cell cycle; cell surface receptor linked signal transduction; 
peptide cross-linking; keratinocyte differentiation; regulation of cell 
proliferation; arachidonic acid secretion;  cornified envelope; cytoplasm; sarcolemma;
 phospholipase inhibitor activity; receptor binding; 
structural molecule activity; calcium ion binding; calcium-
dependent phospholipid binding; phospholipase A2 
inhibitor activity; protein binding, bridging;
7057 THBS1
 cell motility; inflammatory response; cell adhesion; multicellular 
organismal development; nervous system development; blood 
coagulation; negative regulation of angiogenesis;  extracellular region; extracellular space;
 endopeptidase inhibitor activity; signal transducer 
activity; structural molecule activity; calcium ion binding; 
protein binding; heparin binding;
7035 TFPI  blood coagulation;  extracellular region;
 serine-type endopeptidase inhibitor activity; protease 
inhibitor activity;
858 CAV2
 negative regulation of endothelial cell proliferation; protein 
oligomerization;
 plasma membrane; integral to plasma membrane; caveolar 
membrane; transport vesicle; lipid raft; perinuclear region;  protein binding; protein homodimerization activity;
7082 TJP1  intercellular junction assembly;
 membrane fraction; nucleus; plasma membrane; septate 
junction; tight junction; intercellular canaliculus;  protein binding;
3569 IL6
 neutrophil apoptosis; acute-phase response; humoral immune 
response; cell surface receptor linked signal transduction; cell-cell 
signaling; positive regulation of cell proliferation; negative regulation of 
cell proliferation; negative regulation of apoptosis; negative regulation of 
chemokine biosynthetic process;  extracellular region; extracellular space;
 cytokine activity; interleukin-6 receptor binding; protein 
binding;
10594 PRPF8
 nuclear mRNA splicing, via spliceosome; visual perception; RNA 
splicing; response to stimulus;  nucleus; spliceosome; snRNP U5;
 protein binding; RNA splicing factor activity, 
transesterification mechanism;
4071 TM4SF1 na
 integral to plasma membrane; membrane; integral to 
membrane; na
3939 LDHA
 tricarboxylic acid cycle intermediate metabolic process; anaerobic 
glycolysis;  cytoplasm; cytosol;
 L-lactate dehydrogenase activity; protein binding; 
oxidoreductase activity;
284119 PTRF
 transcription; transcription termination; regulation of transcription, DNA-
dependent; transcription initiation from RNA polymerase I promoter;  nucleus; membrane;
 RNA polymerase I transcription termination factor 
activity; protein binding; rRNA primary transcript binding;
5054 SERPINE1 blood coagulation; fibrinolysis; regulation of angiogenesis;  extracellular region;
 protease binding; serine-type endopeptidase inhibitor 
activity; protein binding; plasminogen activator activity;
2034 EPAS1
 angiogenesis; response to hypoxia; regulation of transcription, DNA-
dependent; transcription from RNA polymerase II promoter; signal 
transduction; multicellular organismal development; cell differentiation;  nucleus;
 RNA polymerase II transcription factor activity, enhancer 
binding; transcription coactivator activity; signal 
transducer activity; protein binding; histone 
acetyltransferase binding;
2919 CXCL1
 chemotaxis; inflammatory response; immune response; G-protein 
coupled receptor protein signaling pathway; intracellular signaling 
cascade; nervous system development; cell proliferation; negative 
regulation of cell proliferation; actin cytoskeleton organization and 
biogenesis;  extracellular region; extracellular space;
 chemokine activity; enzyme activator activity; growth 
factor activity;
800 CALD1  cell motility; muscle contraction;  membrane fraction; cytoskeleton; actin cap;
 actin binding; calmodulin binding; tropomyosin binding; 
myosin binding;
9526 MPDU1 na  membrane; integral to membrane; na
966 CD59
 defense response; immune response; cell surface receptor linked 
signal transduction; blood coagulation;  membrane fraction; plasma membrane;  protein binding; GPI anchor binding;
5954 RCN1 na  endoplasmic reticulum; endoplasmic reticulum lumen;  calcium ion binding;
10410 IFITM3  immune response; response to biotic stimulus;  plasma membrane; integral to membrane; na
5376 PMP22
 synaptic transmission; peripheral nervous system development; 
sensory perception of sound; mechanosensory behavior; negative 
regulation of cell proliferation;
 membrane fraction; integral to plasma membrane; 
membrane; na
26064 RAI14 na  mitochondrion; cytoskeleton; na
8754 ADAM9  proteolysis; protein kinase cascade;  integral to plasma membrane; membrane;
 metalloendopeptidase activity; integrin binding; protein 
binding; zinc ion binding; SH3 domain binding; protein 
kinase binding; metal ion binding;
87 ACTN1
 regulation of apoptosis; focal adhesion formation; actin filament bundle 
formation; negative regulation of cell motility;  cytoskeleton; focal adhesion; Z disc; pseudopodium;
 actin binding; integrin binding; calcium ion binding; 
protein binding; vinculin binding; actin filament binding;
9518 GDF15
 signal transduction; transforming growth factor beta receptor signaling 
pathway; cell-cell signaling;  extracellular region; extracellular space;  cytokine activity; growth factor activity;
598 BCL2L1
 anti-apoptosis; negative regulation of survival gene product activity; 
apoptotic mitochondrial changes; response to radiation; regulation of 
apoptosis; positive regulation of anti-apoptosis;
 nucleus; mitochondrion; mitochondrial outer membrane; 
membrane; integral to membrane;  identical protein binding;
55379 LRRC59 na  membrane; integral to membrane;  protein binding;
11343 MGLL
 lipid metabolic process; aromatic compound metabolic process; 
inflammatory response; na
 lysophospholipase activity; serine esterase activity; 
hydrolase activity; acylglycerol lipase activity;
140576 S100A16 na na  calcium ion binding;
3383 ICAM1  cell-cell adhesion; regulation of cell adhesion;  plasma membrane; integral to plasma membrane;  transmembrane receptor activity; protein binding;
131566 DCBLD2
 cell adhesion; negative regulation of cell growth; intracellular receptor-
mediated signaling pathway; wound healing;  integral to plasma membrane; cell surface; membrane;  protein binding;
Table 4.6 40 Genes with potential binding sites for at least 3 of the 5 TF identified as 
a novel TF module in CLL. The 25 genes predicted to interact with one another by 




Next, I wanted to determine whether these 40 genes were involved in the same processes, as the 
coordinate expression of genes involved in the same functions is important biologically, for example 
in the mechanism of cell cycle control (199). DAVID Bioinformatics Resources (200, 201) were used 
to provide batch annotation and gene-GO term enrichment analysis of these 40 genes compared to 
genes from the reference database. Table 4.7 shows the top 10 most significant GO terms identified 
in the annotations of the 40 genes analysed. 11 of the 40 genes are annotated with the GO term 
‘regulation of cell proliferation’. The enrichment of GO terms in these 40 genes suggests that their 




I then analysed these data using the DAVID Functional Annotation Clustering tool. This algorithm 
measures relationships between annotated terms based on the degree of their co-association genes 
to group the similar, redundant and heterogeneous annotation from different resources into 
annotation. This helps to reduce the problem of associating similar redundant terms, improving 
biological interpretation of datasets. Table 4.8 shows the top five most significant annotation clusters 
identified by this analysis all of the data is shown in Supplementary Table 4.2.10. The presence of 
annotation clusters demonstrates that these genes are associated with particular functions or 
processes such as response to oxidative stress in annotation cluster 1. This is suggestive of a 




GO Term Count % PValue List Total Pop Hits Pop Total
Fold 
Enrichment FDR
GO:0042127~regulation of cell proliferation 11 28.21 1.53E-05 35 787 13528 5.40 2.38E-02
GO:0032270~positive regulation of cellular protein 
metabolic process 7 17.95 2.20E-05 35 233 13528 11.61 3.41E-02
GO:0051247~positive regulation of protein 
metabolic process 7 17.95 2.79E-05 35 243 13528 11.13 4.33E-02
GO:0009725~response to hormone stimulus 8 20.51 2.92E-05 35 367 13528 8.43 4.53E-02
GO:0009611~response to wounding 9 23.08 3.88E-05 35 530 13528 6.56 6.03E-02
GO:0009719~response to endogenous stimulus 8 20.51 5.47E-05 35 405 13528 7.63 8.49E-02
acetylation 16 41.03 7.39E-05 39 2635 19235 2.99 8.93E-02
GO:0044093~positive regulation of molecular 
function 9 23.08 7.90E-05 35 586 13528 5.94 1.23E-01
GO:0044459~plasma membrane part 17 43.59 1.29E-04 37 2203 12782 2.67 1.54E-01
GO:0010035~response to inorganic substance 6 15.38 1.48E-04 35 205 13528 11.31 2.30E-01
Table 4.7 DAVID Functional Annotation of 40 genes with 3 putative TF binding sites. 










GO:0010035~response to inorganic substance 15.38 1.48E-04 11.31 2.30E-01
GO:0006979~response to oxidative stress 10.26 7.95E-03 9.43 1.17E+01
GO:0000302~response to reactive oxygen species 7.69 1.52E-02 15.46 2.11E+01




GO:0009611~response to wounding 23.08 3.88E-05 6.56 6.03E-02
GO:0042060~wound healing 12.82 1.28E-03 10.12 1.97E+00
GO:0050817~coagulation 10.26 2.10E-03 15.16 3.21E+00
GO:0007596~blood coagulation 10.26 2.10E-03 15.16 3.21E+00
GO:0007599~hemostasis 10.26 2.47E-03 14.32 3.77E+00
GO:0050878~regulation of body fluid levels 10.26 5.24E-03 10.96 7.83E+00
hsa04610:Complement and coagulation cascades 7.69 3.82E-02 9.21 3.22E+01
GO:0005576~extracellular region 25.64 1.01E-01 1.72 7.19E+01
Secreted 17.95 1.12E-01 2.04 7.61E+01




GO:0044459~plasma membrane part 43.59 1.29E-04 2.67 1.54E-01
GO:0005886~plasma membrane 56.41 3.00E-04 2.01 3.57E-01
cell membrane 20.51 1.36E-01 1.80 8.28E+01
membrane 43.59 1.39E-01 1.34 8.35E+01




GO:0032101~regulation of response to external 
stimulus 10.26 7.30E-03 9.72 1.08E+01
GO:0045765~regulation of angiogenesis 7.69 1.09E-02 18.41 1.56E+01
GO:0051241~negative regulation of multicellular 
organismal process 7.69 6.37E-02 7.07 6.40E+01




GO:0006928~cell motion 15.38 6.27E-03 4.88 9.31E+00
GO:0051099~positive regulation of binding 7.69 1.63E-02 14.87 2.26E+01
GO:0051098~regulation of binding 7.69 5.63E-02 7.58 5.94E+01
Table 4.8 DAVID Functional Annotation Cluster analysis of 40 genes with 3 putative 




I then used HumaNet to perform a  network analysis of these 40 genes. This analysis predicted that 
25 of the 40 genes interact with one another, these connected genes are highlighted in yellow in 
Table 4.6. Figure 4.12 below shows that the predicted interactions occur in three modules. These 
can be explained functionally; for example the interlukin-6 (IL-6), Chemokine C-X-C motif ligand 1 
(CXCL1) and serpin peptidase inhibitor clade E (SERPINE1) all have roles described in 
inflammation (202-204). SERPINE1 is also known as Plasminogen Activator Inhibitor-1 (PAI-1) and 
is expressed by endothelial cells such as those in blood vessels (205) and inhibits the activity of 
matrix metalloproteinases, (206) which play a crucial role in invasion. These bioinformatic analyses 
are suggestive of a common transcriptional control mechanism responsible for the coordinated 

















CLL cells die rapidly by apoptosis when cultured in the laboratory (207), therefore supportive co-
culture systems are employed by many laboratories in order to keep CLL cells alive for further 
functional investigations into the disease mechanism. A common approach is to attempt to recreate 
some of the interactions in a culture flask which may occur in the tumour microenvironment. 
Endothelial cells are one class of accessory cell reported to exist in the tumour microenvironment in 
proliferation centres in the lymph node (52) and have been a focus of co-culture work carried out in 
our laboratory (1, 61, 173). This chapter has focused on determining whether there are any common 
transcriptional changes which occur in CLL cells cultured in two different endothelial cell systems in 
order to help identify any important mechanisms CLL cells may rely on for cytoprotection. Firstly, I 
demonstrated that both immortalised and primary endothelial cells were able to increase CLL cell 
viability in co-cultures compared to CLL cells alone in liquid culture. This observation was 
accompanied by a change in CLL cell phenotype, typically an increase in expression of CD69, CD44 
and CD38. The effects of co-culture were observed in cells isolated from all the CLL patients 
regardless of clinical stratification or phenotype. Next, I investigated the effects of endothelial cell co-
cultures on the mRNAs expressed in primary CLL cells. CLL cells from six different patients with a 
variety of phenotypes were analysed in order to identify mechanisms common to all CLL subtypes, 
which could be responsible for the effects observed in the co-cultures. During a bioinformatics 
rotation, I showed that the data clustered by co-culture condition rather than CLL patient 
stratification. This allowed the six patients to be treated as biological replicates in order to investigate 
the effects of the co-culture condition only.  
There is evidence to suggest that cancer cells become ‘addicted’ to particular signalling pathways, 
making proteins in these cascades ideal targets for intervention (208-211). This is particularly 
evident in CLL (212) and the BCR signalling pathway (213) where new Btk inhibitors (213, 214) are 
providing exciting opportunities for new targeted therapies. We reasoned that genes up-regulated by 
both endothelial co-culture systems were more likely to be important in maintaining CLL cell viability 
than those unique to one particular co-culture system. Using stringent significance and fold change 
criteria, 103 mRNA were found to be up-regulated by HDBEC co-culture and 134 mRNA up-
regulated by HMEC-1 co-culture. Of these, 53 mRNA were significantly up-regulated by both 
systems but only 31 achieved both significance and a fold change >1.5 when compared with liquid 
culture.  
Bioinformatic analyses of the genes encoding these mRNA identified a potential control mechanism 
involving a novel TF module in CLL. The identification of multiple TFs in modules such as the one 
described here may be more informative than individual TF when attempting to identify regulators of 
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a set of genes since TF have been shown to function as regulatory complexes. For example, 
cooperative regulation occurs at an enhancer located upstream of the gene encoding interferon-β 
(IFNB1) (215, 216). Individually, each of the TFs described here have been reported to be activated 
in CLL (p65 (REL A) (217), STAT1 (218, 219)  PU.1 (220), CEBPα (221) and CEBPβ (222)) but not 
as a module. However, these TFs have also been described in macrophages where myeloid cell fate 
is determined by PU.1, CEBPα and CEBPβ (223). The presence of a TF module in CLL which has 
been traditionally studied in the macrophage lineage may reflect the potential for rare trans-
differentiation in the disease. Studies from several groups have shown evidence that some small B-
cell lymphomas can transform into aggressive hematopoietic tumours of another lineage, which 
interestingly are of histiocytic/dendritic cell origin (222, 224-226).  
4.3.1. A final caveat: concerns about RNA used in the microarray study 
 
As discussed in section 4.2.3, it is extremely important to use high quality RNA for microarray 
studies and that the quality is comparable between samples. All samples were quality control 
assessed using an Agilent 2100 Bioanalyser as described in section 2.5.4 (Materials and Methods) 
before being used for microarray analysis and met standard RIN integrity criteria for inclusion in an 
array study. However, after becoming more familiar with the electrophoretic traces generated by the 
Bioanalyser and revisiting the data collected, we can observe extra peaks highlighted by arrows in 
Figure 4.13B, which are smaller than the expected 18S and 28S human rRNA peaks. It is unlikely 
that these extra peaks are degradation products, as they would have to be specific cleavages to 





Figure 4.13 An Agilent 2100 Bioanalyser RNA 6000 Nano chip trace showing extra 
bands A. Shows a computer generated electrophoretic trace for the samples analysed. 
Numbers identify different patients and letters identify conditions A = 0 hours B = 12 hours 
liquid culture C = 12 hours HMEC-1 co-culture D = 12 hours HDBEC co-culture B. Arrows 
indicate extra peaks below the 18S and 28S RNA peaks identified by the algorithm for patient 




One possible explanation for the presence of extra peaks could be an infection in the original 
cultures, such as mycoplasma which would produce 16S and 23S rRNA peaks. The HMEC-1 
endothelial cell line subsequently tested positive for mycoplasma using a PCR based method (EZ-
PCR Mycoplasma Test Kit). Since assays in section 4.2.3 were carried out in 24 well plates, it is 
possible than a mycoplasma infection could have spread between wells containing the HMEC-1 cell 
line and the HDBEC primary cells. However, it is not clear whether such an infection would be 
sufficient to produce these extra RNA peaks. Examining the Bioanalyser results as shown in Figure 
4.13 revealed that extra peaks were present in all co-cultured samples although at varying 
intensities compared with the expected human 18S and 28S rRNA bands. The implication of this is 
that the peaks could be due to a mycoplasma infection. Therefore, to establish whether the 
observations of the extra RNA peaks are consequences of mycoplasma infection, these co-culture 
experiments should be repeated using a mycoplasma negative endothelial cell line in addition to the 

















Cell surface proteome enrichment and identification by 
















5.1.1. Challenge of identifying cell surface proteins  
 
Cell surface proteins play critical roles in cell: cell recognition, signal transduction and molecular 
transport mechanisms (227). Membrane proteins constitute the major targets for protein based 
drugs because of their accessibility (228). Despite their importance in biological processes and drug 
discovery, membrane proteins are usually challenging to study because of the difficulty in preparing 
pure plasma membrane fractions, their biochemical characteristics and complex post-translational 
modifications (229) . Plasma membrane proteins are hydrophobic and they have to be removed from 
the phospholipid bilayer for analysis without aggregation and precipitation occurring. These proteins 
are usually found at relatively low abundance, imposing further challenges for identification and 
further functional experiments. 
Plasma membrane protein fractions can be prepared by a number of different methods. These 
include differential extraction with detergents, such as Triton-X114 (230), density gradient 
sedimentation (typically used to isolate membrane rafts (231)) or cell lysis followed by an 
ultracentrifugation method to separate cellular components (232). Each has their uses, but in many 
cases the preparations are contaminated with abundant intracellular proteins. Therefore, a more 
selective enrichment method is essential for the study of low-abundance membrane and membrane-
associated cell surface proteins. Biotinylation and affinity purification of cell-surface proteins, when 
coupled with mass spectrometry, can improve the detection of membrane proteins in low abundance 
and reduce contamination from other compartments, thereby increasing selectivity (233, 234). 
5.1.2. CLL cell surface proteins 
 
Interactions between CLL cells and accessory cells which recreate the tumour microenvironment 
and promote survival of CLL cells in vitro are discussed in Chapter 3. Direct cell: cell contact and 
soluble factors in these systems are believed to influence the phenotype of CLL cells (63, 65, 172) . 
In vitro data suggest that cell surface proteins on CLL cells play an important role in disease 





5.1.3. Experimental design 
 
In the study presented in this chapter, the cell surface proteome of CLL cells was investigated using 
a biotinylation enrichment method followed by LC-MS/MS. In this method, cells were first labelled 
with Sulfo-NHS-SS-Biotin (Pierce, Thermo Scientific; Figure 5.1), a thiol-cleavable amine-reactive 
biotinylation reagent. Cells were then lysed with a mild detergent and cell surface proteins further 
solubilised with gentle sonication in a water bath. The labelled proteins were then isolated with 
NeutrAvidin agarose (Pierce, Thermo Scientific) and the bound proteins released by incubating with 






5.2.1.  Isolation of cell surface proteins from primary T cells 
 
A cell surface protein biotinylation technique was tested using primary human T cells. These cells 
can be isolated routinely in the laboratory from a single donor leukocyte cone from the National 
Blood Service and were employed before using the method on precious samples from CLL patients. 
Non-activated, quiescent T cells were isolated from human peripheral blood, as described in section 
2.2.6 (Materials and Methods). Typically, more than 98% of these cells are CD3
+
 and not activated, 
as judged by CD69 expression and reported in work from our group by Lea et al. (236). Samples of 
these T cells were taken before (G0) and 48 hours after stimulation with CD3/CD28 activation beads, 
when the cells have entered late G1 and early S-phase of the first cell cycle (236). The percentage of 
cells in different cell cycle phases was determined by staining with PI and free FITC, as used in 
previous studies in our laboratory (155, 236) and described in section 2.3.1 (Materials and Methods). 
This cell model has been used extensively in our laboratory, including a project that identified 
changes in the chromatin and nuclear matrix-bound proteome (155). In the study presented here, 
Figure 5.1 Reaction of Sulfo-NHS-SS Biotin with an accessible primary amine 
(Figure from http://www.piercenet.com/). 
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cell surface proteins were biotinylated using the membrane impermeable Sulfo-NHS-SS-Biotin 
reagent described in section 5.1.3. Cytoplasmic proteins are inaccessible to the biotin and are 
should not be labelled. The reaction was stopped by the addition of Pierce quenching buffer, which 
contains free amine groups. Cells were then lysed, cell surface proteins were solubilised and 
NeutrAvidin beads were used to isolate the biotinylated proteins. These proteins were then released 
from the NeutrAavidin scaffold using reducing and denaturing conditions (boiling in SDS sample 
buffer, containing DTT). In order to determine whether the method had worked, western blotting as 
shown in Figure 5.2 was used to investigate the presence of a cell surface protein (CD5) and a 
cytoplasmic protein (Cdk6) in the fraction eluted from the NeutrAvidin matrix and the unbound which 





The cell surface protein CD5 is present in the fraction of proteins eluted from the NeutrAvidin beads, 
but the cytoplasmic protein Cdk6 is only present in the unbound fraction. Therefore, the data in 
Figure 5.2 indicate that this method specifically biotinylated and isolated cell surface proteins rather 
than intracellular proteins from primary human T cells. 
Figure 5.2 Western blot of cell surface proteins isolated from primary human T 
cells. Quiescent (G0) and CD3/CD28 stimulated (G1) human primary T cells were treated 
using a cell impermeable biotinylation reagent and the biotinylated proteins were isolated 
using NeutrAvidin beads. Total cell lysate, proteins eluted from the NeutrAvidin beads and 
unbound proteins were analysed by western blotting for human CD5 (cell surface protein) 




5.2.2. Optimisation of lysis conditions to increase cell surface protein 
solubilisation 
 
Proteolytic digestion (as required for MS analyses) of complex protein mixtures can be limited by 
protein solubility in solution and the folded states of proteins (237). Similarly, protein complexes 
present in protein mixtures often require detergents to denature complexes to make the proteins 
more accessible and susceptible to enzymatic cleavage. The amphiphilic nature of detergents 
encourages unfolding of hydrophobic cell surface proteins by stabilising the unfolded state. In order 
to maximise the recovery of cell surface proteins for identification by LC-MS/MS, the lysis conditions 
were optimised. Since the design of the experiment includes shotgun proteomics, a highly 
expressed cell surface protein, MHC1 was used as a surrogate measure of solubility of cell surface 
proteins. Four commonly used lysis buffers for cell surface protein solubilisation were tested using 
primary human T cells. CD3/CD28 stimulated (G1) human primary T cells were firstly treated using a 
cell impermeable biotinylation reagent, as described above and then the sample was divided and 
lysed in one of the following four buffers: (i) Pierce proprietary lysis buffer, (ii) RIPA buffer (150 mM 
NaCl, 1.0% (v/v) NP-40 , 0.5% (w/v) sodium deoxycholate, 0.1% (w/v) SDS, 50 mM Tris-HCl, pH 
8.0, (iii) buffer containing 1% (w/v) CHAPS, 1% (w/v) OGP and (iv) buffer containing 1% (v/v) Triton 
X-100. These buffers were chosen because they are typically used to solubilise membrane proteins. 
Solubilisation of the cell surface protein MHC1 by each of the conditions and its capture with 




Figure 5.3 Western blot of cell surface proteins isolated from primary T cells using 
different lysis conditions. CD3/CD28 stimulated human primary T cells were treated 
using a cell impermeable biotinylation reagent and lysed in Pierce proprietary lysis buffer, 
RIPA buffer, a buffer containing 1% (w/v) CHAPS, 1% (w/v) OGP or 1% (v/v) Triton X-
100. Total cell lysate, proteins eluted from the NeutrAvidin beads (biotinylated proteins) 
and unbound proteins (non biotinylated proteins) were analysed by western blotting using 
a mouse anti human MHC class 1 primary antibody. 
123 
 
The solubilisation and recovery of MHC1 cell surface protein was comparable between the Pierce 
proprietary lysis buffer, RIPA buffer and CHAPS/OGP buffer. In this case, Triton X-100 was an 
inferior detergent for protein solubilisation. Pierce proprietary cell surface lysis buffer was chosen for 
subsequent experiments because it is MS compatible and achieved similar recovery for the MHC1 
cell surface protein to the other detergent combinations tested. 
5.2.3. Analyses of HeLa total cell lysate by LC-MS/MS 
 
Experiments were carried out to test sample preparation conditions prior to LC-MS/MS analysis 
while I was at the University of Texas at Austin, where I could not isolate peripheral blood T cells. 
Therefore, in order to test conditions, HeLa cell samples were analysed, before using the precious 
CLL patient samples. A total cell lysate of HeLa cells was prepared by lysis in Pierce proprietary 
protein lysis buffer. The samples were prepared for LC-MS/MS analysis by first removing detergent. 
This was done by running the samlpes into an SDS-PAGE gel (section 2.6.3 (Materials and 
Methods)) for a very short time. This concentrates the proteins in a small portion of the gel without 
separating them. The gel slice was then excised and the proteins were digested into peptides using 
trypsin. The full method is in section 2.6 (Materials and Methods). The tryptic peptides eluted from 
the gel were then separated on a C18 reverse phase column and analysed by MS/MS using the 
LTQ-Orbitrap or Velos-Orbitrap mass spectrometers (ThermoFisher). The analyses were carried out 
in collaboration with Dr. Daniel Boutz in Professor Marcotte’s laboratory at the University of Texas at 
Austin, USA. I spent three months in the laboratory in Texas where I prepared and ran samples and 
learned analysis methods. Further samples were also run by Dr Boutz on my return to London. Each 
biological replicate was analysed three times, producing three technical injections and the data were 
combined for subsequent analyses. The MS/MS data were analysed by the Sequest search 
algorithm in the Proteome Discoverer suite and proteins were identified using Percolator (238), part 
of Mascot (147). Criteria for identification were that each protein had two or more independent tryptic 
peptides identified and proteins must be detected in at least two technical injections. Proteins were 
only included which had a FDR <1% at the spectral count level.  
Using the criteria described above, a total of 473 proteins were identified in the HeLa total lysate and 
Table 5.1 shows the top twenty most abundant proteins identified by total peptide counts summed 
over three replicate injections. A full list of proteins identified is available in Supplementary Table 
5.2.3. Of the 473 proteins identified, 25 are annotated with only one GO term describing the cellular 
compartment with 2610 annotations attributed to the remaining 448. GO annotations are very 
general and complexities such as changes in sub-cellular localisations are not included.  For 
example, CD44 has been shown to have roles in adhesion and cell migration at the cell surface 
(239) but also has a form in the nucleus where it acts as a signalling molecule (240). This makes 
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annotation of the identified proteins difficult. Approximately 22% of all proteins coded by the human 
genome are found at the cell surface (228, 241), but cell surface and transmembrane proteins are 
underrepresented in the literature and in high throughput data analyses (242). 81 of the 473 proteins 
identified in this HeLa dataset (17%) have the annotation ‘plasma membrane’ or ‘integral to plasma 








Table 5.1 Analyses of HeLa Total Lysate. HeLa cells were lysed in Pierce proprietary cell 
surface protein lysis buffer and samples of peptides produced by tryptic digests were 
analysed by LC-MS/MS. The table shows total counts from three injections for the top 20 




5.2.4. Identification of HeLa cell surface proteins by LC-MS/MS 
 
In order to test the biotinylation method for identifying cell surface proteins, HeLa cells were treated 
with Sulfo-NHS-SS-Biotin as described in section 2.6.1 (Materials and Methods) or with the reagent 
diluent, PBS as a control. Cell surface proteins isolated from these samples using NeutrAvidin beads 
were then identified by LC-MS/MS. In order to exclude abundant proteins and to improve cell 
surface protein enrichment, proteins identified in the biotinylated fractions were only included in the 
final dataset if they were significantly observed compared to the HeLa consensus total cell lysate 
protein list obtained in section 5.2.3. 
To determine whether a protein was significantly identified in the biotinylated sample compared to 
the control, a Z score was calculated using the summed counts for the biotinylated versus the 
summed counts for control samples from three technical repeat injections. Of the proteins identified, 
188 have a significant Z score (>1.96, corresponding to a 95% confidence interval) and 100 of these 
have been identified as plasma membrane or cell surface proteins by a manual literature search 
using either GeneCards (http://www.GeneCards.org/) or NCBI (http://www.ncbi.nlm.nih.gov/) 
annotations.  The data were then filtered using a cut off value of fold change (FC) >2. The label-free 
MS data of the peptides identified from cells treated with Sulfo-NHS-SS-Biotin, compared with the 
PBS control were quantified by a spectral counting method, which was developed by our 
collaborators in Texas (154) and which we used in a previous study (155). The top 25 proteins 









Table 5.2 Analyses of the cell surface proteome of HeLa cells. HeLa cells were treated 
with biotinylation reagent Sulfo-NHS-SS-Biotin or PBS control, lysates were incubated with 
NeutrAvdin beads and proteins were eluted using DTT. Isolated proteins were analysed by 
LC-MS/MS. Of the proteins identified, proteins were selected with a Z score >1.96 and <1.96 
with FC >2 compared with the control. The table shows the top 25 proteins with greatest FC 




Given the issues associated with ontology annotation discussed in section 5.2.3, it may be helpful to 
consider the enrichment of cell surface proteins in a given sample relative to their expected 
observation frequency in a reference database. David Functional Analysis Tools (200, 201) 
searches for enriched biological themes or GO terms in a list to highlight the most relevant GO terms 
associated with a given gene list. This function clustering tool uses a novel algorithm to measure 
relationships among the annotation terms based on the degrees of their co-association. This groups 
the similar, redundant and heterogeneous annotation terms from the same or different resources 
into annotation groups, thus reducing the problem of similar redundant terms and makes the 
biological interpretation more focused at a group level. David functional analyses were carried out on 
the 137 proteins identified with a significant Z score Z >1.96 and fold change>2 in the biotinylated 
sample compared to the PBS treated control on HeLa cells shown in Table 5.3. The full dataset is 
available in Supplementary Tale 5.2.4a. 
This dataset showed a clear enrichment for cell surface proteins as a result of biotinylation with the 
highest scoring annotation clusters being associated with proteins integral to the plasma membrane 
and the following two clusters being functions associated with cell surface proteins, namely cell-cell 
adhesion and cell migration. These David analyses are in agreement with the manual search 
described in Table 5.2. Of the 137 proteins identified by the cell surface biotinylation, 69.8% are 
annotated with the GO term ‘plasma membrane’ by David Functional Analysis, representing an 
enrichment of 2.5 fold compared to calculated expected observations. An even greater enrichment 
of 4.8 fold was observed for the GO term, ‘integral to plasma membrane’ and ‘intrinsic to plasma 
membrane’. Only 22 proteins were identified in both the cell surface datasets from the HeLa total 
lysate and the HeLa cell surface protein biotinylation enrichment. This may be due to the high 
abundance of these 22 proteins, since the MS method is based on statistical sampling. The proteins 
which were identified in the total lysate but not in the biotinylated sample may have been 
inaccessible to the biotin reagent, possibly due to being heavily glycosylated or they may not contain 




5.2.5. DNase1 treatment of the protein sample to remove actin and reduce 
non-specific interactions 
Table 5.3 David Functional Analysis of HeLa cell surface proteins. The 137 proteins 
identified in section 5.2.4 (with significant Z scores and FC>2 in the biotinylated samples 
compared with the control) were analysed using David Functional Analysis Tools 
(http://david.abcc.ncifcrf.gov/). The top five annotation clusters are shown. The full dataset is 




The protein identified most frequently in a HeLa total lysate is the highly abundant beta actin (Table 
5.1). This has several implications for this project. Firstly, a technical issue called ion suppression 
can arise due to the presence of a highly abundant protein in a sample. Ion suppression occurs 
when there is an overrepresented ion in a sample. The ion trap will fill with the highly abundant ion, 
masking signal from other low abundance ions. This is also a common problem with contaminants 
such as keratins which can be introduced during sample preparation before MS. Secondly, many 
proteins are known to bind to actin monomers, polymers or both and between 60 and 100 actin-
binding proteins have been reported (243). This raises the issue of distinguishing between a specific 
identification of a protein and one which is co-purified with actin. This is a challenge, particularly 
when working with large, hydrophobic or ‘sticky’ proteins, many of which are present in low 
abundance. One solution to diminish intracellular background from studies is to pre-clear samples 
using biotin agarose beads and to include non-biotinylated control samples in the analyses, as 
described above. Another solution is to prevent aggregation of proteins in the lysis buffer and 
increase the solubility of membrane proteins. This can be achieved by adding glycerol to the lysis 
buffer or using specific lysis conditions, as discussed in 5.2.2.  Another approach as described by 
Karhemo et al. (244) is the use of DNase1 to digest high-molecular weight, viscous DNA. DNase1 
treatment is known to depolymerise the F-actin network. DNase1 binds to the terminal actin 
monomers at the pointed ends of actin filaments (245) and alongside the filament (246). It also acts 
as a depolymerising protein by increasing the depolymerisation rate constant of actin at the pointed 
filament end (247). DNase1 addition to cell extracts has been used in proteomic studies to remove 
cytosolic actin proteins associated with viscous DNA. This approach has been used to liberate a 
maximal amount of membrane proteins, while removing co-purifying contaminants (244). Therefore, 
the method was tested whereby DNase1 was added to the HeLa samples at 25µg/ml and processed 
as described in section 2.6.2. 
The data in Figure 5.4A and B show that there is significant overlap between the proteins identified 
in the DNase1 treated sample and the untreated sample; 85% for the biotinylated samples and 89% 
for the PBS control samples. In addition, Figure 5.4C shows that DNase1 treatment results in 
slightly fewer proteins being identified when compared with the untreated sample. Although the 
DNase1 was shown to be active in a test digest using a plasmid (data not shown), actin was still 
highly abundant in the DNase1 treated HeLa cell samples and treatment did not increase the 
number or proportion of cell surface proteins substantially enough for the method to be utilised 








5.2.6. Isolation of cell surface proteins from primary CLL patient samples 
 
The western blot in Figure 5.2 shows that cell surface proteins can be enriched from primary human 
T cells. Further experiments described above using HeLa cells and the biotinylation method 
described in section 5.2.1 show that proteins known to be associated with the plasma membrane 
can then be identified by mass spectrometry. The method was then used to identify the cell surface 
proteome of cells isolated from CLL patients. PBMCs are routinely isolated from peripheral blood of 
CLL patients using Ficoll Histopaque density centrifugation and either used immediately or stored in 
liquid nitrogen until required. In preliminary experiments, CLL PBMC samples were defrosted and 
2x10
7 
cells were biotinylated immediately, using the same method employed to biotinylate normal T 
cells and HeLa cells. When this cell surface biotinylation method was applied to cryopreserved 
Figure 5.4 Analyses of HeLa cell surface extracts with or without DNAse1 treatment. A. 
HeLa cells were treated with biotinylation reagent, with or without DNAse1 treatment. B. HeLa 
cells treated with PBS control with or without DNAse1. C. Number of proteins identified in 
each condition. Protein identifications were included in the dataset if they were observed in at 
least two technical replicates. The graph shows total counts from three injections into the MS. 





primary CLL cells it was unsuccessful due to poor CLL cell viability. CLL cells are more fragile than 
the primary human T cells or HeLa cells and they began to die when defrosting and during the 
biotinylation procedure. The percentage of live cells was determined routinely by cell counting with 
trypan blue stain. The dying cells had a permeable cell membrane, allowing the biotinylation reagent 
into the cells, resulting in the labelling of cytoplasmic proteins. This was observed when protein 
samples were analysed by western blotting. I attempted to troubleshoot the application of this 
method to cryopreserved CLL cells by separating viable cells from dead cells after biotinylation using 
a subsequent round of Ficoll Histopaque density centrifugation; however the resulting yield of viable 
cells was too low for this method to be used further.   
Next, fresh CLL cells brought straight from the clinic at King’s College Hospital were biotinylated 
using the same protocol. The western blot in Figure 5.5 below shows an analysis of the plasma 
membrane protein MHC1 and the intracellular protein Bcl-2 in samples of freshly isolated CLL cells, 
which were treated with bioinylation reagent or with PBS control and isolated with NeutrAvidin 
beads. These data suggest that the cell surface biotinylation protocol is suitable for use on freshly 
isolated CLL cells. Bcl-2 is observed only in the unbound fraction of both samples, which shows that 
the integrity of the plasma membrane was maintained during the labelling procedure. In contrast, the 
cell surface protein MHC1 is detected in the bound fraction of the sample treated with biotinylation 
reagent but not in the sample treated with PBS control.  
These data indicate that MHC1 is biotinylated and is not simply binding non-specifically to the 
NeutrAvidin beads. A small amount of the MHC1 protein is present in the insoluble pellet fraction. 
The blot was deliberately over-exposed and the amount of MHC1 in this insoluble fraction 
constitutes perhaps only a few percent of the total. The labelling reaction itself may not be 100% 
efficient as the majority of MHC1 does not bind to the NeutrAvidin column. This could be because of 
post-translational modifications, which make lysines inaccessible to the reagent. Alternatively, some 
MHC1 may have been localised in a different cellular compartment. Further optimisation of lysis and 
labelling conditions was not undertaken to maximise recovery of biotinylated (bound) MHC1 as it 
was being used as a surrogate marker for total cell surface proteins. Each of the fresh CLL samples 
is precious and troubleshooting conditions using these primary cells is wasteful. Conditions which 
maintained cell viability whilst isolating some of the cell surface proteome and subsequent 








Maintenance of cell membrane integrity is of vital importance to this experiment and CLL cells are 
especially fragile and die by apoptosis the longer they are out of the body, even during basic 
laboratory manipulations such as centrifugation, gentle pipetting and cell counting. For this reason, 
the viability of the CLL cells was monitored continually throughout the isolation from whole blood and 
the biotinylation labelling process. Assessment of sample viability by flow cytometry of Annexin 
V/7AAD was not always practical, so viability was assessed by cell counting with trypan blue. Only 
samples which were >99% viable after biotinylation were included in the study. It is possible that the 
requirement for good cell viability after manipulation self selects a cohort of CLL patients for this 
study whose cells are more resistant to spontaneous apoptosis, however this is unavoidable. The 
cell numbers required for the procedure (at least 1 x 10
8
) also selects for patients with high WBC 
and typically more aggressive disease. Initial experiments were carried out on CLL PBMCs; later 




cells (as described in section 2.2.9 (Materials 
and Methods)). This step was introduced to ensure that the cell surface proteome of CLL cells and 
not other cell types was analysed. The purity after selection was typically 98% as described in 
section 4.1.1 (Chapter 4) and their viability was monitored as described above. 
 
Figure 5.5 Western blot of cell surface proteins isolated from primary CLL cells.  Primary 
CLL cells were treated using a cell impermeable biotinylation reagent or PBS control and then 
lysed as described. Total cell lysates were incubated with NeutrAvidin beads. The insoluble 
pellet after lysis, the proteins eluted from the beads (bound) and unbound proteins were 




To assess the efficiency of the biotinylation labelling reaction, Sulfo-NHS-SS-Biotin and PBS treated 
CLL cells were incubated with streptavidin-FITC and the proportion of streptavidin-FITC positive 
cells was analysed by flow cytometry. This assay was carried out for each CLL sample analysed and 




Figure 5.6 shows that at least 60% of the CLL cells are streptavidin-FITC positive and therefore 
labelled during the biotinylation reaction. Due to the large numbers of cells available from CLL 
patient samples, this level of labelling was deemed sufficient for further studies.  
5.2.7. Identification of cell surface proteins from primary CLL cells by LC-
MS/MS–  a pilot study 
 
Preliminary studies were performed to identify cell surface proteins isolated from three different CLL 





) at King’s College London and LC-MS/MS sample preparation was 
performed at the University of Texas at Austin, USA by Dr. Daniel Boutz. For these samples, an in-
solution digest was performed and the peptides were then separated by C18 reverse phase columns 
and analysed by LC-MS/MS using the LTQ-Orbitrap, as described in section 2.6.6 (Materials and 
Methods). For these initial experiments, only biotinylated samples were analysed by LC-MS/MS. 
Figure 5.7A below shows that there is considerable overlap between the proteins identified in each 
patient sample. The cellular localisation of the 213 proteins identified in common between all three 
patient samples was investigated using annotations from Panther and HumanNet classifications. 
Figure 5.6 Analysis of CLL cell Biotinylation by flow cytometry. Fresh CLL cells were 
biotinylated as described in section 2.6.1 (Materials and Methods) and biotin labelling of the 
cell surface was measured by flow cytometry after incubation with streptavidin-FITC. Plots 
were gated on single cells and a 1% positive gate was set using the PBS control sample.  
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Only 2.4% of the proteins identified were annotated with the term ‘plasma membrane’ G0:0005886. 
This is much lower than would be expected from the method, given the preliminary experiments 
using HeLa cells described in section 5.2.4, where the same methods produced very efficient 
enrichment of cell surface and membrane proteins, which were17% of the total identified and were 





The CLL LC-MS/MS data contains a larger proportion of intracellular proteins, as illustrated in 
Figure 5.7. One explanation for this observation could simply be due to differences in cell type and 
cell structure. CLL cells are comparatively much smaller, with a smaller cytoplasm and produce less 
protein per cell than HeLa. The CLL cells are also more spherical than HeLa and so have a smaller 
cell surface per cell. However, some of the non plasma membrane proteins identified have recently 
been reported to be able to bind to stereotyped BCRs in CLL (248). These proteins include vimentin, 
cofilin 1 and non-muscle myosin heavy chain 9 (also known as non muscle myosin heavy chain IIA), 
which are highlighted yellow in Table 5.4. The complete dataset is shown in Supplementary Table 
5.2.7.Other proteins were identified that could be co-purifying with cell surface proteins. These 
include ezrin and moesin, two of the ERM proteins (Ezrin, Radixin and Moesin) which have been 
shown to associate with a positively charged amino acid cluster in the juxta-membrane cytoplasmic 
domain of CD44, CD43 and intracellular adhesion molecule 2 (ICAM-2) (249). Therefore, it is 
possible that some of the cytoplasmic proteins identified are being co-purified due to interactions 
with cell surface proteins. 
Figure 5.7 Proteins identified from cell surface fractions of primary CLL cells. Cell surface 
proteins were isolated from cells of three CLL patients and samples were analysed by LC-
MS/MS. Protein identifications were included in the dataset if they were observed in at least two 
technical replicates. A. Shows overlap between different CLL patient datasets. B. The sub 
cellular locations of proteins identified were determined using Panther classifications 




Reference Gene ID GO Process GO Component GO Function HGNC symbol Total Count
vimentin  ENSG00000026025  cell motility  cytoplasm  structural constituent of cytoskeleton VIM 351
hemoglobin, beta  ENSG00000244734  transport  hemoglobin complex  oxygen transporter activity HBB 308
HLA class I histocompatibility antigen, B-8 alpha 
chain Precursor  ENSG00000223532 184
hemoglobin, delta  ENSG00000223609  transport  hemoglobin complex  oxygen transporter activity HBD 183
actin, beta  ENSG00000075624  cell motility  soluble fraction  nucleotide binding ACTB 182
actin, gamma 1  ENSG00000184009  cell motility  soluble fraction  nucleotide binding ACTG1 182
HLA class I histocompatibility antigen, B-48 alpha 
chain Precursor  ENSG00000234745 173
HLA class I histocompatibility antigen, A-11 alpha 
chain Precursor  ENSG00000206503  antigen processing  integral to  PM  protein binding 170
HLA class I histocompatibility antigen, A-80 alpha 
chain Precursor  ENSG00000224320 164
protein tyrosine phosphatase, receptor type, C  ENSG00000081237
 negative regulation of T cell 
cytotoxicity  integral to  PM  protein tyrosine phosphatase activity PTPRC|PTPRC 159
major histocompatibility complex, class I, A  ENSG00000235657 HLA-A|HLA-A 157
actin, alpha 1, skeletal muscle  ENSG00000143632  muscle contraction  stress fiber  nucleotide binding ACTA1 151
actin, alpha, cardiac muscle 1  ENSG00000159251  muscle contraction  cytoskeleton  nucleotide binding ACTC1 151
HLA class I histocompatibility antigen, A-32 alpha 
chain Precursor  ENSG00000223980 147
POTE ankyrin domain family, member E  ENSG00000188219 na na na POTEE 146
POTE ankyrin domain family, member F  ENSG00000196604 POTEF 146
H2A histone family, member J  ENSG00000111332 H2AFJ 139
histone cluster 1, H2ad  ENSG00000196866 na na na HIST1H2AD 139
histone cluster 1, H2ai  ENSG00000196747 na na na HIST1H2AI 139
histone cluster 1, H2aj  ENSG00000182611 na na na HIST1H2AJ 139
histone cluster 2, H2aa3  ENSG00000183558  nucleosome assembly  nucleosome  DNA binding HIST2H2AA3 139
histone cluster 2, H2ac  ENSG00000184260  nucleosome assembly  nucleosome  DNA binding HIST2H2AC 139
histone cluster 1, H2ah  ENSG00000184825  nucleosome assembly  nucleosome  DNA binding HIST1H2AH 139
HLA class I histocompatibility antigen, Cw-2 alpha 
chain Precursor  ENSG00000228299 137
hemoglobin, epsilon 1  ENSG00000213931  transport  hemoglobin complex  oxygen transporter activity HBE1 131
hemoglobin, gamma A  ENSG00000213934  transport  hemoglobin complex  oxygen transporter activity HBG1 131
hemoglobin, gamma G  ENSG00000196565  transport  hemoglobin complex  oxygen transporter activity HBG2|HBG2 131
HLA class I histocompatibility antigen, A-25 alpha 
chain Precursor  ENSG00000206505 125
histone cluster 1, H2ab  ENSG00000137259  nucleosome assembly  nucleosome  DNA binding HIST1H2AB 123
histone cluster 1, H2ac  ENSG00000180573  nucleosome assembly  nucleosome  DNA binding HIST1H2AC 123
histone cluster 3, H2a  ENSG00000181218  nucleosome assembly  nucleosome  DNA binding HIST3H2A 123
major histocompatibility complex, class I, C  ENSG00000204525  ciliary or flagellar motility  axonemal dynein complex  microtubule motor activity HLA-C|HLA-C 121
Major histocompatibility complex, class I, C   ENSG00000233841 121
HLA class I histocompatibility antigen, A-29 alpha 
chain Precursor  ENSG00000231834 120
keratin 1  ENSG00000167768  complement activation  cytoskeleton  receptor activity KRT1 119
Major histocompatibility complex, class I, A 
Fragment   ENSG00000227715 116
HLA class I histocompatibility antigen, Cw-1 alpha 
chain Precursor  ENSG00000237022 116
peripherin  ENSG00000135406 na  intermediate filament  structural molecule activity PRPH 115
POTE ankyrin domain family, member M  ENSG00000196834 POTEI|POTEM 112
HLA class I histocompatibility antigen, B-52 alpha 
chain Precursor  ENSG00000232126 110
histone cluster 1, H4a  ENSG00000196176 na na na HIST1H4A 104
peroxiredoxin 1  ENSG00000117450  skeletal development na  oxidoreductase activity PRDX1 99
HLA class I histocompatibility antigen, B-35 alpha 
chain Precursor  ENSG00000206450
 antigen processing and 
presentation of peptide 
antigen via MHC class I  membrane fraction  MHC class I receptor activity 99
ubiquitin C  ENSG00000150991  protein modification na na UBC 99
major histocompatibility complex, class II, DR 
alpha precursor   ENSG00000204287
 antigen processing and 
presentation of peptide or 
polysaccharide antigen via 
MHC class II  lysosome  MHC class II receptor activity 97
major histocompatibility complex, class II, DR 
alpha  ENSG00000206308 HLA-DRA|HLA-DRA|HLA-DRA97
hemoglobin, alpha 1  ENSG00000206172 na na na HBA1 90
POTE ankyrin domain family, member J  ENSG00000222038 POTEJ 89
heat shock 70kDa protein 9  ENSG00000113013  protein folding  cytoplasm  nucleotide binding HSPA9 88
HLA class I histocompatibility antigen, B-49 alpha 
chain Precursor  ENSG00000224608 88
major histocompatibility complex, class I, B  ENSG00000228964 HLA-B|HLA-B|HLA-B 88
malate dehydrogenase 2, NAD  ENSG00000146701  glycolysis  mitochondrion  L-lactate dehydrogenase activity MDH2 88
H2A histone family, member V  ENSG00000105968  nucleosome assembly  nucleosome  DNA binding H2AFV 86
H2A histone family, member Z  ENSG00000164032  nucleosome assembly  nucleosome  DNA binding H2AFZ 86
H2A histone family, member X  ENSG00000188486
 double-strand break repair via 
HR  nucleosome  damaged DNA binding H2AFX 80
HLA class I histocompatibility antigen, Cw-8 alpha 
chain Precursor  ENSG00000206435 80
histone cluster 1, H2aa  ENSG00000164508  nucleosome assembly  nucleosome  DNA binding HIST1H2AA 80
histone cluster 2, H2ab  ENSG00000184270  nucleosome assembly  nucleosome  DNA binding HIST2H2AB 80
HLA class II histocompatibility antigen, DRB1-15 
beta chain Precursor  ENSG00000196126
 antigen processing and 
presentation of peptide or 
polysaccharide antigen via 
MHC class II  membrane  MHC class II receptor activity 77
major histocompatibility complex, class II, DR beta 
1  ENSG00000206306 HLA-DRB1|HLA-DRB1|HLA-DRB177
HLA class II histocompatibility antigen, DRB1-10 
beta chain Precursor  ENSG00000228080 77
glyceraldehyde-3-phosphate dehydrogenase  ENSG00000111640  glucose metabolic process  cytoplasm 
 glyceraldehyde-3-phosphate 
dehydrogenase  GAPDH 73
heterogeneous nuclear ribonucleoprotein A2/B1  ENSG00000122566  nuclear mRNA splicing  nucleus  nucleotide binding HNRNPA2B1 66
microRNA 7-1  ENSG00000165119  mRNA processing  nucleus  nucleic acid binding HNRNPK|MIR7-1 65
keratin 10  ENSG00000186395  epidermis development  keratin filament  protein binding KRT1 65
actin, alpha 2, smooth muscle, aorta  ENSG00000107796 na  cytoskeleton  nucleotide binding ACTA2 62
actin, gamma 2, smooth muscle, enteric  ENSG00000163017 na  cytoskeleton  nucleotide binding ACTG2 62
cofilin 1  ENSG00000172757  anti-apoptosis  intracellular  actin binding CFL1 55
heterogeneous nuclear ribonucleoprotein H1  ENSG00000169045  mRNA processing  nucleus  nucleotide binding HNRNPH1 55
major histocompatibility complex, class I, E 
precursor   ENSG00000204592
 antigen processing and 
presentation of peptide 
antigen via MHC class I  membrane  MHC class I receptor activity 51
major histocompatibility complex, class I, E  ENSG00000206493 HLA-E 51
HLA class I histocompatibility antigen, alpha chain 
E Precursor  ENSG00000229252 51
myosin, heavy chain 9, non-muscle  ENSG00000100345
 cellular morphogenesis during 
differentiation  stress fiber  microfilament motor activity MYH9 50
major histocompatibility complex, class II, DR beta 
5  ENSG00000198502
 antigen pr cessing and 
presentation of peptide or 






5.2.8. Identification of cell surface proteins from primary CLL cells by LC-
MS/MS – optimisation 
 
In order to determine whether some of the proteins observed in Table 5.4 were binding non-
specifically to the NeutrAvidin beads, the experiment was modified to include a sample treated with 





 cells were selected from PBMCs isolated from CLL patient samples as described in 
section 2.2.9 (Materials and Methods), then half of the cells were treated with biotinylation reagent 
and half with PBS. 
Cells from four different CLL patients were analysed by LC-MS/MS and total peptide counts were 
summed from three replicate injections. Of the proteins identified, proteins were selected with a 
significant Z score (>1.96 or <1.96) and with FC >2 in the biotinylated sample compared to the PBS 
control for each pair of samples. Next, a consensus dataset was formed of proteins identified in all 
four CLL patient samples (average FC >2 and a combined-Z score (>1.96 or <1.96) was calculated 
by summing the individual Z-scores calculated for each patient). Table 5.5 shows a consensus list of 
the top 20 proteins with greatest FC and significant Z scores across all four patient samples and GO 
ontology annotations, which were retrieved from HumanNet. 169 proteins were identified which 
satisfied the filtering requirements and 22 (13%) of these proteins are cell surface associated by 
ontology annotation and 22% of all proteins are localised at the cell surface (228, 241). Table 5.5 
below shows the top 20 proteins identified by FC for the CLL cell surface enrichment dataset. The 
complete dataset is in Supplementary Table 5.2.8. In section 5.2.7 only 2.7% of proteins were 
identified as cell surface associated when a matching PBS control for non-specific binding was not 
available. Therefore, filtering the dataset against a PBS control to remove non-specific protein 
identifications increases the proportion of protein identifications associated with the cell surface. 
However, the cell surface protein enrichment achieved is not as great as that observed for HeLa 
cells in section 5.2.4 where this method enriched cell surface proteins to almost 70% of total protein 
identifications in the dataset.  
The 169 proteins identified as the consensus cell surface protein list were analysed by David 
Functional Annotation Tools, as described in section 5.2.4 and Table 5.3. Cell surface and plasma 
Table 5.4 Most abundant proteins identified from cell surface isolations of CLL cells 
from 3 patients, ranked by peptide count. GO ontology annotations were retrieved from 
HumanNet (http://www.functionalnet.org/humannet/). A full list of the proteins identified is in 




membrane proteins were not significantly enriched in this clustering analysis. This is unsurprising 
given that only 13% of the proteins had been annotated as cell surface proteins by HumanNet 
ontology analysis. The presence of annotation cluster 3 (actin and cytoskeletal related proteins) in 
the analysis (Table 5.6) is also not surprising given the high abundance of this protein, as discussed 
in section 5.2.3 and the nature of the effects of sampling in MS techniques. Annotation cluster 2 
includes regulation of apoptosis and cell death related terms. This is particularly interesting given 
that the CLL cells are known to over express many anti-apoptotic proteins (250-252) and undergo 








 cells. CLL cells 
were treated with biotinylation reagent or PBS control. Isolated proteins were analysed by 
LC-MS/MS. Proteins were selected with a Z score >1.96 and <1.96 with FC >2. The Table 
shows the top 20 proteins with greatest FC and significant Z scores. GO ontology 
annotations were retrieved from HumaNet (http://www.functionalnet.org/humannet/). The 










Change GO Process GO Component GO Function
ENSG00000005961
ENST00000262407 integrin, alpha 2b (platelet 
glycoprotein IIb of IIb/IIIa complex, antigen CD41)  7.33 13.24
 cell adhesion; cell-matrix 
adhesion; integrin-mediated 
signaling pathway;
 focal adhesion; integrin 
complex; external side of 
plasma membrane; 
membrane; integral to 
membrane;
 receptor activity; calcium ion 
binding; protein binding; identical 
protein binding; extracellular 
matrix binding;
ENSG00000136167
ENST00000323076 lymphocyte cytosolic protein 1 (L-
plastin)  9.69 11.14  actin filament bundle formation;
 ruffle; phagocytic cup; 
cytoplasm; cytosol; actin 
filament;
 actin binding; calcium ion 
binding; identical protein binding; 
actin filament binding;
ENSG00000108518 ENST00000225655 profilin 1  8.51 10.72
 neural tube closure; regulation of 
transcription from RNA 
polymerase II promoter; 
cytoskeleton organization and 
biogenesis; actin cytoskeleton 
organization and biogenesis;
 nucleus; cytoplasm; actin 
cytoskeleton;
 actin monomer binding; protein 
binding;
ENSG00000177156 ENST00000319006 transaldolase 1  6.24 9.38
 carbohydrate metabolic process; 
pentose-phosphate shunt; 
metabolic process;  cytoplasm;
 catalytic activity; transaldolase 
activity; protein binding; 
transferase activity;
ENSG00000074800 ENST00000234590 enolase 1, (alpha)  7.43 9.35
 negative regulation of 
transcription from RNA 
polymerase II promoter; 
glycolysis; transcription; negative 




 magnesium ion binding; 
transcription factor activity; 
transcription corepressor 
activity; phosphopyruvate 
hydratase activity; protein 
binding; plasminogen activator 
activity; lyase activity;
ENSG00000101444 ENST00000217426 adenosylhomocysteinase  5.69 9.01





ENST00000335972 ubiquitin-like modifier activating 
enzyme 1  5.72 8.99  DNA replication; ubiquitin cycle; na
 nucleotide binding; catalytic 
activity; ubiquitin activating 
enzyme activity; protein 
binding; ATP binding; ligase 
activity;
ENSG00000089220
ENST00000261313 phosphatidylethanolamine binding 
protein 1  5.56 8.53 na na
 nucleotide binding; serine-type 
endopeptidase inhibitor activity; 




ENST00000542276 Rho GDP dissociation inhibitor (GDI) 
beta  5.47 8.01
 cell motility; immune response; 
negative regulation of cell 
adhesion; Rho protein signal 
transduction; multicellular 
organismal development; actin 
cytoskeleton organization and 
biogenesis;
 cytoplasm; cytoskeleton; 
cytoplasmic membrane-
bound vesicle;
 Rho GDP-dissociation inhibitor 
activity; GTPase activator 
activity; protein binding;
ENSG00000102144 ENST00000373316 phosphoglycerate kinase 1  7.04 7.78  glycolysis; phosphorylation; na
 nucleotide binding; 
phosphoglycerate kinase 
activity; ATP binding; 
transferase activity;
ENSG00000109971 ENST00000227378 heat shock 70kDa protein 8  6.74 7.74
 protein folding; response to 
unfolded protein;
 intracellular; nucleus; cell 
surface;
 nucleotide binding; protein 
binding; ATP binding; ATPase 
activity, coupled;
ENSG00000137076 ENST00000314888 talin 1  7.51 6.95
 cell motility; cytoskeletal 
anchoring; intercellular junction 
assembly;
 ruffle; cytosol; 
cytoskeleton; intercellular 
junction; focal adhesion;
 actin binding; structural 
constituent of cytoskeleton; 
binding; protein binding; vinculin 
binding; LIM domain binding;
ENSG00000128340
ENST00000249071 ras-related C3 botulinum toxin 
substrate 2 (rho family, small GTP binding protein 
Rac2)  3.99 6.80
 chemotaxis; signal transduction; 
small GTPase mediated signal 
transduction; cell projection 
biogenesis; actin cytoskeleton 
organization and biogenesis;
 intracellular; membrane 
fraction; nuclear envelope; 
cytoplasm;
 nucleotide binding; GTPase 
activity; protein binding; GTP 
binding;
ENSG00000204388 ENST00000375650 heat shock 70kDa protein 1B  3.92 6.74
 protein folding; response to 
unfolded protein; na
 nucleotide binding; ATP 
binding;
ENSG00000117592 ENST00000340385 peroxiredoxin 6  4.87 6.45
 response to oxidative stress; 
phospholipid catabolic process; lipid 
catabolic process;  lysosome; cytosol;




ENSG00000143549 ENST00000341485 tropomyosin 3  6.90 6.37
 cell motility; regulation of muscle 
contraction;
 cytoskeleton; muscle thin 
filament tropomyosin;  actin binding;
ENSG00000080824
ENST00000216281 heat shock protein 90kDa alpha 
(cytosolic), class A member 1  5.75 6.33
 protein folding; mitochondrial 
transport; response to unfolded 
protein; signal transduction; 
protein refolding; positive 
regulation of nitric oxide 
biosynthetic process;  cytosol;
 nucleotide binding; ATP 
binding; nitric-oxide synthase 




ENSG00000163737 ENST00000296029 platelet factor 4  3.63 6.32
 immune response; negative 
regulation of angiogenesis; 
cytokine and chemokine mediated 
signaling pathway; platelet 
activation; leukocyte chemotaxis; 
negative regulation of 
megakaryocyte differentiation;
 extracellular region; 
extracellular space;
 chemokine activity; heparin 
binding;
ENSG00000172757 ENST00000308162 cofilin 1 (non-muscle)  5.31 6.16
 anti-apoptosis; Rho protein signal 
transduction; actin cytoskeleton 
organization and biogenesis;
 intracellular; nucleus; 
cytoplasm; cytoskeleton;  actin binding; protein binding;
ENSG00000170542
ENST00000380698 serpin peptidase inhibitor, clade B 
(ovalbumin), member 9  4.55 6.13
 anti-apoptosis; signal 
transduction;  cytoplasm; cytosol;
 serine-type endopeptidase 











Term Count % PValue
Fold 
Enrichment FDR
GO:0042470~melanosome 22 13.84 1.55E-22 21.94 2.04E-19
GO:0048770~pigment granule 22 13.84 1.55E-22 21.94 2.04E-19
GO:0031988~membrane-bounded vesicle 36 22.64 4.62E-17 5.63 6.07E-14
GO:0016023~cytoplasmic membrane-bounded vesicle 34 21.38 1.04E-15 5.49 1.31E-12
GO:0031982~vesicle 37 23.27 1.35E-15 4.90 1.75E-12
GO:0031410~cytoplasmic vesicle 35 22.01 1.48E-14 4.84 1.96E-11
Annotation Cluster 2
Enrichment Score: 7.65
Term Count % PValue
Fold 
Enrichment FDR
GO:0042981~regulation of apoptosis 32 20.13 4.68E-10 3.64 7.83E-07
GO:0043067~regulation of programmed cell death 32 20.13 5.97E-10 3.60 9.98E-07
GO:0010941~regulation of cell death 32 20.13 6.53E-10 3.59 1.09E-06
GO:0043066~negative regulation of apoptosis 18 11.32 2.94E-07 4.65 4.91E-04
GO:0043069~negative regulation of programmed cell death 18 11.32 3.58E-07 4.58 5.99E-04
GO:0060548~negative regulation of cell death 18 11.32 3.72E-07 4.57 6.23E-04
GO:0006916~anti-apoptosis 14 8.81 3.77E-07 6.21 6.30E-04
Annotation Cluster 3
Enrichment Score: 6.83
Term Count % PValue
Fold 
Enrichment FDR
GO:0030029~actin filament-based process 19 11.95 1.22E-10 7.21 2.04E-07
GO:0015629~actin cytoskeleton 20 12.58 1.49E-10 6.60 1.96E-07
GO:0030036~actin cytoskeleton organization 18 11.32 3.71E-10 7.28 6.20E-07
GO:0003779~actin binding 20 12.58 7.37E-09 5.24 1.02E-05
actin-binding 15 9.43 1.70E-08 7.35 2.29E-05
actin binding 8 5.03 3.28E-08 24.19 4.41E-05
GO:0007010~cytoskeleton organization 21 13.21 5.13E-08 4.40 8.58E-05
cytoskeleton 22 13.84 6.07E-08 4.18 8.16E-05
GO:0007015~actin filament organization 10 6.29 7.85E-08 12.70 1.31E-04
GO:0008092~cytoskeletal protein binding 22 13.84 3.70E-07 3.73 5.13E-04
GO:0005856~cytoskeleton 35 22.01 6.70E-06 2.25 0.00881
GO:0043228~non-membrane-bounded organelle 50 31.45 6.40E-05 1.71 0.08414
GO:0043232~intracellular non-membrane-bounded organelle 50 31.45 6.40E-05 1.71 0.08414
GO:0044430~cytoskeletal part 18 11.32 0.03699 1.68 39.0814
Annotation Cluster 4
Enrichment Score: 5.65
Term Count % PValue
Fold 
Enrichment FDR
SP_PIR_KEYWORDS Chaperone 14 8.81 6.25E-10 10.72 8.40E-07
GO:0051082~unfolded protein binding 14 8.81 7.47E-10 10.40 1.04E-06
molecular chaperone 6 3.77 4.28E-08 55.83 5.76E-05
GO:0006457~protein folding 13 8.18 5.02E-07 6.71 8.39E-04
GO:0006986~response to unfolded protein 8 5.03 1.15E-05 10.30 0.01929
stress response 7 4.40 1.69E-05 12.83 0.02272
GO:0051789~response to protein stimulus 8 5.03 1.63E-04 6.83 0.27284
GO:0010033~response to organic substance 20 12.58 3.00E-04 2.54 0.50123
SP_PIR_KEYWORDS ATP 7 4.40 0.01343 3.59 16.6268
Annotation Cluster 5
Enrichment Score: 5.53
Term Count % PValue
Fold 
Enrichment FDR
site:Interaction with phosphoserine on interacting protein 7 4.40 2.02E-12 120.21 2.94E-09
SM00101:14_3_3 7 4.40 2.90E-12 110.72 2.70E-09
IPR000308:14-3-3 protein 7 4.40 4.60E-12 104.77 6.28E-09
PIRSF000868:14-3-3 7 4.40 1.29E-10 59.65 1.46E-07
PIRSF000868:14-3-3 protein 7 4.40 1.29E-10 59.65 1.46E-07
hsa04722:Neurotrophin signaling pathway 12 7.55 1.77E-05 5.07 0.02045
GO:0008104~protein localization 25 15.72 2.66E-05 2.59 0.04442
GO:0019904~protein domain specific binding 15 9.43 3.16E-05 3.87 0.04379
GO:0045184~establishment of protein localization 22 13.84 8.54E-05 2.61 0.14279
GO:0046907~intracellular transport 20 12.58 9.08E-05 2.78 0.15183
GO:0015031~protein transport 21 13.21 2.17E-04 2.52 0.36249
GO:0034613~cellular protein localization 13 8.18 0.00176 2.89 2.89893
Table 5.6 David Functional Analysis of consensus CLL cell surface proteins. The 169 
proteins identified in section 5.2.4 (with significant Z scores and FC>2 in the biotinylated 
samples) were analysed using David Functional Analysis Tools 
(http://david.abcc.ncifcrf.gov/). The top five annotation clusters are shown. The complete 
dataset is available in Supplementary Table 5.2.8b. 
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5.2.9. Analyses of CLL cell total cell lysates by LC-MS/MS 
 
The relative representation of cell surface proteins in biotinylated samples isolated from HeLa cells 
was increased when these lists were filtered with respect to the abundance of proteins identified by 
analyses of total cell lysates (section 5.2.4). In order to investigate the relative representation of cell 
surface proteins in CLL cells, LC-MS/MS analyses were performed on total cell lysates from three 
different CLL patients. Cells were lysed in Pierce proprietary lysis buffer, as described in Materials 
and Methods and analysed by LC-MS/MS. A consensus list of proteins identified in all three patient 
samples was created from protein identifications observed in at least two of the technical replicates 
from each of the three patients analysed. Once again, actin and its binding partners are highly 
abundant. A large degree of overlap in protein identifications was observed between each of the 




Table 5.7 below shows the total counts from three injections for the top 20 most abundant proteins 
in the consensus list. A complete dataset is available in Supplementary Table 5.2.9. In order to 
improve cell surface protein enrichment, proteins identified in biotinylated protein isolates were only 
included in the final dataset if they were significantly observed compared to the CLL consensus total 
lysate protein list. However, this comparison using the total lysate did not increase the % of cell 
surface annotated proteins over the enrichment achieved by filtering the biotin sample against the 
PBS control. 
Figure 5.8 Proteins identified from total lysates of cells isolated from three CLL patients. 
Total cell protein samples were analysed by LC-MS/MS. Protein identifications were included in 























2215 2160 2810 7185 2395.00
ENST00000366684 actin, 
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ENST00000224784 actin, 
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ENST00000377364 histone 
cluster 1, H4b [Source:HGNC 
Symbol;Acc:4789]
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ENST00000216181 myosin, 
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ENST00000331380 histone 




669 832 534 2035 678.33
ENST00000323076 
lymphocyte cytosolic protein 
1 (L-plastin) [Source:HGNC 
Symbol;Acc:6528]
84.53 7 44
674 593 715 1982 660.67
ENST00000551208 tubulin, 
beta class I [Source:HGNC 
Symbol;Acc:20778]
74.48 21 6
646 671 648 1965 655.00
ENST00000289316 histone 




673 782 462 1917 639.00
ENST00000262030 ATP 
synthase, H+ transporting, 





666 712 524 1902 634.00
ENST00000234590 enolase 
1, (alpha) [Source:HGNC 
Symbol;Acc:3350]
71.66 3 24







711 650 440 1801 600.33
ENST00000314088 histone 




562 715 439 1716 572.00
ENST00000369160 histone 




573 725 414 1712 570.67
ENST00000227378 heat 




512 604 582 1698 566.00
ENST00000345042 heat 




527 608 428 1563 521.00
Table 5.7 Consensus list of proteins identified from total lysates of three CLL 
patient samples. A complete dataset is available in Supplementary Table 5.2.9. 
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5.2.10. Identification of cell surface proteins from primary CLL cells by LC-
MS/MS – Annexin V negative cells 
 




 CLL cell surface proteins described in 5.2.8 and Table 5.6 
highlight the enrichment of a cluster of proteins involved in regulating apoptosis. One explanation for 
this may be the over expression of anti-apoptotic proteins by CLL, resulting in the appearance of 
enrichment in the peptides identified when compared with a reference dataset. If this were the case, 
an enrichment of anti-apoptotic proteins would be expected from a David Functional Analysis of CLL 
consensus total cell lysate proteins. However, the enrichment score for apoptosis related terms in 
the consensus total lysate was 2.74 compared to 7.65 in the CLL consensus cell surface proteins. 
This suggests that there is an enrichment of apoptosis related proteins specifically at the cell surface 
of the CLL cells analysed. Despite the over expression of anti-apoptotic proteins, it is also 
recognised that populations of CLL cells are dynamic with considerable cell turnover and cell death 
rates of up to 2% of the clone per day have been reported (35). Recent publications have also 
highlighted the potential for intracellular proteins to act as a source of auto antigens for the BCR in 
CLL (253).  
I investigated whether the cell surface ‘apoptosis regulation' signature identified in Table 5.6 was 




 cells selected 
from three CLL patients were each separated into two samples and one of the samples was then 
treated with the Annexin V MicroBead kit (Milteyni) to remove any Annexin V positive cells. The 




 sample were then treated 
with biotinylation reagent and their cell surface proteome was analysed as described above using 
the LTQ-Orbitrap. A consensus dataset was created as described in 5.2.8 from the three different 
CLL patient samples. 86 proteins were identified with a significant Z-score between the biotinylated 





population compared with the Annexin V negative cells and 22 were identified with 





population. The proteins most significantly enriched in the Annexin V negative fraction 
are shown in Table 5.8 below and the full dataset is shown in Supplementary Table 5.2.10. The 
proteins identified include several nuclear proteins such as high mobility group box 2 (HMGB2) and 
Histones. This is somewhat surprising given that these cells were selected to be Annexin V negative 
and therefore should have be a viable population of cells. However, these data are consistent with 
the expression of intracellular proteins at the cell surface of viable cells, which occurs in certain 















ENST00000296503 high mobility group box 2 [Source:HGNC 
Symbol;Acc:5000] 10.53 3.09
ENSG00000005022
ENST00000317881 solute carrier family 25 (mitochondrial carrier; adenine 
nucleotide translocator), member 5 [Source:HGNC Symbol;Acc:10991] 10.53 3.09
ENSG00000138029
ENST00000545822 hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA 
thiolase/enoyl-CoA hydratase (trifunctional protein), beta subunit 
[Source:HGNC Symbol;Acc:4803] 10.30 3.04
ENSG00000124575 ENST00000244534 histone cluster 1, H1d [Source:HGNC Symbol;Acc:4717] 9.43 6.04
ENSG00000215021 ENST00000542912 prohibitin 2 [Source:HGNC Symbol;Acc:30306] 7.90 2.64
ENSG00000176619 ENST00000582871 lamin B2 [Source:HGNC Symbol;Acc:6638] 7.36 2.48
ENSG00000213585
ENST00000265333 voltage-dependent anion channel 1 [Source:HGNC 
Symbol;Acc:12669] 6.46 4.61
ENSG00000183311 ENST00000551208 tubulin, beta class I [Source:HGNC Symbol;Acc:20778] 6.40 3.44
ENSG00000078668
ENST00000022615 voltage-dependent anion channel 3 [Source:HGNC 
Symbol;Acc:12674] 6.14 2.28
ENSG00000198712
ENST00000361739 mitochondrially encoded cytochrome c oxidase II 
[Source:HGNC Symbol;Acc:7421] 6.14 2.28
ENSG00000105202 ENST00000221801 fibrillarin [Source:HGNC Symbol;Acc:3599] 6.14 2.28
ENSG00000167085 ENST00000446735 prohibitin [Source:HGNC Symbol;Acc:8912] 6.14 2.28
ENSG00000169100
ENST00000381401 solute carrier family 25 (mitochondrial carrier; adenine 
nucleotide translocator), member 6 [Source:HGNC Symbol;Acc:10992] 6.14 2.28
ENSG00000116251 ENST00000234875 ribosomal protein L22 [Source:HGNC Symbol;Acc:10315] 6.03 3.90
ENSG00000144381
ENST00000345042 heat shock 60kDa protein 1 (chaperonin) [Source:HGNC 
Symbol;Acc:5261] 5.87 3.88
ENSG00000127483
ENST00000375004 heterochromatin protein 1, binding protein 3 
[Source:HGNC Symbol;Acc:24973] 5.85 3.71
ENSG00000134440
ENST00000423481 asparaginyl-tRNA synthetase [Source:HGNC 
Symbol;Acc:7643] 5.27 2.08
ENSG00000163631 ENST00000509063 albumin [Source:HGNC Symbol;Acc:399] 5.27 2.08
ENSG00000167553 ENST00000301072 tubulin, alpha 1c [Source:HGNC Symbol;Acc:20768] 5.01 3.77
ENSG00000178952
ENST00000313511 Tu translation elongation factor, mitochondrial 
[Source:HGNC Symbol;Acc:12420] 4.70 3.76
Table 5.8 Consensus list of proteins identified as significantly different between total CLL 
cells and Annexin V negative cells from three different CLL patient samples. The full 





The aim of the work in this chapter was to establish a method for identifying the cell surface 
proteome and to apply this method to the analysis of cells obtained from patients with CLL. Both 
homotypic cell: cell interactions and interactions between cell surface proteins and extracellular 
ligands are crucial for the survival of CLL cells in vitro suggesting that cell surface proteins are 
important for CLL cell survival. In this chapter I established a method to enrich for cell surface 
proteins using a cell-surface biotinylation and identification of these proteins using a shotgun 
proteomics approach, which I applied to the analysis of cells from CLL patients. 
Firstly, I tested a cell surface biotinylation method to isolate cell surface proteins. Initially, I used 
primary human T cells and the HeLa cell line to test and optimise the methodology and I then 
applied this method to CLL patient samples. Because of the fragile nature of these cells, 
experiments had to be carried out immediately on CLL cells straight from the clinic and I showed that 
cryopreserved CLL cells were not suitable for such analyses.  
Next, during a rotation in Professor Marcotte’s laboratory at the University of Texas at Austin, I 
tested different sample preparation methods to optimise cell surface protein identification by LC-
MS/MS. This work was carried out on readily available lysates which I obtained from HeLa cells. 
These experiments allowed me to select and optimise the methods to process patient samples for 
LC-MS/MS. 
A CLL cell total lysate consensus list was made so that enrichment of cell surface proteins could be 
tested against the representation of these proteins in a total lysate. All of the cell surface proteins 
identified with significant Z scores and FC>2 (biotinylated proteins bound to the NeutrAvidin column, 
compared with the PBS control) also had a significant Z score when compared with the CLL 
consensus total lysate. I then analysed biotinylated cell surface proteins by LC-MS/MS. After filtering 
against a paired control, 169 proteins met the inclusion criteria for the CLL cell surface dataset. 13% 
of these proteins are annotated as being cell surface related. When CLL proteins without a paired 
control were analysed by LC-MS/MS, only 2.7% were annotated as being cell surface proteins. This 
indicates that paired controls are important to create meaningful, smaller datasets with fewer false-
positive identifications. When HeLa samples were analysed, 100 of 188 proteins identified with a 
significant Z score had a cell surface annotation. This suggests that the method is successful in 
isolating and identifying cell surface proteins and the lower enrichment of cell surface proteins 
observed in the CLL samples is cell type specific. 
Somewhat surprisingly, a significant number of proteins were identified in samples of biotinylated 
CLL cell proteins which have traditionally been classified as intracellular proteins. These include 
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cytoplasmic (e.g. Hsp90), nuclear (e.g. GAPDH) and cytoskeletal (e.g. vimentin, myosin non-muscle 
heavy chain-9, cofilin-1, ezrin, radixin) proteins. The heat shock protein Hsp90 has been shown to 
be present on the cell surface of a number of cancer cells (254) and may be a therapeutic target for 
Hsp90 inhibitors, which are not cell-permeable (255). CLL cells are also known to be capable of 
presenting antigens (256) and normal B-cells can bind, internalise, process and present cell surface 
antigens that become exposed during apoptosis (257). As noted earlier, most CLL BCRs recognise 
molecular motifs associated with apoptosis. Interestingly, vimentin and cofilin-1 have all been 
previously identified as specific binding partners for CLL B-cell receptor stereotypes 32 and 1 
respectively (258). In the case of subset 6 (Vh1.69), the CLL BCR has been shown to bind myosin 
heavy chain IIA (NMHC-II-A), which is exposed on the surface of a subset of apoptotic cells termed 
Myosin Heavy Chain IIA Exposed Apoptotic Cells (MEACS) (248). Analyses of Jurkat cells 
undergoing apoptosis has shown that Histone proteins also appear on the cell surface (259) and this 
could be the case for CLL cells in the early stages of apoptosis, but which still have an intact plasma 
membrane. 
After observing an enrichment of proteins associated with the GO term ‘regulation of apoptosis’ in 
the cell surface fraction of CLL cells, I carried out an experiment to determine whether these proteins 
were identified because of the presence of a sub-set of intact CLL cells undergoing apoptosis, which 
were Annexin V positive. I removed Annexin V positive cells and analysed the cell surface proteome 




cells and compared the data with the cell surface proteome 




cells. David Functional Analyses of these datasets showed that 





 Annexin V negative cells from primary CLL PBMCs was technically 
very challenging due to the fragile nature of CLL cells. The multiple selection procedures required 
manipulation of cells through numerous washing steps, magnetic negative selection using EasySep 
and negative selection using Milteyni AnnexinV MicroBeads. The Milteyni selection especially was 
found to produce variable results with some CLL samples dying as a result of passage though the 
selection column. The yield of CLL cells after several rounds of selection produced small amounts of 
protein for analysis. Again, these observations highlight the possibility that the CLL cells that were 
amenable to study are a self-selecting sub-set of the disease, because these cells are robust 
enough to withstand the selection procedures and time spent in the laboratory away from a 
supportive environment. However, the data indicate that the intracellular proteins associated with 
‘regulation of apoptosis’ are from an Annexin V positive sub-set of cells. They may be biotinylated 
because the plasma membrane of a proportion of these cells is compromised or because these cells 
express intracellular proteins on their cell surface. More experiments are now needed with larger cell 
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numbers to obtain a consensus list of the cell surface proteome of the cells in CLL that are in the 
process of undergoing apoptosis.   
The role of self-antigen in CLL is contentious, with some groups reporting that the BCR is 
constitutively activated (260), whilst others show evidence for stimulation by antigen (261). It has 
been suggested that several intracellular proteins, including vimentin, cofilin 1 and non-muscle 
myosin heavy chain 9 (highlighted yellow in Table 5.4) are able to bind to some CLL BCRs. If self-
antigen is able to bind to the BCR, a potential source could be the large pool of CLL cells in the 
patient, some of which will be undergoing apoptosis at a given time. Other cells in the tumour 
microenvironment may also act as sources of antigen. For example vimentin has been reported to 
be on the surface of viable stromal cells (262). 
In summary, the study described here presents a method to isolate and identify cell surface proteins. 
It highlights in particular the effects of cell type and behaviour on the quality of the data produced by 
an experiment. The behaviour of cells during labelling and the MS data produced from HeLa cells 
was different from that obtained for primary CLL cells, highlighting the importance of identifying 
suitable controls against which to filter high content datasets.  
The CLL cell surface proteome has been investigated by other groups using methods different from 
those described in this chapter. Kohnke et al. (263) used a hydrazine-coupling technique to enrich 
for N-linked glycoproteins combined with an iTRAQ labelling method followed by 2D LC-MS/MS to 
monitor Fludarabine and Cladarabine induced changes in cell surface proteins of the cell line MEC1 
(CLL in prolymphocytoid transformation (264)). They identified 232 N-linked glycopeptides, 50% of 
which were annotated as plasma membrane proteins and 19% identified as integral membrane 
proteins. These are similar to the enrichment levels achieved in the HeLa datasets presented in this 
chapter but much higher than the CLL datasets I have described. Although their work was carried 
out using cell lines, their data suggests that enriching for glycosylated proteins is a viable alternative 
for analysing cell surface proteins, which might be applied to the analysis of primary CLL cells. A 
study from Boyd et al. (265) analysed the cell surface proteome of primary CLL cells using a sub 
cellular fractionation method based on density centrifugation (232) followed by 1D gel separation 
and MALDI-TOF analysis. This study identified 365 proteins in total and 238 (65%) were identified 
as membrane-associated proteins. The remaining 35% were known non-membrane proteins, 
reflecting contamination of the membrane preparation with cytosolic proteins. 133 (56%) of these 
‘membrane-associated proteins’ were in some way localized to the plasma membrane, meaning that 
only 36% of the total proteins identified were associated with the plasma membrane. This indicates 
that the architecture of primary CLL cells may hinder cell surface protein enrichment when compared 
to the analysis of cell lines. 
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One of the proteins identified in the CLL cell surface enrichment analyses described in section 5.2.7, 
integrin beta 3 (ITGB3) has recently been identified as a therapeutic target in Mixed Lineage 
Leukaemia (MLL) (266).  Miller et al. (267) used an in vivo shRNA screening approach to identify 
novel regulators required for MLL-AF9 leukaemia. They showed that leukemic cells with a reduced 
level of ITGB3 had impaired homing and engraftment potential in the bone marrow upon 
transplantation in both mouse and humanized xenograft models. The ITGB3/ITGAV heterodimer is 
expressed on MLL cells and mediates the interaction with ligands on the surface of stromal cells in 
the bone marrow niche. This demonstrates that attempts to catalogue the cell surface proteome of 
cancer cells could help direct future targets for therapies. 
5.3.1. Other applications of the method 
 
The cell surface protein isolation and identification method described here has now been utilised in 
other projects. We have used it to investigate the unknown mechanism of action of a drug, 
Thiabendazole (TBZ) on Human Umbilical Vein Endothelial Cells (HUVEC) (135). The effect of TBZ 
on endothelial cells was discovered through a ‘Phenolog’ approach, combined with a drug 
repurposing method by our collaborators, Professor Marcotte’s laboratory at the University of Texas 
at Austin. The ‘Phenolog’ approach is based on the evolutionary conservation of genetic modules. 
For example, the function of one particular gene module in yeast is to maintain cell walls, whilst in 
vertebrates the same gene module regulates neovascularisation (133). Cha et al. (135) analysed 
this gene module to search for small molecules which target the yeast pathway and which could 
then be tested as angiogenesis inhibitors. TBZ, an antifungal drug already in clinical use was 
identified by this method and it was shown to inhibit angiogenesis in animal models and HUVEC 
cells. 
I carried out an experiment to determine quantitative changes in the cell surface proteome of 
HUVEC cells caused by TBZ treatment using the methods described in this Chapter. Only 11 
proteins met the strict filters of the data shown in Table 5.9 (Z score > 1.96 or > 1.96 and with a 
FC>2). The protein identified with the largest fold change and a significant Z score was myosin 
phosphatase Rho interacting protein (MPRIP). MPRIP is a member of the myosin phosphatase 
complex that directly binds RhoA (268, 269) and targets myosin phosphatase to the actin 
cytoskeleton. Depletion of MPRIP leads to an increased number of stress fibres in smooth muscle 
cells through stabilization of actin fibres by phosphorylated myosin (270).  
The identification of MPRIP fits with the expected mechanism of action of TBZ on endothelial cells, 
because the drug behaves as a vascular disrupting agent. TBZ has been shown to impede migration 
of HUVECs in a wound scratch assay and treatment with the Rho Kinase inhibitor Y27632 reverses 
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TBZ’s effects (135). This suggests that TBZ may be acting on the Rho kinase pathway. Use of the 
Y27632 inhibitor elicited a significant and dose-dependent rescue of the TBZ-induced HUVEC cell 
motility defect. Together, these data suggest that vascular disruption by TBZ results from 
hyperactive Rho signalling and the data in Table 5.9 support the conclusions of Cha et al. (135), that 
a major effect of TBZ treatment is the modulation of the Rho kinase pathway. Interestingly, MPRIP 
siRNA-treated HeLa cells were significantly less invasive (271). These data show that the method 
described in this Chapter could be applied to help uncover details of unknown mechanisms involving 














Table 5.9 Analyses of the HUVEC cell surface proteins identified by mass spectrometry 
over represented in TBZ treated compared to DMSO control. HUVEC were treated with 
biotin ester or DMSO control and the cells were lysed and processed as described. Proteins 
were selected with a Z score > 1.96 or > 1.96 and with a FC>2 and the top 11 are shown. The 



















The aim of my PhD project was to apply Systems Biology methods to answer biological questions 
about interactions between CLL cells and the tumour microenvironment, including: (i) the effects of 
co-culture model systems on primary CLL cell viability and phenotype, (ii) investigating the 
transcriptional effects of endothelial cell co-culture on primary CLL cells, particularly control 
mechanisms responsible for co-ordinated gene expression and (iii) a systematic identification of 
primary CLL cell surface proteins. Increasing our knowledge of CLL biology provides more potential 
targets for rational therapeutic intervention. 
The study in Chapter 3 focused on the effects of co-culture on primary CLL cells. CLL cells undergo 
apoptosis when cultured in the laboratory away from the supportive tumour microenvironment found 
in the body. Laboratories across the world employ different methods to keep CLL cells alive in 
culture so that the biology of the disease can be investigated. Most of these methods seek to 
replicate interactions which occur in the tumour microenvironment. In Chapter 3 and recently 
published in the British Journal of Haematology, we presented a direct comparison of the effects of 
different co-culture systems on primary CLL cells. We evaluated the effects of interactions between 
primary CLL cells and endothelial cells (HMEC-1), and also with mouse fibroblasts expressing the 
human proteins CD40L (expressed on activated T cells) and CD31 (expressed on endothelial cells), 
which have been reported to exist in the tumour microenvironment. The results showed that all co-
culture systems increased CLL cell viability compared with liquid culture and induced a change in 
CLL cell phenotype consistent with that found in poor prognosis disease in vivo. However, 
differences were observed in proliferation assays, with only the fibroblast models able to induce CLL 
cell proliferation in culture. 
The study in Chapter 4 expanded on the co-culture analyses carried out in Chapter 3 and examined 
the mRNA changes which occur when cells from CLL patients are co-cultured with an endothelial 
cell line, HMEC-1 and the primary endothelial cells, HDBEC. Based on the observation that both co-
culture systems improved CLL cell viability and induced a similar phenotype in CLL cells, I sought to 
determine whether there were mRNA changes which occurred in the cells from all CLL patients as a 
result of co-culture. The rationale behind these biofinformatic analyses was that any mRNA or 
pathways up-regulated in both systems may represent cellular mechanisms which the CLL cells 
have become addicted to and rely upon for survival and therefore present targets for intervention. 53 
mRNA were identified as significantly up-regulated by both co-culture systems. Other groups have 
investigated the transcriptional effects of one co-culture system (65) and compared microarray-
based expression profiles of CLL cells before and after three different survival-inducing culture 
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conditions: (i) HS-5 stromal cell co-culture, (ii) stromal cell conditioned medium and (iii) high cell 
density cultures of unsorted peripheral blood mononuclear cells (156). Their bioinformatic approach 
focussed on Ingenuity Pathways Analysis (IPA) to identify the top canonical pathways of genes 
common to each condition. These analyses identified Toll-like receptor signalling, NRF2-mediated 
oxidative response, ATM signalling, TREM1 signalling and p53 signalling all which have roles 
previously identified in CLL. However, the bioinformatic approach in my study has predicted the 
presence of a novel TF module for CLL, which may be responsible for the co-ordinated expression 
of the 53 mRNA up-regulated by both endothelial co-culture systems. The TF module contains 
CEBP-α, CEBP-β, NFκB p65, STAT1 and PU.1 and has been described to occur in macrophages. 
This potential control mechanism represents a novel way in which to target CLL cell survival 
pathways. 
The final study in Chapter 5 focussed on identifying cell surface proteins on primary CLL cells which 
may be required for cell:cell contacts made in the tumour microenvironment and therefore may be 
important to receive signals which can result in the transcriptional changes observed in Chapter 4. I 
optimised methods to identify cell surface proteins by MS using HeLa cells, achieving enrichment of 
up to 70% cell surface related proteins, which was comparable with reports in the literature for other 
cell types. I then applied these methods to analyse the cell surface proteins isolated from primary 
CLL cells. The preparations were digested with trypsin, separated on a C18 reverse phase column 
and analysed using tandem MS. The results showed a lower than expected enrichment of cell 
surface proteins from primary CLL cells (17%). This may be a feature of CLL cells and bioinformatic 
analyses highlighted an enrichment of apoptosis related proteins in the cell surface preparations. 
One explanation could be that the CLL cells are in an early stage of apoptosis either in the body or 
as a result of isolation and selection methods before biotinylation. Therefore, I then sought to 
determine whether the cell surface proteins identified from Annexin V negative cells would differ 
significantly from those of total CLL cells using a Milteyni Annexin V depletion protocol. The data 
from these experiments are preliminary as only three samples could be isolated with sufficient 
viability for biotinylation. However, these data showed that the apoptosis-related proteins identified 
are not present on the Annexin V negative CLL cell population and so may come from a sub-set of 
dying CLL cells.  
The biological plausibility of the protein identifications made in this study remains to be verified. As 
previously discussed, a number of the proteins identified are not usually associated with expression 
at the cell surface. Additionally, some proteins identified (such as those in Table 5.5) are abundant 
in platelets or in endothelial cells (for example SERPINE1 as shown in Figure 4.12). Therefore, 
further experiments are required to verify the expression of these proteins in CLL cells for example 
by western blotting. 
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Investigation of interactions between cancer cells and the tumour microenvironment are crucial to 
better understand the biology of the disease in the hope of targeting pathways critical for cancer cell 
survival (157). This may require targeting the cancer cell itself, or modulating the tumour 
microenvironment to block signalling between the tumour cell and the stroma. In the context of solid 
tumours, it is thought that interactions between neoplastic cells and the tumour microenvironment 
play an important role in metastasis and disease progression. This has been shown to occur in 
colorectal cancer, where TGFα-EGFR signalling creates a microenvironment that is conducive for 
metastasis (158), providing a rationale for attempts to inhibit EGFR signalling in TGFα-positive 
cancers. Another example of paracrine signalling in the tumour microenvironment is in the 
progression from in situ to invasive breast carcinoma, where loss of stromal Cav-1 expression and 
acquisition of MCT4 stromal expression are reported in invasive ductal carcoinomas (159).  
Many laboratories are working towards model culture systems which recreate the tumour 
microenvironment more accurately. Multiple Myeloma (MM), like CLL is dependent on the tumour 
microenvironment and depends on myeloma cell-bone marrow interactions. Three-dimensional 
culture models are being developed to further study the biology of MM and response to therapy 
(160). Advanced intra-vital microscopy or 'dynamic histopathology' techniques are also providing 
insights into cancer progression as a dynamic step-wise process within anatomic and functional 
niches provided by the microenvironment (161). 
 
6.2 Future work 
 
The conclusions from each study are summarised in section 6.1, however the results raise additional 
questions which could be addressed in future projects. 
6.2.1. Determination of labelling location 
 
In order to clarify whether biotin labelling was cell surface or cytoplasmic, further bioinformatic 
analyses of the raw MS data are required. The biotinylation procedure modifies the lysine residue 
and alters its mass. Therefore, we could search the data from the MS spectra for the predicted 
modified mass of the labelled residue. We could then determine the precise location of the labelling 
modification by analysing the orientation of the modified residue in the native protein. This analysis 
would help to determine whether the labelling reagent was entering the cell and labelling residues 





6.2.2. Cellular localisation of proteins identified by mass spectrometry 
 
The proteomics data of the cell surface protein preparations presented in Chapter 5 suggest that 
numerous proteins whose typical biological function is mainly characterised in the cytoplasm, 
nucleus or other organelles within the cell occur at the cell surface in CLL. It would be of interest to 
investigate whether these proteins or fragments of these proteins exist at the cell surface in CLL 
cells. This could be achieved experimentally by immunostaining the proteins without permeabilising 
the cells. Comparisons could be made between CLL cells from peripheral blood and lymph node to 
determine whether the cell surface proteome differs between the CLL compartments. Co-localisation 
with other known cell surface proteins could be investigated by multi-colour confocal microscopy. It 
would also be of interest to determine whether such proteins are only localised at the cell surface of 
a sub-set of cells, such as those undergoing apoptosis. A previous study showed that Histone 
proteins are present on the cell surface of (Jurkat) cells dying by apoptosis (259) and such a 
mechanism may account for the cell surface expression of intracellular proteins in samples from 
patients with CLL. The chaperone proteins, Hsp90 have also been identified on the cell surface of 
other cancers including prostate cancer (254), melanoma (272) and secreted in exosomes (273, 
274). Cell surface Hsp90 modulates prostate cancer cell adhesion and invasion through the integrin-
β1/focal adhesion kinase/c-Src signalling pathway (275). Studies such as these have led to the 
identification of cell surface Hsp90 as a therapeutic target. Cell impermeable Hsp90 inhibitors are 
active functionally and inhibit tumour cell invasion and metastasis (255, 276). It would be interesting 
to investigate whether treatment with a cell impermeable Hsp90 inhibitor would kill CLL cells. Cell 
surface proteome profiling in other cancers including SH-SY5Y neuroblastoma, A549 lung 
adenocarcinoma, LoVo colon adenocarcinoma, and the Sup-B15 acute lymphoblastic leukaemia (B 
cell) cell lines and ovarian patient tumour cells have identified an abundance of proteins with 
chaperone function including GRP78, GRP75, HSP70, HSP60, HSP54, HSP27, and protein 
disulfide isomerase (277).  This study provides further evidence to suggest that inhibitors of other 
chaperones may have therapeutic benefits in cancer. 
 
6.2.3. Functional characterisation of cell surface proteins 
 
If the proteins identified in my study are present on the cell surface in CLL, it would be of interest to 
investigate whether these proteins have a functional role. It would be interesting to determine for 
example, whether these proteins are simply products from nearby dying cells, or from the subset of 
CLL cells undergoing apoptosis and whether they then bind non-specifically to the cell surface or 
specifically to other cell surface proteins such as the BCR. Data from other laboratories suggest that 
some of the proteins identified in this study are capable of binding to certain classes of BCR (248) 
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and that auto-antigenic targets of BCRs are able to induce proliferation of CLL cells (253). Potential 
auto-antigens from the MS dataset could be expressed in the laboratory and presented to CLL cells 
to determine whether they play a functional role in BCR activation. BCR activation could be 
measured by western blotting for activated, phosphorylated proteins which are part of the BCR 
signalling pathway and CLL proliferation could be measured by BrdU incorporation into DNA. 
Identifying cell surface proteins which have functional roles in CLL could lead to future therapies in 
CLL. For example, therapies have been developed which use an antibody targeting HER2 which is 
over expressed at the cell surface in breast cancers (278) and other therapies target the 
extracellular ligand binding region of epidermal growth factor receptor (279) which is expressed in 
many cancer types including lung, colon and breast.  
 
6.2.4. Identifying cell surface proteins from Annexin V negative CLL cells 
 
The proteomics data presented in Chapter 5 suggest that the CLL cell surface preparation contained 
proteins with a signature related to apoptosis and regulation of apoptosis. Chu et al. showed that 
when undergoing apoptosis, cells are capable of presenting proteins on the cell surface which are 
usually intracellular, including non muscle myosin heavy chain IIA (MYHIIA) (248). Their study also 
demonstrated that CLL antibodies recognise apoptotic cells with exposed MYHIIA, potentially 
providing a role for apoptotic cell surface proteins in CLL. An example of apoptotic cells also 
expressing Histone proteins on their surface is described above (259). In Chapter 5, I isolated 




CLL cells using a Milteyni Annexin V depletion 
kit. However, because CLL cells are extremely fragile, this meant that the protocol was not reliably 
reproducible. Cell sorting by flow cytometry to select Annexin V negative CLL cells for cell surface 
biotinylation may provide samples with greater viability and reproducibility for a larger number of CLL 
patient samples.  
 
6.2.5. Identifying a novel TF module in CLL by ChIP-Sequencing 
 
The bioinformatic analyses presented in Chapter 4 predict a novel TF module in CLL. GSCA (195) 
predicts that this TF module is responsible for the co-ordinated expression of genes up-regulated in 
CLL cells by both endothelial co-culture systems. Chromatin immunoprecipitation (ChIP)-sequencing 
could be performed to determine whether any of these TF binding sites are occupied in primary CLL 
cells. The methods and ChIP-grade antibodies have been described in other ChIP-seq studies and 
could be applied directly to analysing CLL cells. If TF occupancy is confirmed, the effects of reducing 
the expression of these TF in CLL cells could be investigated. Knockdown of each TF individually 
and in combinations could determine whether the expression changes observed required the 
155 
 
presence of the entire module or if a sub-set of the TFs are capable of inducing the expression of 
some or all the genes encoding the mRNA which I showed are regulated. Those involved in protein 
interaction sub-networks that are known to be involved in apoptosis, cell proliferation or migration 
could be predicted by bioinformatics algorithms, such as HumanNet (132), which was used in a 
recent study by our laboratory (155). This is important for identifying the best therapeutic target or 
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